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Chapter 1
General introduction and outline of this thesis
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Vulvar squamous cell carcinoma
Vulvar cancer is the fourth most common type of gynaecological cancer (besides 
cancer of the uterine corpus, ovary and cervix) and comprises five percent of all 
malignancies of the female genital tract. The majority of vulvar cancers are 
squamous cell carcinomas (SCC). Vulvar basal cell carcinoma, melanoma, 
adenocarcinoma, Paget's disease and sarcoma are less common. Vulvar cancer is 
encountered most frequently in postmenopausal women with a mean age at 
diagnosis of 65 years.
A etio lo gy
Vulvar SCC and its precursor lesions originate following two separate pathways.12 
(Figure 1) In 2004, the nomenclature of the precursor lesions was revised.3 
The first and most common pathway occurs in older women and leads to mostly 
differentiated keratinizing SCC, in a background of Lichen Sclerosus (LS) and/or 
differentiated vulvar intraepithelial neoplasia (dVIN).2 This type accounts for the 
majority of all vulvar SCC and is not caused by high-risk HPV. dVIN is seldom 
diagnosed in its solitary form because it is thought to have a relatively brief in­
traepithelial phase before progression to invasive carcinoma, and is a difficult 
clinical and histological diagnosis.3'5 The oncogenesis of LS to vulvar SCC and its 
connection with dVIN remains to be elucidated.
The second pathway primarily affects younger women and consists of mainly 
nonkeratinizing SCCs. In this pathway, an infection with high-risk HPV, 
predominantly HPV 16 and 18, is involved.2 Carcinogenesis largely resembles that 
of cervical SCCs and HPV vaccines will probably prevent most of these HPV 16 and 
18 related vulvar SCCs in the future. This type of vulvar SCC is associated with 
usual VIN (uVIN). The role of the immune system seems to be a central one in the 
processes associated with both progression to invasive disease and spontaneous 
regression of uVIN, with almost a fifth of patients having an immunosuppressive 
condition.3 6 Tobacco use is very common in patients with an HPV related vulvar 
(pre) malignancy.6 Multicentric HPV infections (cervix, vagina and anus) are 
common in these patients,67 and therefore, a cervical smear should be performed 
in the work-up of patients with vulvar SCC and uVIN.7
Figure 1 Two pathways leading to vulvar SCC 
Diagnostics
The diagnosis of vulvar SCC is often delayed. Self-examination of the vulva is not 
common, especially among older women. Moreover, patients may feel too 
embarrassed to visit the family doctor8 and vulvar SCC may give rise to aspecific 
symptoms. Owing to the unfamiliarity with vulvar SCC and the similarity of 
complaints with more common diagnoses such as Candida infections or LS there 
also may be a doctors' delay.8
The diagnosis vulvar SCC is made by an incision- or punch biopsy for histopatho- 
logical examination. The optimal biopsy is taken from the edge of tumour to 
normal tissue. An excision biopsy may be an attractive alternative when an earlier 
biopsy has not led to a diagnosis; however, this may interfere with the sentinel 
lymph node (SLN) procedure. When there is a multifocal tumour, mapping of the 
vulva is necessary; multiple biopsies should be taken. Although palpation is 
unreliable for assessing the node status when small metastases are concerned, it 
should be performed to diagnose large groin metastases.
Treatm ent
The cornerstone of treatment of vulvar SCC is surgery, with a limited role for 
radio- and/or chemotherapy.9 Surgery provides best chances for local and regional 
tumour control.10 In the early 1950s, Stanley W ay introduced radical vulvectomy 
with 'en bloc' bilateral inguinofemoral lymphadenectomy as standard treatment 
for all operable vulvar SCCs.11 This strategy resulted in excellent five-year survival 
rates, however, postoperative wound breakdown and infection after an 'en bloc' 
procedure occurred with a frequency of up to 61%.912 Psychosexual disturbance 
and lymph oedema of the legs were major long-term problems.13 Since then, 
major modifications have been introduced in the standard surgical treatment to 
reduce morbidity without compromising the prognosis.14 The current generally 
accepted standard treatment is a wide local excision of the tumour with bilateral 
inguinofemoral lymphadenectomy with separate incisions. In the case of a lateral 
tumour (>1 cm from the midline), it is sufficient to perform a unilateral 
lymphadenectomy. The SLN technique has been introduced to further reduce 
the extent of the surgical treatment.15
Prognosis
With appropriate management, the prognosis for vulvar SCC is generally good, 
with an overall five-year survival rate in operable cases of approximately 70%. 
Lymph node status is the most important prognostic factor as represented in the 
International Federation of Gynaecology and Obstetrics (FIGO) staging system 
(Table 1), which was converted from a clinical to a histopathological staging in 
1988. In 2009, a revised FIGO staging for vulvar SCC was introduced;1617 major 
changes consist of the number and morphology of the involved nodes that have 
been taken into account (e.g., size and whether these are intra- or extra-capsular). 
The bilaterality of positive nodes has been discarded as an independent prognostic 
factor.17 In addition, tumours with adjacent spread to lower urethra, vagina or 
anus are now classified as FIGO II (formerly FIGO III). Patients with negative 
inguinofemoral lymph nodes have a five-year survival rate of approximately 90% 
and this falls to approximately 50% for patients with positive inguinofemoral 
lymph nodes.10 The current literature still often uses the FIGO classification as 
introduced in 1988.
Vulvar SCC
Stage 1 Tumour confined to the vulva
IA Lesions <2 cm in size, confined to the vulva or perineum and with 
stromal invasion <1.0 mm*, no nodal metastasis.
IB Lesions >2 cm in size or with stromal invasion >1.0 mm*, confined to the 
vulva or perineum, with negative nodes.
Stage II Tumour of any size with extension to adjacent perineal structures (1/3 
lower urethra % lower vagina, anus) with negative nodes.
Stage III Tumour of any size with or without extension to adjacent perineal 
structures (1/3 lower urethra % lower vagina, anus) with positive 
inguinofemoral lymph nodes.
IIIA - With 1 lymph node metastasis (>5mm) or,
- 1-2 lymph node metastasis (es) (<5mm)
IIIB - With 2 or more lymph node metastases (>5mm), or
- 3 or more lymph node metastases (<5mm)
MIC With positive nodes with extracapsular spread
Stage IV Tumour invades other regional (2A upper urethra, 2A upper vagina) or 
distant structures.
IVA Tumour invades any of the following:
- Upper urethral and/or vaginal mucosa, bladder mucosa, rectal 
mucosa, or fixed to pelvic bone or
- Fixed or ulcerated inguinofemoral lymph nodes
IVB Any distant metastasis including pelvic lymph nodes.
Table 1 The new FIGO (2009) classification of vulvar SCC16.
* The depth of invasions is defined as the measurement of the tumour from the epithelial-stromal 
junction of the adjacent most superficial dermal papilla to the deepest point of invasion.
Recurrence
Recurrence is a frequent event in vulvar SCC. The overall risk of recurrence after 
primary treatment is 19.4-45.5%.1823 Local recurrences are usually diagnosed 
more than two years after primary treatment24 and the majority of local 
recurrences can be cured. At least a subset of local recurrences will be new 
primary (de novo) tumours due to the residue of a premalignant lesion after 
surgery. Rouzier et al. suggested that when the recurrence was more than 2 cm 
distal to the primary tumour, it should be regarded as a new primary tumour 
instead of a local recurrence.24 The majority of groin and skin bridge recurrences
develop within the first year after treatment. Also pelvic and distant recurrences 
generally occur shortly after treatment and have a very poor prognosis.25 With 
the aim to diagnose local recurrences in an early stage, long term follow up of 
patients with vulvar SCC seems sensible, and patients should be instructed to 
perform self examination of the vulva.
Premalignancies of HPV-negative vulvar SCC
The oncogenesis of the HPV-negative vulvar SCC is largely unknown. It is recognized 
that the majority of patients have LS and/or dVIN in the adjacent tissue. Both entities 
have been proposed to be premalignant lesions of HPV-negative vulvar SCC.
LS is a chronic inflammatory skin disorder, most patients complain of itch as the 
most prominent symptom,26 with a significant impact on their quality of life 
(Appendix A). There are different reasons to link LS to the development of vulvar 
SCC.27 First, in up to 62% of cases of vulvar SCC, LS can be found in adjacent 
areas.2829 Furthermore, as reported in multiple case reports, patients (old and 
young) with LS may develop vulvar SCC. Third, in series of LS patients that 
underwent long-time follow-up, 2-6% has been reported to develop vulvar 
SCC.2930 So, only a minority of LS patients will develop a vulvar SCC during her 
lifetime. Examining retrospective and prospective studies of patients with known 
LS provides an estimated accumulated frequency of vulvar SCC arising in LS of 
4.5% (140 of 3093 reported cases) (summarised in the study of Carlson et a/31). 
In the prospective cohort of Carli et a i,  consisting of 211 patients, two patients 
developed invasive vulvar SCC, resulting in a relative risk of 246.6 compared to a 
matched control group.30 In that study, follow up was rather short (median 1 year 
and 8 months). In another prospective study, a less than 5% risk of progression 
was cited.32 The percentage in the review of Carlson was drawn from largely 
symptomatic series of LS patients.31 However, a substantial part of LS patients is 
asymptomatic, and therefore the exact prevalence of LS is unknown. Because this 
denominator is unknown, the exact frequency of SCC arising in LS cannot be 
adequately assessed.31 In practice, a percentage of 4-5% is applied in the literature 
on LS and in the information for patients with LS.
It is unknown which patients with LS have an increased risk of developing vulvar 
SCC. The far majority of patients are rather asymptomatic after the initiation of
potent steroid treatment, whereas in other patients the LS remains active, with 
complaints of itch and pain. Whether this difference has consequences for vulvar 
SCC development is not known. Remarkably, most women with vulvar SCC present 
without an antecedent history of clinically and histologically proven LS, but often 
suffer from LS. The patients were either asymptomatic or the LS was unnoticed 
by the family doctor.29'3133'35 Limited studies have been performed to predict 
which LS lesion will ultimately progress to vulvar SCC. In addition, these studies 
often were performed with a small number of lesions. It is suggested that 
hyperplasia, dysplasia or cellular atypia are precursor features linking progression 
of vulvar LS to vulvar SCC.30'32'36 37 Interestingly, these are all characteristics of 
dVIN,45 but in the days of most of these studies, dVIN was not regarded as a 
separate entity. In a series of studies by Raspollini et al. they could not find a role 
for the lymphocytic infiltrate in vulvar carcinogenesis. In all specimens (LS 
unchanged, LS evolved to SCC, and LS adjacent to vulvar SCC) the infiltrates 
contained CD3+, CD4+, and CD8+ cells, and the amount was not statistically 
different between the different LS lesions.38 In addition, they found that LS that 
later progressed to vulvar SCC (n=8) showed a higher Ml B index and p53 expression 
and increased formation of new blood vessels than LS without progression 
(n=8).39'40 We, however, were not able to predict vulvar SCC development on the 
basis of blood- and lymph vessel parameters.41
dVIN is a relatively 'new ' lesion; despite its introduction in the 1960's, its existence 
has long been questioned because it was thought not to represent a clinicopatho- 
logical entity but a border phenomenon adjacent to vulvar SCC.42 Liegl and 
Regauer stated that this atypical epithelial proliferation is common in the 
proximity of cutaneous carcinomas at other sites and hypothesized that the 
atypical epithelial proliferation termed dVIN might not be a vulvar specific 
lesion.42 Recently, more knowledge about dVIN has been gathered and the new 
ISSVD nomenclature3 emphasized the role of dVIN in future studies to the 
HPV-negative vulvar SCC oncogenesis. Despite this, dVIN is rarely diagnosed as a 
solitary lesion; therefore, a lot is unknown about its true incidence, malignant 
potential and biological behaviour. It has been suggested that dVIN is the direct 
precursor of the HPV-negative vulvar SCC, however strong evidence is lacking and 
the suggestion of dVIN being a border phenomenon cannot be excluded yet.
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To gain more insight in 'Lichen Sclerosus and Vulvar Intraepithelial Neoplasia in 
vulvar cancer' we have addressed several subquestions in this thesis:
1. W hat is the exact role of HPV in the two pathways leading to vulvar SCC? 
(Chapter 3)
2. W hat is the incidence of both solitary VIN lesions, has this incidence changed 
in the past years and what is their malignant potential? (Chapter 4)
3. Can we find differences between LS biopsies of patients who later were 
diagnosed with a vulvar SCC and LS biopsies of patients who did not develop 
a vulvar SCC? (Chapter 5)
4. Is the malignant progression of LS and dVIN to vulvar SCC accompanied by 
altered DNA content? (Chapter 6)
5. Can we provide evidence for the fact that dVIN is a likely precursor of vulvar 
SCC based on the inflammatory response? (Chapter 7)

Chapter
Review of squamous premalignant 
vulvar lesions
H.P. van de Nieuwenhof
I.A.M. van der Avoort 
J.A. de Hullu
Critical Reviews in Oncology and Hematology 2008;68:131-56
Abstract
Vulvar squamous cell carcinom a (SCC) develops follow ing two different pathways, 
which have their own prem alignant lesions. In the absence of human papillom avirus 
(HPV), vulvar SCC can develop in a background of lichen sclerosus (LS), 
differentiated vulvar intraepithelial neoplasia (VIN) or both. The other pathway 
leading to vulvar SCC is associated with HPV and the HPV-associated prem alignancy 
is usual VIN.
In this review we will discuss the history, epidem iology, aetiology, histology, 
clinical characteristics, treatm ent options, malignant potential and prevention 
strategies of the three squamous prem alignant vulvar lesions.
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1. Introduction
1.1 Vulvar squamous cell carcinoma and its premalignant lesions
Vulvar squamous cell carcinom a (SCC) accounts for approxim ately 3-5% of all 
gynaecological m alignancies and 1% of all carcinom as in women, with an incidence 
rate of 1-2/100.000.43 In the Netherlands (16 million inhabitants) about 230 new 
patients with vulvar SCC are diagnosed.44 Typically, these cancers occur in the 
seventh decade when com orbidity is common. A rise in absolute numbers of 
vulvar SCC is expected because of the proportional increase in the average age of 
the population. Squam ous cell carcinom as (SCC) are the most common vulvar 
carcinom as. The cornerstone of treatm ent of SCC of the vulva is surgery.9 
There are two different types of vulvar SCC with their own associated prem alignant 
lesions (Figure 1). The most common type occurs in elderly women and leads to 
mostly differentiated keratinising SCC, in a background of lichen sclerosis (LS) and 
often differentiated vulvar intraepithelial neoplasia (dVIN).2There is no association 
with high-risk Human Papillom avirus (HPV) infection. dVIN is underreported, has 
a relatively brief intraepithelial phase before progression to invasive carcinoma, 
and is a d ifficult histological diagnosis.345 The oncogenesis of LS to vulvar 
carcinom a and its connection with dVIN is not exactly known.
The second type of vulvar SCC consists of mainly non-keratinising carcinom as and 
prim arily affects younger women. This type of vulvar SCC is caused by an infection 
with high-risk HPV, predom inantly HPV 16 and 18.246 This type of carcinom a is 
associated with w arty and/or basaloid VIN. These HPV-associated usual VIN 
(uVIN) lesions are seen adjacent to approxim ately 30% of the vulvar SCCs. In the 
processes associated with both progression to invasive disease and spontaneous 
regression of uVIN the immune system seems to play an im portant role.47 
M ulticentric HPV infections affecting both cervix, vagina and/or anus have been 
described, tw enty-tw o percent of uVIN patients has a concurrent cervical intra­
epithelial neoplasia (CIN)48 and up to 71% of uVIN patients has a previous, 
concom itant or subsequent history of vaginal intraepithelial neoplasia (VAIN), 
CIN or cervical carcinom a.49'51 Despite a stable pattern in the incidence of vulvar 
SC C ,5253 the incidence of uVIN and vulvar SCC is increasing in women aged 50 
years and younger.52 54'57 This might be due to a higher incidence of HPV infection 
of the genital tract and/or to an increased awareness of uVIN.
In this review an outline is given on vulvar prem alignant lesions. For an overview  
of vulvar carcinom as we refer to the review  of de Hullu et al.9 Clinical and 
histopathological characteristics, the different treatm ent m odalities and 
m alignant potential of prem alignant vulvar lesions are described.
HPV
? ?
Figure 1 Tw o  p a th w ays le a d in g  to  v u lv a r  SC C .
1.2 Data sources
Relevant studies were identified by a com puter search in the Pubmed database 
(last date of search February 4th 2008). We searched the medical literature using 
com binations of the follow ing terms: vulvar intraepithelial neoplasia, simplex, 
differentiated, usual, classic, VIN, lichen sclerosus, HPV, incidence, vaccines, 
vaccination, treatm ent, surgery, steroids, o intm ents, im iquim od, interferon, 
photodynam ic therapy, 5 fluorouracil, cidofovir, recurrence, progression, 
oncogenesis and m alignant potential. W ith the button 'related articles' in 
Pubmed, additional papers were identified. The reference lists from the selected 
artic les were used in order to identify other relevant publications. Also 
gynaecologic oncology handbooks and relevant theses were used.
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1.3 Diagnostics
1.3.1 Biopsy
Vulvar biopsy is the only method to get a histopathological diagnosis when there 
is a vulvar lesion of uncertain significance, or in the presence of persisting 
sym ptom s, such as vulvar irritation or itching. The optimal biopsy is a punch- or 
small incision biopsy, preferably taken from the edge of the lesion, including a 
small piece of normal tissue (Figure 2). In case of a suspected m alignancy, the 
biopsy should be taken from the most suspicious part of the lesion. A punch 
biopsy will produce a core-shaped specimen that is very small, but descends 
through the full thickness of the epithelium . It can be perform ed under local, 
topical anaesthesia. Infiltration anaesthesia, using lidocaine 1% (which may be 
combined with adrenalin), may be preceded by the application of EMLA® spray or 
cream, which contains lidocaine and prilocaine as a surface anaesthetic. 
D isposable punch biopsy devices are available, and a minimal size of 4 mm is 
advisable for a reliable diagnosis.
Figure 2 T a k in g  a p unch  b io p sy. 1) T h e  d isp o sa b le  p unch  b io p sy  d e v ice  sh o u ld  be p laced  
on th e  edge  o f th e  le sio n  w ith  n o rm al t is su e . In a g e n tle , tu rn in g  m ot ion, th e  p unch  sh o u ld  
be in se rte d  in th e  sk in . 2) A fte r  ca re fu l re tra ctio n  o f th e  d e v ice , th e  skin  co re  can be cut 
o ff, ca re fu lly  h o ld in g  it in p o s it io n  w ith  a tw e e z e r  to  p re ve n t cru sh  a rte fa c ts .
After taking the biopsy, pressure should be applied to the biopsy site, and when 
necessary for haem ostasis, the wound can be closed by one or two approxim ating 
resolvable stitches or by using a silver nitrate stick. When the lesion is multifocal,
the most divergent lesions should be biopsied to obtain the diagnoses of the 
entire vulvar area. O btaining the right diagnosis is greatly helped by providing the 
pathologist with a description of the clinical picture and providing a differential 
diagnosis. When the results of a punch biopsy are inconclusive, an incision or 
excision (especially in unifocal lesions that cause symptoms) biopsy can be an 
attractive alternative. A photograph can be taken for consultation with other 
medical specialties, to note the localisations of the biopsies that were taken, and 
to docum ent changes during follow  up (Figure 6B).
1.3.2 Vulvoscopy
Vulvoscopy consists of careful observation and the possible use of a 5% acetic 
acid solution the entire vulvar area to facilitate examination of the vulva by the 
colposcope. It may result in identification of previously unidentified, subclinical 
lesions and better define the distribution of clinically evident d isease.58 After 
application of acetic acid solution clearly dem arcated, dense acetowhite areas in 
the epithelium  and abnormal vascular patterns, like mosaicism and punctuation 
(which reflect the underlying capillary distribution) can be seen.58 However, 
acetow hitening has low sensitivity as a predictor of HPV infections,5960 although 
it can be used to determine the extent of the VIN lesion. Another disadvantage is 
the use of acetic acid, which can be very painful on ulcerative or de-epithelised 
lesions. In conclusion, vulvoscopy gives limited additional inform ation in the 
diagnostics of vulvar disease and the painful experience make that there is only a 
limited role for vulvoscopy. Moreover, perform ance of a biopsy remains required 
to establish the diagnosis.
1.4 Psychology and sexology
The effect of vulvar lesions on quality of life is unmistakable. Many LS patients 
feel em barrassed and have sexual problem s.61'62 Some psychological disturbance 
has been noted in surveys of women with LS, but this disturbance is thought to be 
a consequence rather than a cause of the disease.63 64 Patients may be embarrassed 
by the disfiguring changes that may occur and avoid sexual intimacy. Limited data 
that focus on the effect of LS on sexual function are available. A study regarding 
the impact of LS on wom en's sexual satisfaction showed that women with LS were 
less likely to be sexually active (vaginal intercourse, oral intercourse, and 
m asturbation) than controls.65 The m ajority of women with LS reported 
dyspareunia, apareunia and difficu lty achieving orgasms and 71% of the patients 
with a reduced frequency of intercourse experienced an im provem ent in sexual
functioning after treatm ent with topical stero ids.66 Introital dyspareunia in 
patients with LS may be related to three different causes; dryness of the vulvar 
mucosa, posterior synechiae of the labia minora and rarely introital stenosis. 
The dryness can be treated with topical steroids and lubricants. The synechiae 
of the labia minora and the introital stenosis may require limited surgical 
intervention.67
Also the diagnosis VIN can have a great im pact on the quality of life. In a review 
of eight studies on the sexual function for patients treated for VIN, only a small 
number of women had chronic vulvar pain after vulvar excision, however the 
m ajority of women did not return to baseline sexual function.68 The type of 
surgery significantly correlates with the m agnitude of sexual d ifficulties, with 
greater sexual problem s among those who underwent radical vulvectom y than 
among patients treated with wide local excision (W LE).69'71 However, in the study 
of Green et al. the sexual dysfunction after vulvectom y did not correlate with the 
extent of surgery or type of vulvectom y.72 Not all changes in sexual functioning 
after cancer treatm ent autom atically lead to sexual dysfunctioning. In patients 
treated for a gynaecological m alignancy, sexual dysfunctioning depended on 
personal and social factors, and the context in which changes in sexual functioning 
occurred.73 It is likely that this mechanism can also be applied to patients suffering 
from a vulvar premalignancy.
Most studies focussed on surgically treated patients; less inform ation is available 
about the initial effect of pain and pruritus, the two main com plaints in patients 
with LS and VIN lesions. Sargeant and O'Callaghan report that patients with vulvar 
pain have a significantly worse health-related quality of life in com parison with 
women w ithout vulvar pain. Moreover, women w ithout vulvar pain were 
significantly happier in their relationships than those with pain. In addition, 
women with vulvar pain reported significantly higher levels of distress related to 
sexual activities. It is im portant to teach a couple to broaden their sexual 
repertoire, such that intercourse does not become the major part of sexual 
activities. Assisting couples dealing with vulvar conditions may lead to an increase 
in couple happiness and a decrease in sex-related distress.74 
In conclusion, the number of studies regarding sexuality and LS and/or VIN is very 
limited. This im portant aspect of care for patients with LS and/or VIN deserves 
clinical and scientific attention.
2. Lichen sclerosus
2.1 History
Over the years, a variety of names and descriptions has been used for the disease 
that is currently named lichen sclerosus (LS). In 1892, Darier was the first to 
describe the histological features of the disease.7576 Lichen sclerosus et atrophicans 
has been an often used term for a longtim e. In 1975, the removal of 'et atrophicans' 
w as proposed by the Term inology Com m ittee of the International Society for the 
Study of Vulvar Disease (ISSVD, later the name was changed to International 
Society for the Study of Vulvovaginal Disease), because not all LS is histologically 
atrophic.77'78
2.2 Epidemiology
LS occurs at all ages, but not in neonates and is rare in the first year of life. It has 
a bimodal peak incidence in prepubertal girls and menopausal w om en.79 In a 
study to the prevalence of LS in childhood, a prevalence of 1:900 was found.80The 
m ajority of patients consists of women aged 50-70 years, while 5-15% of the LS 
patients are children.62 Recently, an increase in incidence in childhood LS was 
noted in the United Kingdom .80 No definite associations with age at menarche, 
menopause, first pregnancy or sexual intercourse, number of sexual partners, 
number of pregnancies, education, sm oking habits, Body Mass Index (BMI), 
hysterectomy, or use of oral contraceptives or horm one-replacem ent therapy 
have been found.76 81 However, the sym ptom s of LS can be modified by hormonal 
events in some w om en.82 The fem ale to m ale-ratio is 6:1-10:1,7576 and most 
reports have been on Caucasians. In young girls, the signs and sym ptom s of LS are 
som etim es mistaken for sexual abuse.83 However, childhood LS and sexual abuse 
are not m utually exclusive diagnoses.84 In a series of 42 cases of childhood LS, in 
12 cases there was evidence of sexual abuse.85
The true incidence of LS is unknown and d ifficult to establish as the care of 
patients is fragm ented: specialties treating LS include derm atology, gynaecology, 
urology, geriatrics, fam ily medicine and paediatrics, depending on the location of 
the disease and the patient's age and the responsiveness to therapy. Furthermore, 
patients can feel em barrassed or frightened and not visit any doctor or have LS 
that runs an asym ptom atic course.62 86 No recent studies of the incidence of LS in 
the general population are available. In 1971, W allace calculated incidences of 
1:300 to 1:1000 in new patients, referred to a general hospital.87 Only a limited 
number of studies report on the prevalence or incidence of LS in specific groups
of patients. Am ong women with chronic vulvar sym ptom s 7-13% suffered from 
l _ S  s s . s s  y^g rate 0f biopsy proven vulvar LS in one general gynaecology private 
practice was approxim ately 1.7% (1 in 60 w om en).79 One study suggests that 1 in 
30 elderly women (nursery home population) has LS.90
2.3 Aetiology
Based upon epidem iologic data, a number of m echanism s have been proposed to 
explain the cause and developm ent of LS. As the highest incidence of LS is 
observed in patients with low oestrogen physiological states (prepubertal girls 
and postm enopausal women), hormonal factors have been suggested as a cause 
for LS. Friedrich and Kalra have shown apparent underlying abnorm alities in 
androgen metabolism (defect in 5 alpha reductase) in women with LS.63 However, 
neither oestrogens nor testosterone bring benefit in terms of treatm ent of 
sym ptom s or prophylaxis of the disease.63 91
There is a strong association of LS with autoim m une disorders. Between 21.5 and 
34% of all patients have an autoimmune disease and up to 74% are found to have 
auto-antibodies.92'94 Alopecia areata and vitiligo were the most common 
associated disorders, but thyroid disease, pernicious anaemia, diabetes mellitus, 
and cicatrical pemphigoid were also reported.62'92'93 95 Nevertheless, no statistically 
significant differences in the natural history of LS were noticed between those 
patients with autoim m une disorders and those w ithout associated autoimmune 
disorders.91 In patients with LS, the fam ily history for autoim m une disease is 
often positive.96 There is no evidence that screening for autoim m une disorders in 
LS patients is beneficial.97 However, thorough history taking is im portant and 
when there are signs and sym ptom s of concurrent disease, appropriate tests 
should be ordered. Im m unogenetic studies have dem onstrated a significant 
association with HLA class II antigens, particularly DQ7.62'98 This association was 
strongest in the patients with early-onset LS.96 Most HLA class 11-related diseases 
(rheumatoid arthritis, lupus erythem atosus) have an im m unologic basis. This 
suggested im m unogenetic profile may be one of many presumed factors involved 
in LS developm ent, extent, and risk of m alignancy.98 The frequency of one of the 
alleles of the interleukin l receptor antagonist (I L-1RN) gene is related to increasing 
disease severity. Thus, IL-1RN may be a candidate gene or severity factor for LS or 
may possibly be a linked marker to another, as yet undefined, gene.99 Studies by 
Carli et al. give support to the involvem ent of the skin immune system  in 
pathogenesis of LS.100'101
A genetic influence favouring LS can be derived from fam ilial LS reports.6291 LS 
has been reported in identical and non-identical tw ins,93'95 sisters, and mothers 
and daughters.96 However, no consistent genetic pattern has been determined 
and the number of case reports of fam ilial LS is limited.
Several infectious agents have been postulated to induce LS, but such a 
relationship has not been conclusively dem onstrated.102 LS shares several clinical 
and histological signs with morphea and acroderm atitis chronica atrophicans 
(ACA), which both have been associated with Borrelia burgdorferi. Borrelia has 
been identified in sam ples of LS by modified silver stain,103 and using immunoper- 
oxidase m ethods.104 However, polym erase chain reaction (PCR) assessm ent has 
yielded conflicting results, summed up by W eide et al.105 In Europe and Asia, 
borrelial DNA was detected in nine of 28 of the cases with LS, whereas in the 
United States (US) none of 48 patients was positive. Possible explanations are 
that a subset of LS is caused by a special subspecies of B. burgdorferi that is 
present in Europe and Asia but does not occur in the US, or that B. burgdorferi is 
no causal inducer of LS. Also technical differences of the detection methods 
might contribute to the difference. In some LS lesions however, B. burgdorferi 
might very well play a role as an observational study by Shelly et al. showed 
positive effects of penicillin and cephalosporin therapy on patients with LS who 
had responded poorly to treatm ent with potent topical corticosteroids. All 
patients (n=13, four men and nine women) showed a significant response, evident 
within a few w eeks.106 A small study of only four LS patients, suggested an 
aetiological role of M ycobacterium  because of the finding of acid-fast bacteria in 
all skin biopsies.107 Furtherm ore, hepatitis C (HCV) has been suggested because of 
a case-report of LS associated with chronic hepatitis C and the suspected but 
non-proven association of HCV with lichen (ruber) planus.108 
No relationship between HPV infection and LS was found in w om en291 but has 
been shown in men.109111 In a study of 23 boys (4-14years) with penile LS, HPV-DNA 
was detected with PCR in 70% ,112 although it is not clear w hether there is a causal 
relation between LS and HPV. Powell et al. compared genital carriage of HPV DNA 
in prepubertal girls with and w ithout vulvar disease and concluded that HPV 
appeared to be common in all pre-pubertal girls, but children with LS more often 
carried high-risk HPV types and their mothers had a high incidence of abnormal 
cervical sm ears.113
In the itch-scratch-lichen sclerosus hypothesis, LS is postulated to occur as a 
Köbner phenomenon (the occurrence of LS lesions at sites of injured skin) in 
women with the susceptible im m uno-phenotype who scratch because of genital
irritants.114115 W him ster showed that healthy skin grafted onto the vulva became 
affected by LS and a full-th ickness graft from diseased vulva transplanted onto 
the thigh became norm al.62 This suggests that local dermal factors may facilitate 
disease expression. This hypothesis is supported by a recent study that showed 
that the use of m oisturizer on LS-affected vulvar skin helps to prevent relapse 
after use of derm atocorticosteroids.116 In childhood LS, it has been postulated 
that sexual abuse could trigger LS as a Kobner effect.117
In conclusion, no cause for LS has been found. Careful history taking remains 
im portant and further research is needed. When the aetiology is clarified, more 
specialised and targeted therapies can be developed and prevention might be 
possible.
2.4 Histology
The classical histological features of LS include a thinned epiderm is with loss of 
normal rete pegs, basal layer vacuolar changes, and paucity of m elanocytes.118 
Furtherm ore, a wide band of homogenised collagen below the derm o-epiderm al 
junction and a band-like lym phocytic infiltrate below the homogenised area are 
present. The derm is shows variable degrees of oedem a.61'7991 Oedema is a stage 
of LS. After oedema, hyalinisation and fibrosis can occur. In severe cases the 
subepithelial vacuolar change may progress to the form ation of bullae.118 A certain 
degree of spongiosis and vacuolar degeneration may exist in the cells of the 
deepest layer. Hyperkeratosis and follicular plugging are highly variable, but 
may be m arked.118 An example of the typical histology of LS can be found in 
Figure 3A.
In a recent 'Clinical Opinion' by Jones et a i, it was suggested that it should be the 
role of the pathologist to firstly diagnose LS, then place it into one of the follow ing 
three categories: atrophic (classic) LS, LS with histological evidence of epidermal 
thickening, and LS with dVIN.119
Recently, Regauer et a i have introduced a hypothesis describing early LS as a 
separate entity. The histological features that they describe as belonging to early 
LS are quite subtle, and often more prom inent in the adnexal structures than in 
interfollicular skin. Biopsy specim ens of early LS rarely display all features that 
they describe as typical for early LS.120 So far, no studies follow ing this concept 
have been described, and up till now there has been little debate about the 
concept of early LS.121 Regauer's criteria have not gained any acceptance and have 
no pathogenetic basis.
Figure 3 Histo logical p ictures of lichen sclerosus, d ifferentiated VIN, usual VIN and vu lvar SCC. 
A) In lichen sclerosu s the  epithelium  is th inn ed  and w ith ou t atyp ia . Th ere  is loss of rete ridges, 
a hom ogenous, hyalin ised zone of oedem a beneath the  basem ent m em brane and a bandlike 
in filtrate  of lym p ho cytes B) H&E sta ined  slid es of a d ifferentiated  VIN lesion (adjacent to  SCC). 
N uclear atyp ia  and the  presence of m itotic figures in d ifferentiated  VIN are confined  to  the 
basal cell layers. H yperkerato sis  and dyskerato sis  are present and the  rete ridges are e lo ngated. 
C) H&E sta ined  slide  of a usual VIN lesion w ith ou t ad jacent SCC; atyp ica l nuclei can be found 
th ro u gh o u t the  entire  epith elium . D) Invasive  nests of vu lva r SC C  (adjacent to  d ifferentiated
2.5 Clinical characteristics
LS runs a relapsing and rem itting course and there is a poor correlation between 
the extent of the clinical signs and the sym ptom s.86 At least one third of patients 
may be asym ptom atic.79 Com plications, most often encountered in severe cases 
of LS, are secondary infection, adhesion of the clitoral hood with form ation of a 
sm egm atic pseudocyst and narrow ingof the introitus, which can make intercourse 
im possible and m icturition difficu lt.76
Next to the genital form of LS, in 11-20% of the patients, extra-genital m anifestation 
of the disease is present.122 123 These can be found on the trunk and neck, upper 
legs, around the w rists and on the head. Extragenital LS consists of white papules 
and atrophic maculae. Sporadically, an oral form of LS, w ithout genital or 
cutaneous m anifestations, is described, which consists of asym ptom atic white 
macular lesions.124 125 Most extra-genital m anifestations of LS are asym ptomatic, 
however some rare cases of severe itching of the scalp have been described.122 
Because other derm atoses, such as lichen (ruber) planus, vitiligo, psoriasis inversa 
and oestrogen deficiency, can mimic LS, the diagnosis in adult patients should 
preferably be confirm ed with a punch biopsy,6191 perform ed as described earlier 
(see Paragraph 1.3.1).
2.5.1 Signs
Typically, the lesions are white plaques and papules, often with areas of erythema, 
ecchymosis, hyperkeratosis, pallor, fissuring, telangiectasia, hyperpigm entation, 
bullae, excoriation, oedema and/or ulceration. The signs can vary from subtle 
(Figure4A) to very extensive (Figure4B). In advanced LS, often there is destruction 
of vulvar architecture, with scarring of the clitoral prepuce, resorption of the 
labia minora and narrowing of the introitus.79 Typically, there is a figure of 
eight-pattern in the genital area, as can be seen in Figure 4B. The labia minora 
and majora are most frequently affected, but the entire vulva, perineum and 
peri-anal area can be affected .58 In contrast with lichen (ruber) planus, in LS, the 
vaginal mucosa is usually unaffected, however incidental cases of vaginal LS have 
been reported.126 In an extensive study by Cooper et al., pallor and atrophy 
(wrinkled skin and textural change) were the most frequent findings in both adults 
and children (in 89% and 62% of patients, respectively). Erythem a, atrophy, pallor, 
hyperkeratosis, and ulceration were all significantly more frequent in women but 
purpura was more frequent in children (p=0.001).123 An example of prepubertal 
LS can be seen in Figure 4C.
2.5.2 Symptoms
Presenting sym ptom s of LS may include intense pruritus, soreness, pain, burning, 
dyspareunia, dryness, irritation, urinary com plaints, constipation/bow el pain, 
bleeding and blistering. Painful skin fissures can occur with or after sexual 
intercourse and defecation. Anogenital pruritus and soreness are the most 
frequently reported sym ptom s in both women and children. Prepubertal girls 
usually present with soreness or itching of the vulva, constipation or dysuria. The
Figure 4 C lin ica l p icture  of d ifferent patients w ith lichen scle ro su s. A) Lichen scle rosu s in a 
pre -m en o pau sa l w om an sho w in g  sub tle  loss of a rch itectu re  and erythe m a. B) A d vanced  stage 
lichen scle rosu s in a p ostm eno pa usa l w om an, sho w in g  the  typ ica l 'figure  of e ight'. C) Lichen 
scle rosu s in a p rep ub erta l girl.
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signs of LS in young girls may be confused with those of sexual abuse, especially 
because of local bleeding.7680123 As described earlier, LS and sexual abuse may 
coexist (Paragraph 2.2 Epidem iology).
2.6 Treatment
2.6.1 Introduction
In general, LS has no cure in adults, and lifelong treatm ent is required. However 
in some cases, especially prepubertal girls, LS can spontaneously resolve.61127 The 
reasons for treating LS are alleviating and m inim ising sym ptom s and the possible 
prevention of architectural changes.6186 120 127 It is not known w hether successful 
control of the disease reduces the long-term risk of m alignancy,128 although a 
protective effect from m alignant evolution is suggested.127
2.6.2 Surgery
The role of surgery for the treatm ent of LS is limited in the absence of dVIN or 
m alignancy.6186129 Surgical options include vulvectom y (with or w ithout a skin 
graft), laser ablation and cryosurgery. There is a high recurrence rate in patients 
with LS who have been treated with surgery, even if full thickness skin grafts have 
been placed.61 86 129 Next to architectural changes due to surgery, scarring can 
cause additional anatom ical changes. Therefore, surgical treatm ent of LS should 
be used as a last resort to release a buried clitoris, to separate fused labia or to 
widen a narrowed introitus. Perineoplasty can provide good functional results for 
women with introital stenosis related to LS.67 Vaginal dilation and corticosteroids 
may be necessary after operation.
2.6.3 Medical
2.6.3.1 Dermatocorticosteroids
The treatm ent with the best evidence of efficacy is topical ultrapotent 
corticosteroid ointment. Corticosteroids have anti-inflam m atory, antipruritic, 
and vasoconstrictor effects. Various studies show good clinical response and 
histological im provem ent with the use of these drugs.86 123 127 128 The use of 
ultrapotent topical steroids for LS has now become accepted for fist-line 
management of LS in both children and adults. Recent British Association of 
Derm atologists (BAD) (w w w .bad.org.uk) guidelines advocate their use, and give 
specific guidance on length of initial treatm ent and on m aintenance treatment. 
There have been no randomised controlled trials on the efficacy of corticosteroids, 
but evidence for efficacy comes from several small case series.130 132 Ultrapotent 
topical steroids can reverse some of the histological changes caused by LS,120 130 133 
however there is no convincing evidence that the treatm ent of LS influences 
its prognosis. Cooper et al. investigated the reversibility of clinical signs with 
treatm ent. They stated that in some patients no signs of LS were present at
follow -up, but there is no inform ation on the recurrence rates after use of 
ultra-potent steroids was stopped.123
There is no universally accepted treatm ent schedule. In general, short-term  use 
of an ultrapotent corticosteroid is followed by less frequent use of the high-potency 
steroid (or long-term use of a lower potency topical steroid). Thickened 
hypertrophic plaques may respond better to intralesional steroids, which can be 
given in combination with prilocaine.134 The side effects of topical corticosteroids 
are burning, irritation, dryness, flaking, m aceration, hypopigm entation, and 
dermal atrophy. M aintenance therapy is often advised, as sym ptom s can recur in 
women who term inate therapy.86 128 Long-term m aintenance therapy of vulvar LS 
with a m oisturising cream can maintain the symptom relief induced by topical 
corticosteroids.116 However, this study was perform ed as an open trial w ithout 
the use of a control group that did not use a moisturizer.
2.6.3.2 Testosterone
Som e reports have noted that patients with LS have decreased serum levels of 
testosterone compared to age-m atched controls w ithout the disease.63 Topical 
treatm ent with testosterone has been used and controversy exists about its 
effectiveness.135 Topical testosterone can cause virilisation (clitoral enlargem ent, 
voice alterations), especially in hyperandrogenic w om en.136 
In a prospective, randomised, double-blind evaluation of 58 cases of vulvar LS, 
2% testosterone propionate was as effective as petrolatum 137 and in several 
studies it was less effective than clobestasol.138 139 Numerous studies emphasise a 
lack of efficacy and report severe side effects of testosterone; therefore 
testosterone is considered to be obsolete now adays.61'76 86136
2.6.3.3 Retinoids
Retinoids are vitam ins, because retinol (vitamin A) is not synthesised in the body 
and must be derived from diet. Retinoids are also considered hormones because 
retinol is transform ed into m olecules that bind to nuclear receptors, exhibit their 
activity, and are subsequently inactivated. Topical retinoids normalise hyperk- 
eratinisation and have dem onstrated significant anti-inflam m atory effects. Skin 
diseases like psoriasis and related disorders, congenital disorders of keratinisation, 
acne, photo-aging and hypovitam inosis A are approved indications of retinoid 
treatm ent.140
Retinoids appear to reduce connective tissue degeneration in LS. Although orally 
adm inistered retinoids showed good results, use of these drugs is limited because
of significant and potentially harmful side effects such as cheilitis, xerosis, 
teratogenicity, elevated liver enzymes, hypertriglyceridem ia, abdominal pain, 
and alopecia. Therefore, retinoids should be saved for severe LS cases that are 
non-responsive to corticosteroid treatm ent, and consultation with a derm atologist 
is recom m ended before initiating therapy.6186
2.6.3.4 Tacrolimus /  pimecrolimus
Tacrolim us and pim ecrolim us have an anti-inflam m atory and im m unom odulating 
effect and were first introduced as a new second-line treatm ent for atopic 
derm atitis. The main side effects are local sensation of heat and burning and 
therefore it is often discontinued by patients.91141 New research has been 
published on the use of tacrolim us and pim ecrolim us for LS and reported to be 
successful.141 No long-term  effects of tacrolim us and pim ecrolim us use in LS 
patients have been investigated and described yet. Although tacrolim us is not 
genotoxic and does not interact directly with DNA, it may have a potential to 
impair local im m unosurveillance. Carcinogenicity studies conducted with topical 
application of tacrolim us in mice dem onstrated a dose-dependent developm ent 
of lymphoma. At the Food and Drug Adm inistration (FDA), 19 cases of tacrolim us 
(Protopic)-related m alignancies have been reported, including nine lymphomas,
10 cutaneous tum ours, seven of which occurred at the site of tacrolim us 
application, as well as cases of SCC, cutaneous sarcoma, malignant melanoma 
and other tum our types. Therefore the use of tacrolim us should be limited and 
preferably conducted in a w ell-designed study.
2.6.3.5 Other
Various other (experim ental) treatm ents for LS have been summed up in recent 
review  articles: antim alarial agents, oral potassium  para-am inobenzoate, 
calcipotriol, oxitom ide and photodynam ic therapy using am inolevulinic acid. 
However, the number of cases in these studies is limited and the results are 
inconclusive.62'86'91'141
2.6.4 Supportive care
Correlated com plaints of LS should also be treated. Topical oestrogen is 
recom m ended for vaginal atrophy. In secondary infections, antibacterial- or 
antifungal therapy may be needed. Vulvodynia may be treated with xylocaine 5% 
(or 3%) ointm ent and antidepressants are a treatm ent option in unresponsive 
cases.6176 Nocturnal itching can be relieved with antihistam ines like hydroxyzine
hydrochloride (10-40 mg A.N.); the sedative effect contributes to its usefulness 
to relieve pruritus.
In general, and especially in patients with LS, vulvar care and hygiene is im portant: 
use lipid-rich neutral creams (e.g., cremor lanette) to soften the skin, no or only 
neutral soap, cotton underwear, no panty liners and scratching should be avoided. 
The use of lubricants to facilitate sexual intercourse is recom m ended.128 Recently, 
the results of a prospective non-random ised trial were published, showing that 
long-term  m aintenance therapy of vulvar LS with a m oisturising cream can 
m aintain the symptom relief induced by topical corticosteroids.116 W ritten 
inform ation and inform ation about support groups should be offered.128
2.7 Malignant potential
There are different reasons to link LS to the developm ent of vulvar SCC.142 First, 
the m ajority of vulvar SCCs has LS, squamous cell hyperplasia or dVIN in the 
adjacent epithelium . In up to 62% of cases of SCC of the vulva, LS can be found in 
adjacent areas.2829 Furtherm ore, as reported in m ultiple case reports, patients 
(old and young) with LS may develop vulvar SCC. Third, in series of LS patients 
that underwent long-tim e follow -up, 2-6% has been reported to develop vulvar 
SC C.29'30
A protective effect from symptom control is suspected but has not been proven.123 
Neither the presence nor duration of sym ptom s nor the loss of vulvar architecture 
is a useful indicator of malignant potential in LS.123
There is an impression that itch and scratch damage (related to the duration of 
symptoms), is associated with the risk of developing vulvar SCC.114 Chronic 
inflamm ation seems to play an im portant role, but the exact pathogenesis of 
progression to m alignancy has not yet been established.91 The im m unogenetic 
profile may also determ ine (part of) the risk of malignant disease.76 
Extra-genital LS is not associated with m alignancy,91 and could prove to be an 
interesting control group in the search for factors that determine the risk of 
malignant transform ation in vulvar LS. Furtherm ore, the exact mechanism of 
m alignant progression remains to be elucidated. dVIN is the possible precursor 
lesion of HPV-negative SCC but the exact pathogenesis from LS to dVIN and a 
subsequent SCC is unknown. Some authors claim a role for squamous cell 
hyperplasia as a next stage after LS in the developm ent of HPV-negative vulvar 
SCC but the exact pathway rem ains to be e lucidated.143 Recently, high 
p53-expression in LS has been postulated as a marker for increased likelihood to 
progress to vulvar SC C.39144
2.8 Prevention
Since the cause of LS is unknown, no prevention strategies are available. It has 
been suggested that an early start with derm atocorticosteroids might prevent 
signs of advanced LS in patients with early LS.120 It has been suggested that 
treatm ent with steroids also prevents the developm ent of a m alignancy. The 
long-term follow -up of women with LS has been addressed in the guidelines series 
of the British Association of Derm atologists (BAD); it is suggested that yearly 
follow -up and examination should be undertaken. Balasubram aniam  and Lewis 
audited the rate of follow -up by general practitioners (GPs) after discharge from 
secondary care. Tw enty-six percent of patients had not been seen for two years 
after discharge, and 38% had never seen their GP at all. Seventeen percent had 
seen their GP specifically about their LS but had not been examined. Interestingly, 
82% of patients were receiving ongoing therapy for their LS.145 There is no 
evidence that fo llow -up in LS leads to earlier detection or prevention of a vulvar 
malignancy. However, a prospective study by Oonk et al. indicated that routinely 
scheduled follow -up m eetings with patients treated for vulvar carcinom a resulted 
in the detection of sm aller recurrences in a substantial proportion of patients 
compared with self-reported recurrences.146 It is recom m ended that women with 
vulvar LS are followed in specialised clinics when d ifficu lty exists with symptom 
control or when there is clinical evidence of localised skin thickening. Follow-up 
by a specialist (instead of a GP) is also recom m ended when the pathologist 
expresses concern and is unable to make a definitive diagnosis of dVIN.119
3. Differentiated Vulvar Intraepithelial Neoplasia
3.1 History
dVIN was first described in the 1960s by Abell as a highly differentiated form of 
vulvar carcinoma in situ (CIS) and designated 'intraepithelial carcinom a of simplex 
type' to distinguish it from 'intraepithelial carcinom a of Bowen's type' (which 
nowadays would be called uVIN). In 1977, the term 'differentiated' was introduced 
to highlight the marked differentiated m orphologic features of this entity.4 In the 
subsequent ISSVD revisions of the classificatio n that fo llow ed, 'VIN 3, severe 
dysplasia, d ifferentiated type' was replaced by the current term 'VIN, 
differentiated type'. The nom enclature of the WHO spoke of 'carcinoma in situ 
(simplex type) (VIN3)'.
3.2 Epidemiology
dVIN accounts for a small proportion (<2-5%) of all VIN lesions compared with the 
usual type.51147 Because of a d ifficult clinical and histological diagnosis there 
probably is a considerable underdiagnosis. dVIN characteristically occurs in 
postm enopausal women (mean age 67 years) and is associated with LS.4 As dVIN 
is seldom found in an isolated form, some authors believe it is actually part of the 
adjacent vulvar SC C.42 In cases where dVIN is found w ithout any sign of invasion, 
often the patient has been previously treated for vulvar SCC, and also suffers 
from LS,148 however also isolated dVIN lesions can occur in patients w ithout a 
history of vulvar SCC. Isolated dVIN is believed to have high malignant potential. 
Unlike uVIN, dVIN is mostly un icentric.5
3.3 Aetiology
HPV is very uncommon in dVIN and does not play an im portant role in its 
genesis.5 147149150 The aetiology of dVIN remains to be elucidated. Because of its 
high concurrence with LS, a causative role for LS is likely but also other factors 
might play a role. Squam ous cell hyperplasia has a close relationship to dVIN. 
However, it is still unclear w hether it is a direct precursor of invasive vulvar SC C .5 
Squam ous cell hyperplasia with atypia might represent a step in the 
carcinogenesis.151 Some have suggested a role for p53-alterations but a study by 
Regauer et al. suggested that p53-expression in LS is a sign of ischem ic stress 
rather than a sign of dVIN.42
3.4 Histology
Histologically, dVIN is a more subtle lesion than uVIN and can be mistaken easily 
for a benign derm atosis or epithelial hyperplasia. The recognition of dVIN is 
hindered by a high degree of cellular differentiation combined with an absence of 
w idespread architectural disarray, nuclear pleomorphism  and diffuse nuclear 
atypia.152 The atypia in dVIN lesions is strictly confined to the basal and parabasal 
layers of the epithelium , where the cells have abundant cytoplasm  and form 
abortive pearls.4 58 Scattered mitotic figures are common in the basal areas, but 
can extend into the upper levels of the epiderm is.5 Typically, the epiderm is is 
thickened and has a parakeratotic surface reaction.4 The nuclei are relatively 
uniform in size and contain coarse chromatin and prom inent nucleoli leading to 
paradoxical m aturation abutting on the epithelial-strom al junction. The superficial 
layers of the epithelium  have normal m aturation and do not show koilocytosis. 
Furtherm ore, in dVIN the epithelium  exhibits elongation of rete pegs.558147
Intercellular bridges typically are very prominent, probably as a result of loss of 
cohesion between cells rather than spongiosis.4 dVIN is characterised by an 
increased amount of eosinophilic cytoplasm  in dysplastic cells im m ediately above 
the basal cell layer. This is indicative of premature differentiation or keratinisation. 
At low power, the epithelium  looks eosinophilic because of the large amount of 
intracytoplasm ic keratin. These abnormal keratinocytes are the hallm ark of dVIN. 
At higher power, nuclear changes of enlargement, pleomorphism, hyperchromatism 
and mitoses are present.4,58 148 In the underlying or adjacent papillary dermis, a 
chronic inflam m atory cell infiltrate, consisting of predom inantly lym phocytes, 
plasma cells, and occasionally eosinophils, is present4 (Figure 3B).
When dVIN invades the dermis, nodules of enlarged eosinophilic keratinocytes 
appear to fall from the basilar epiderm is or from  elongated rete ridges. 
In superficial biopsies, the distinction of dVIN from early invasive vulvar squamous 
cell carcinom a may be d ifficu lt.4
The use of MIB1 can be helpful to distinguish between normal vulvar epithelium 
and dVIN as the basal cell layer in dVIN has a higher proliferation index (percentage 
of MIB1 positive cells), than normal vulvar epithelium , where the basal cell layer 
often is negative for MIB1.153 Im m unostainingfor p53 may be of value in identifying 
dVIN in d ifficult cases. The p53-labeling-index (LI) of the basal cell layer in dVIN is 
often >90%, and p53-positive cells extend above the basal cell layer (suprabasilar 
extension) into higher levels of the epiderm is.5
3.5 Clinical characteristics
3.5.1 Signs
dVIN is infrequently seen as a solitary lesion, and is more comm only identified 
adjacent to LS and/or invasive SCC. However, also a patient with dVIN that 
developed vulvar SCC w ithout presence of LS has been described.154 
It can present as an area of grey-white discoloration with a roughened surface 
(Figure 5A), an ulcerative red lesion (Figure 5B), an erythem atous red lesion 
(Figure 5C and D), or as an ill-defined raised white plaque. It may be difficult to 
distinguish from the often-present background of LS .5 In general, dVIN is believed 
to produce less bulky lesions than uVIN does. Yang and Hart described a series of 
12 patients with lesions varying from 0.5-3.5 cm in greatest dim ension.5
3.5.2 Symptoms
Patients are, due to the underlying LS, often sym ptom atic with a long-lasting 
history of itching and other LS-related symptoms (described in Paragraph 2.5.2).5
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Figure 5 C lin ica l p ictures of d ifferentiated  V IN . A) D ifferentiated  VIN arising  in a background 
of lichen scle rosu s. An incision b iopsy w as taken  at the  site of the  e llipse  and show ed 
d ifferen tiated  V IN . H isto lo gica l exam ination  of the  excision  of the  entire lesion revealed vu lvar 
squ am o us cell carcinom a, w ith a depth of invasion of m ore than 1 m m . B) D ifferentiated  VIN in 
a patient w ho w as treated  by m ultip le excision s and a vu lve cto m y w ith p lastic su rge ry  because 
of th e rap y  resistant lichen scle rosu s. C) Th e  red lesion w ith in  the  dotted line did not im prove 
upon d erm ato co rtico ste ro id  application  and w as rem oved by excision al b iopsy. Th e  h isto logy 
show ed d ifferentiated  V IN . D) A  c lo se-u p  of the  d ifferen tiated  VIN lesion.
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3.6 Treatment
dVIN generally requires a more extensive surgical approach than uVIN, and as 
dVIN often is unifocal, radical surgical excision is the preferred treatm ent. dVIN is 
usually confined to non hair-bearing areas or the external sides of atrophic labia 
minora, where vulvar reconstruction is feasible. Recurrent lesions are common 
and so far, there is no place for medical therapy.147 Follow-up of patients previously 
treated for dVIN should occur at a specialised vulvar clinic or by a vulvar specialist 
(a consultant derm atologist or gynaecologist who has had additional and educated 
training in managing vulvar disease).119
3.7 Malignant potential
dVIN is associated with the developm ent of keratinising SC C .5155 The exact 
pathway of carcinogenesis has not yet been established. It is suggested that dVIN 
is highly proliferative and might be more likely to progress to an invasive SCC than 
LS and uVIN.5 154 156 The observation that most SCCs are dVIN-related and most 
VIN lesions w ithout concurrent invasion are of the usual type, combined with the 
frequent finding of dVIN adjacent to rapidly growing invasive vulvar SCC, reinforces 
this presum ption.2 5 Therefore, any suspicious area should be biopsied.5147
4. Usual Vulvar Intraepithelial Neoplasia
4.1 History
H istorically, various term s have been used to define vulvar SCC precursors. 
In 1912, Bowen described 'squam ous intraepithelial lesions' (also referred to as 
Bowen's disease) and since then a myriad of clinical and histopathological terms 
have been employed to describe what is currently known as uVIN.147 The first 
series of Bowen's disease of the vulva was described in 1943 by Knight et al. 
referred to in157. In 1965, Kaufman separated non-neoplastic from neoplastic 
vulvar lesions. He divided the precancerous lesions into three groups: Queyrat's 
erythroplasia, Bowenoid carcinom a in situ, and carcinom a sim plex.147 In 1976, the 
ISSVD sim plified the term inology: carcinom a in situ and vulvar atypia were 
replaced by Vulvar Intraepithelial Neoplasia (VIN).147 According to our Pubmed 
search, VIN was introduced into medical literature in 1980.
4.2 Grading
For vulvar grading, two system s have been used. The three-grade system of the 
ISSVD made a subdivision between the lesions according to the amount of 
epithelium  involved by dysplasia, similar to CIN lesions. In VIN 1 the m aturation is 
present in the upper tw o-thirds of the epithelium , and the superficial cells contain 
variable but usually mild dysplasia. In VIN 2 the dysplasia involves the lower 
two-third of the epithelium , and in VIN 3 the dysplasia extends into the upper 
third of the epithelium , but not involving the full th ickness.58 158 When the entire 
epithelium  is involved, the lesion is classified as carcinom a in situ, which is 
gathered in VIN 3. The two grade system  of Bethesda makes a subdivision between 
Low grade vulvar intraepithelial lesions (LGVILS) and High grade vulvar intrae­
pithelial lesions (HGVILS).150 We will discuss both system s of grading.
4.2.1 ISSVD classification
In 2003, the ISSVD decided to abolish the three grade system  of VIN because 
clinicopathological data did not appear to support the concept of a continuum 
spectrum  of VIN lesions leading to vulvar carcinom a, that does exist for CIN and 
cervical carcinom a.3147 The abandonm ent of VIN 1 and the consolidation of VIN 2 
and 3 into one category simply termed (high-grade) VIN, best fitted the studies 
that have been perform ed on grading of VIN so far.3 In Table 1 an overview  of 'old' 
and 'new' nom enclature is given. VIN as a single diagnostic category included two 
different vulvar prem alignancies that have a different malignant potential.147 
In the light of the two different types of vulvar carcinom a the VIN term inology 
has been modified by the ISSVD, and a 2-tier classification has been suggested: 
VIN usual type and VIN differentiated type.3159 uVIN has been divided into basaloid 
and w arty subtypes. The w arty subtype was earlier described as Bowen's disease. 
Basaloid VIN occurs in an older age group, is more likely to become invasive and 
less likely to regress. These two subtypes may be seen in a single VIN lesion and 
cases with mixed features are com m on.159 Both subtypes are associated with 
high-risk HPV types, especially HPV 16, often occur as m ulticentric genital tract 
neoplasia and should be considered as prem alignant lesions.147 In clinical practice, 
no difference is made between the two uVIN lesions. For dVIN, we refer to 
Chapter 3 of this review.
4.2.2 Bethesda classification
Many gynaecologists and some pathologists have suggested analogous term s of 
high-and low-grade changes of the vulva as also exist for CIN lesions. In 2005,
Old nomenclature New nomenclature3
VIN 1 No cancer precursor
(Classic) VIN 2/3 Usual VIN (uVIN)
Warty VIN
BasaloidVIN
Mixed (warty-basaloid)
(Well-)differentiated VIN 3 / VIN simplex Differentiated VIN (dVIN)
Table 1 O v e rv ie w  o f th e  old and new  n o m e n c la tu re  of V IN  le s io n s.
M edeiros et al. proposed a Bethesda-like grading system of low and high-grade 
vulvar intraepithelial lesions: low grade vulvar intraepithelial lesions (LGVILS) and 
high grade vulvar intraepithelial lesions (HGVILS).150 When a Bethesda like system 
is applied to vulvar histopathology, by far most frequent lesions fitting  into the 
LGVILS category are condylom ata acuminata, which carry a negligible risk for 
m alignant progression and require no follow up. It seems inappropriate and 
unnecessary that such lesions are placed in a new category of vulvar prem alignant 
lesions.159
In our opinion a Bethesda-like grading system is not sufficient because no 
distinction is made between uVIN and dVIN. Because of the extensive differences 
in clinicopathological behaviour and m alignant potential between uVIN and dVIN 
lesions, we favour the above-m entioned ISSVD classification.
4.3 Epidemiology
The incidence of uVIN is approxim ately five per 100.000 women per year and 
increasing w orldw ide.160 In several countries the age-adjusted incidence rates 
have surpassed the incidence rate of invasive vulvar carcinom a.52 55161162 uVIN has 
a predilection for relatively young women, often in their 30s and 40s. Cigarette 
sm oking is reported in about 60-80%  of the cases. Condylom ata, a history of 
genital herpes, and infection with Human Im m unodefiency Virus (HIV) are 
particularly common in young women with uVIN.4 Moreover, the use of im m uno­
suppressants to prevent rejection after transplantation or to treat a chronic 
autoim m une disease increases the risk of developing uVIN. The increase in 
incidence of uVIN lesions is in concordance with the increase in HPV prevalence. 
Despite the increase in uVIN, no increase in the overall incidence of SCC of the
vulva was found.52 53 In young women an increase in SCC incidence is seen, possibly 
due to the younger age of first sexual intercourse and the increasing incidence of 
HPV infections.52 54'57 162 The increase of uVIN w ithout a clear increase of vulvar 
carcinom a may have different reasons. The main reason is the more liberal use of 
vulvar biopsy, which contributed to earlier diagnosis of VIN lesions that might 
have been missed in the past. This earlier diagnosis and treatm ent of VIN may 
prevent the ultimate developm ent of invasive SCC. Moreover, the m alignant 
progression is estim ated to be <10%, so only a limited number of uVIN lesions 
progress to invasive vulvar SCC.163 For more inform ation about the m alignant 
potential see Paragraph 4.8 of this review.
4.4 Aetiology
In the 1970s, zur Hausen first proposed the hypothesis that HPV, and not herpes 
sim plex as previously thought, was the most likely aetiological agent for the 
developm ent of cervical carcinom a.164165 From laboratory studies as well as 
epidem iological studies it became clear that HPV plays a major role in the 
aetiology of not only CIN and cervical carcinom a, but of all squamous anogenital 
cancers (vulvar, vaginal and anal SCC).157 In 1982, detection of HPV DNA in VIN 
was described for the first tim e.166 Only high-risk HPV subtypes, mainly HPV 16 
and 18, are able to induce uVIN or vulvar SCC.
The mean HPV positivity in VIN lesions is 85% (calculated from nine studies,1'50 51 167' 
172 see Table 2), and in the largest study 100% HPV positivity has been show n.50 It 
is im portant to know which type of VIN (uVIN or dVIN) is subject of study, which 
DNA detection method has been used and which HPV types are determined. The 
difference in HPV positivity between u- and dVIN is illustrated by Table 2. A 
possible explanation for the higher percentage of HPV in VIN com parable to SCC 
of the vulva (about 30%) is that SCC can have developed in both LS and dVIN as 
well as in uVIN.
The immune system seems to play an im portant role in clearance and persistence 
of the HPV infection and developm ent of uVIN. Women infected with HIV are 
approxim ately four tim es more likely to be infected with HPV. The prevalence of 
uVIN in HIV infected women was reported to range from 0,5 to 37%.173 Also 
women who use im m unosuppressants to prevent rejection after transplantation, 
had a 10 to 30 fold risk of cancer of the vulva, mainly caused by HPV 16 and 18, 
that are found at a higher rate in transplant patients compared with im m unocom ­
petent w om en.174'176
Study Number VIN lesions Test Percentage 
HPV positive
Hoevenaars, 20081 45 uVIN HrHPV 84%
75 dVIN 0%
Van Beurden, 199551 47 x uVIN HPV 92%**
lx d V IN
Hampl, 200650 183 VIN HPV 92%
Hillemanns,2006 167 30 VIN HPV 80%
H0rding, 1991168 19 VIN HPV 6,11,16,18,33 79%
Lerma, 1999169 12 uVIN HPV 42%
6 dVIN HPV 0%
Rufforny, 2005170 24 VIN HPV 16 79%
Skapa, 2007171 82 uVIN HPV 99%
12 dVIN HPV 8%
Srodon, 2006172 34 VIN HrHPV 100%
Total 186 uVIN 
290 VIN*** 
93 dVIN
89.9% 
89.8% 
1.0 %
Table 2 H PV p o s it iv ity  in V IN  le s io n s.
* HrHPV: high risk  HPV su b typ e s  16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 68, 73, and 82
uVIN  = u su al VIN
dVIN  = d iffe re n tia te d  VIN
W hen sp e c if ie d , o n ly  V IN  2/3 case s w e re  in c lu d e d
** It is not m en tio n e d  w h e th e r th e  d VIN  le sio n  co n ta in e d  HPV. T h e  d VIN  le s io n s w e re  not 
ta ke n  into a cco u n t in th e  ca lc u la t io n  in th e  H PV p o s it iv ity  o f d V IN  le s io n s. T h e  uVIN  le s io n s 
w e re  co n sid e re d  to  be 9 2 %  H PV p o s it iv e .
*** S u b ty p e  o f V IN  not sp e c ifie d , it is know n th a t > 9 0 %  of VIN lesion are of the  usual typ e.
4.5 Histology
Histopathologically, uVIN lesions are easy to recognize. An example of the 
histology of uVIN can be found in Figure 3C. Typically, the epiderm is is thickened 
and is accom panied by a surface reaction of hyperkeratosis and/or parakeratosis
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of the most superficial of cell layers.4 58 The characteristic m icroscopic features 
include a wind-blown appearance of the epidermis that produces a disorganisation 
of keratinocytes, high nuclear-to-cytoplasm ic ratio, nuclear hyperchromasia, 
irregularities of the nuclear membranes, and numerous mitotic figures at all levels 
of the epiderm is. Dyskeratotic cells with dense eosinophilic cytoplasm  and 
pyknotic nuclei probably representing apoptotic cells are common. Cells with a 
clear or vacuolated cytoplasm  that appears to form clear halos around shrunken 
pyknotic nuclei corresponding to so-called 'koilocytes' may be numerous. 
M ultipolar and abnormal m itotic figures are easily found. uVIN lesions 
characteristically are aneuploid in upper cell layers of the epithelium .4 The 
histological correlates of aneuploidy have been reported to be abnormal mitotic 
figures and nuclear enlargem ent with hyperchromatism  and pleomorphism , 
especially in the basal and parabasal zones. Two types of uVIN exist; in the w arty 
pattern the involved epiderm is has an undulating or spiked surface creating a 
w arty or condylomatous appearance and there is a striking cellular pleomorphism. 
M ultinucleated cells and koilocytes are common. In the basaloid pattern, the 
surface is relatively flat and non-papillam atous with a diffuse replacem ent of the 
epiderm is by a hom ogenous population of small, undifferentiated keratinocytes 
with scanty cytoplasm . However, there are overlapping features of these two 
patterns: m ixtures of w arty and basaloid patterns are com m only found in the 
same lesion.4
4.6 Clinical characteristics
4.6.1 Signs
uVIN lesions can have a variety of clinical appearances. The key features are 
raised, well dem arcated and asym m etrical lesions. They often produce large 
whitish (Figure 7) or erythem atous plaques (Figure 6A); while some lesions are 
pigmented (Figure 6C). The most frequently affected sites are the labia majora, 
the labia minora and posterior fourchette. Other, less affected sites are the 
clitoris, mons pubis, perineal and perianal areas.177 M ultifocal involvem ent of the 
vulva occurs in more than 40%  of cases.4177 M ulticentric intraepithelial or invasive 
squamous neoplasia (of the cervix, vagina or anus) is also common, occurring in 
approxim ately 25-66%  of the uVIN patients.448'50'51 The m ulticentricity of uVIN is 
age-related; decreasing from 59% in women aged 20-34 to 10% in patients over 
50 years of age.147 M ulticentric uVIN are more often HPV positive than the 
unicentric uVIN lesions.51 167168 Because of the often-concurring uVIN and CIN, a 
cervical sm ear should always be perform ed. In Figure 5A, 5C-D, and 6, different
appearances of uVIN are depicted: varying from white and condylom atous-like to 
brown lesions.
Figure 6 Clin ica l p ictures of usual V IN . A+B) m apping of usual V IN . In o rd e rto  get inform ation 
of all su sp icio u s lo o king lesions (I, IV, V, VI and VII), and the  e xtent of the  usual VIN lesions, tw o 
norm al looking areas w ere also b iopsied (II and III). S ix  b iopsies show ed usual VIN and in b iopsy 
III no ab no rm alities w ere fo un d. C) Th e  brow n area of b io psy-p ro ven  usual VIN (ind icated  by 
the  arrow ) w a stre a te d  by la se rv a p o risa t io n .T h e  areas indicated by the  asterix, w ere p reviously 
treated  by laser vap o risatio n . D) In the  area indicated  by the  arrow , the  upper layers of the 
epith elium  w ere vap o rised .
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4.6.2 Symptoms
The most common presenting com plaint is pruritus, present in about 60% of the 
patients. Other presenting sym ptom s can be pain, ulceration and dysuria.177 
A significant proportion of patients have no specific complaints, apart from the 
find ing of an abnormal vulvar area by self examination (22%).177
4.7 Treatment
4.7.1 Introduction
There are several options for treatm ent of uVIN, with a major role for surgery. 
When a large number of treatm ent options exist for a particular condition, it is 
likely that none of those treatm ents provides an excellent solution to the problem. 
This seems to be the case considering the treatm ent of uVIN.178 The paucity of 
robust evidence is of critical im portance supporting most of the various treatm ents 
suggested for uVIN.178
Ideally, a treatm ent of uVIN should address some or all of the follow ing:178
- Exclude invasive disease at the outset
- Relief of sym ptom s
- Eradication of HPV infection
- Minimal disruption of adjacent normal epithelium
- Restoration of normal epithelial architecture
- Reduction in the risk of malignant progression
- Sustained remission
uVIN is considered as an uncommon chronic skin disorder with a high risk of 
recurrence after treatm ent and a risk of progression to invasive vulvar SCC. 
Removal has been standard treatm ent for all suspicious and/or sym ptom atic 
lesions. Due to the recurrent character of uVIN, young women are at risk to require 
repeated treatm ent over a prolonged period of follow -up. As a consequence, they 
may suffer from psychosexual m orbidity.70 72 This leads to the need for alternative 
treatm ent options.
4.7.2 Surgery
4.7.2.1 Cold knife surgery
In the past, extensive surgery has been perform ed for uVIN. During the 1970s, 
several authors addressed vulvectom y as overtreatm ent for uVIN. The main 
reasons to favour more limited surgery were the m utilating treatm ent for a 
disease with an increasing incidence in young women, with a recurrent character 
and the lack of knowledge about the biological behaviour of the disease.179
In 1984, W olcott et al. reported an increase in recurrences when wide local 
excision (WLE) was perform ed instead of radical vulvectom y, and they found that 
positive surgical m argins were a significant predictor of recurrence.180 This 
observation paved again the way towards more extensive surgery for uVIN since 
that tim e.177 Recent reports showed that positive surgical m argins rarely predict 
the developm ent of invasive disease. Therefore WLE, consisting of removal of all 
visible lesions, is the surgical technique of choice.179181
4.7.2.2 Laser excision, vaporisation, and Loop Electrosurgical Excision Procedure 
(LEEP).
Vulvar laser surgery was introduced more than a decade ago and seemed an 
appropriate treatm ent particularly for uVIN because of the low thermal effect on 
vulvar tissue.147182 Laser excision com bines the advantages of both surgical 
excision (high cure rate and correct diagnosis), and laser vaporisation (cosmetic 
and functional results).147 Laser vaporisation is a destructive technique and has 
the disadvantage of destroying the treated tissue, w ithout the possibility of 
histological evaluation.147 In laser excision and vaporisation, at the end of the 
procedure the treated areas can be washed with 5% acetic acid to ensure that no 
residual lesion is left behind.182 Before treatm ent with laser vaporisation, invasive 
disease must have been excluded. Both treatm ents can be perform ed under local 
anaesthesia. When a large vulvar area is involved, more treatm ent sessions may 
be necessary, as treatm ent of a large area is painful. Loop electrosurgical excision/ 
fulguration procedure (LEEP) may be an alternative to laser vaporisation with the 
advantage of provision of a specim en for pathology; there is a lot of experience 
with this treatm ent by the w idespread use in patients with CIN.
In several studies, surgical techniques have been compared. In a review about the 
effect of surgical treatm ent in relation to recurrence and progression of uVIN, 
the recurrence rates in 1921 surgically treated patients have been evaluated. 
The recurrence rates were com parable with an overall recurrence rate of about 
20% .181 In Figure 6 C & D, the effect of laser vaporisation is shown. The areas 
marked with an asterix were previously treated by laser and had the same 
appearance as the area indicated by the arrow in between. In Figure 6D the 
situation directly after the laser vaporisation is shown.
4.7.3 Medical
A lot of medical treatm ents have been tried to avoid surgery in patients with uVIN 
lesions. Medical treatm ent does not provide a specimen for histological evaluation 
and occult invasion may be missed. Therefore, mapping of the vulva is im portant, 
before starting any treatm ent to prevent m issing invasive disease.
4.7.3.1 5-Fluorouracil (5-FU)
5-FU is a topical used chem otherapeutical agent. Topical 5-FU was first used in 
the 1960s on skin m etastases from melanoma and adenocarcinom a of the 
colon.183 In 1985, Sillman et al. published a review about the use of 5-FU in lower 
genital intraepithelial neoplasia. Up to then, 68 patients with uVIN 3 were treated 
with 5-FU. Twenty-three patients achieved remission, five patients improvement, 
and 40 patients failed to respond. Pain and burning frequently limited the duration 
of 5-FU treatm ent.183 In other studies 5-FU was badly tolerated and yielded limited 
results.184 187 In conclusion, topical 5-FU has no prom inent role in the current 
treatm ent for uVIN because of the severe side effects and the high failure rates.
4.73.2 Imiquimod
Imiquimod (Aldara®, 3M Pharmaceuticals, St Paul, MN), an imidazoquinoline amine, 
is classified as an immune response modifier. It is widely used in the treatment of 
genital w arts with proven efficacy in terms of clearance of the lesions, and a lower 
recurrence rate compared with conventional surgical treatm ents.188190 
Analogous to high grade CIN, uVIN m icroenvironm ent is associated with a 
decreased expression of the pro-inflam m atory T h l cytokines, Tumour Necrosis 
Factor a  (TNF a) and Interferon y (IFN y). Imiquimod acts by activating macrophages 
and thereby inducing secretion of these pro-inflam m atory cytokines. This in turn 
prom otes a T h l adaptive immune response leading to the secretion of IFNy and 
the up-regulation of cell mediated im m unity.191 By inhibiting viral replication, 
im iquimod focuses on the cause of uVIN and preserves the anatomy and function 
of the vulva.192'193
Several studies evaluated the effect of imiquimod on uVIN lesions; however, all 
but two studies are small and uncontrolled with various lengths of follow  up. 
In most study settings, a two to three tim es per week 5% dose regimen was used. 
After several applications most patients with uVIN experienced side effects, 
varying from irritation to burning, itching, and/or ulcer developm ent. The side 
effects made several patients stop applying the im iquimod treatm ent. Responses 
were reached after six to 30 weeks of treatm ent.193
Up till now, 110 treated patients are reported in uncontrolled studies, with a 
complete response rate of 47%, and a partial response rate of 28%. However, in 
23% treatm ent failed and 20% recurrences were found. Two patients showed 
progression to invasive carcinom a. Two random ised, double blinded, placebo 
controlled studies (32 and 52 patients) have been described. In the study of 
Mathiesen et al., 81% of the patients reached complete remission and another 
10% a partial remission (from VIN 3 to 1). The patients in the placebo group were 
offered imiquimod after the study period; another four out of seven had a 
complete response, two patients had a partial response. All together, 25 out of 31 
patients had a complete or partial response.194 In the study of van Seters et al. 
81% of patients showed reduction in lesion size, whereas none of the placebo 
subjects experienced a response. Imiquimod was significantly associated with 
histological regression and viral clearance. Moreover, relief of itchiness and pain 
sign ificantly  were reduced in com parison with the placebo. Three patients 
progressed to invasion (< lm m ); two of them after placebo, one after 
im iquim od.195
In a study to the T cell responses triggered by im iquimod application, it was 
dem onstrated that these T cell responses were unable to eliminate the virus 
completely, possibly the reservoir of HPV rem aining in the vulvar epithelium  is 
too large, inaccessible or not processed and presented in the appropriate way to 
the immune system. The m agnitude and specificity of the T cell response had no 
correlation with clinical response to im iquim od.196
Follow up of patients treated with imiquimod is still short; long-term effects 
cannot yet be established. The results of imiquimod are prom ising but large 
randomised controlled trials are needed to obtain data on the long term effects. 
Considering the side effects of im iquimod, its use should be restricted to 
motivated patients.
4.7.3.3 Interferon
Interferons inhibit replication of viruses, and anti-proliferative effects on 
non-neoplastic cells have also been described.197 Interferon is used in rheumatoid 
arthritis and hepatitis B & C for its antiviral, anti-proliferative and im m uno­
m odulatory activity. In the 1980s, the use of interferon gel in patients with CIN 
and/or cervical carcinom a was studied. In cervical carcinom a, the tum our 
regressed to about a third of its original size.198 In CIN, four out of nine patients 
treated with interferon vs. seven out of ten patients treated with a placebo 
showed clinical rem issions.199
Two studies on the effect of interferon-a in uVIN patients (n=23) have been 
perform ed. Nine complete responses, two of which recurred at 12 months, and 
eight partial responses were noted. There were few side effects associated with 
treatm ent in these studies.197200 Due to the limited effect of interferon and its 
high costs, its use in the treatm ent of uVIN is not w idely accepted.
4.7.3.4 Cidofovir
Cidofovir is a deoxycytidine m onophosphate analogue, which has potent antiviral 
activity against a broad range of DNA viruses, including HPV.201 The drug is 
approved for treatm ent of cytom egalovirus retinitis in patients with Acquired 
Im m une-Deficiency Syndrome (AIDS).201 Its effect in HPV-related disease might 
result from induction of apoptosis in HPV-infected cells. Cidofovir can reduce E6 
and E7 expression and allow accumulation of tum our suppressor proteins p53 
and pRb in vitro .202
So far, only one study on the use of Cidofovir in uVIN has been reported. Twelve 
patients with uVIN, ten of which completed follow up, were treated with Cidofovir 
1%. Four patients showed complete resolution of all sym ptom s and visible lesions, 
and three patients had partial responses. One patient had invasive disease 
diagnosed in a residual lesion follow ing a partial response to treatm ent. Local 
side effects were limited to ulceration of the affected mucosa, with no effect 
seen on surrounding normal tissue.203 More studies are needed to investigate 
w hether Cidofovir will have a role in the treatm ent of uVIN lesions.
4.7.3.5 Therapeutic Vaccination
Recently, two vaccines have been introduced for the prevention of CIN lesions 
and cervical carcinom a. One vaccine, Gardasil® (Sanofi-Pasteur MSD), acts against 
HPV 6, 11, 16, and 18 and is approved by the Food and Drugs Adm inistration 
(FDA). The other one, Cervarix ™ (Glaxo Smith Kline), acts against HPV 16 and 18 
and is available from Novem ber 1st 2007. Clinical trials have been carried out to 
find out w hether TA/HPV, a recom binant vaccine encoding modified HPV 16 and 
18 E6 and E7, could have a role in the treatm ent of CIN and/or VIN lesions. 
Davidson et al. compared the immune responses of patients with uVIN lesions to 
healthy volunteers. In patients with HPV 16 positive uVIN lesions, both antibody- 
and T-cell responses to the L I  protein were stim ulated, but not always sufficient 
to clear the lesions. E2-specific T-cell responses were rare, and possibly their 
absence facilitates the persistence of usual VIN lesions.47 Because of the above- 
mentioned observations, therapeutic vaccination studies were perform ed in uVIN
lesions to enhance T-cell mediated im m unity in patients with uVIN lesions. 
Results from those studies show that after various schedules of vaccination, only
1 of 85 patients showed a complete response, 23 of 85 patients had a partial 
response, and four patients showed progressio n.204'206 Viral load dim inished 
post vaccination ,205 but the sam e HPV subtypes were detected pre- and post­
vaccination ,204 and in most patients the grade of uVIN lesion remained 
unchanged.204 In a combined analysis of three randomised trials a 49% reduction 
in lesion size in all high-grade uVIN was seen, irrespective of w hether or not HPV 
DNA was isolated from the lesion.207 In women positive for HPV DNA, HPV 16/18 
vaccination does not accelerate clearance of the virus and should not be used to 
treat prevalent infection.208 209 There are currently no therapeutic HPV vaccines 
that have shown high efficacy in clinical tria ls.210
4.7.3.6 Photodynamic therapy (PDT)
Photodynam ic therapy uses the interaction between a tum our-localising photo 
sensitizer and light of an appropriate w avelength to bring about m olecular 
oxygen-induced cell death.211 Topical 5-am inolaevu lin ic acid (ALA) based PDT 
is particularly attractive  because this drug is activated by conversion to 
protoporphurin IX in rapidly growing cells thus reducing incidental damage to 
surrounding normal tissues.212
The safety and efficacy of photodynam ic treatm ent in uVIN has been evaluated in 
five studies. A total of 100 patients treated by PDT have been reported so far. A 
complete response rate of 40%  was achieved.213'217 Patients, who did not reach 
complete response, did have relief of sym ptom s.217 Small unifocal lesions were 
most responsive to PDT,215 and multifocal uVIN proved to be difficult to treat.214 215 
uVIN lesions that failed to respond to PDT were more likely to have detectable 
HPV compared with the responsive uVIN lesions.213215 In general, treatm ent was 
well tolerated and excellent tissue preservation w ithout scarring was achieved.217 
The optimal light dose has to be determined; better results were achieved when 
100J/cm 2 instead of 50J/cm2was used.213 217
In comparison with surgical techniques, PDT appears to be equally effective to 
laser vaporisation or local excision.214 PDT did not induce ulcers or scar formation 
and the healing time was far below the healing time of lesions treated with laser 
vaporisation.214 PDT seems an appropriate treatm ent for small, unifocal lesions, 
but these lesions are also easy to remove surgically. The technique is to be 
prom ising, but larger studies are needed to confirm  its effectiveness in uVIN 
lesions, to establish the optimal light dose and the effect on HPV.
4.7.3.7 Observation
In case of little or no complaints, some patients may not want to undergo 
treatm ent. Considering the relatively low malignant potential, a wait and see 
policy is an option.218 Careful observation, at least every three months, is required 
and greatly helped by photographs. In our clinic, asym ptom atic women who deny 
treatm ent despite a treatm ent advice, are seen in our outpatient vulvar clinic 
every three months. These patients are instructed to contact us when any 
abnorm ality occurs and we have a low threshold to perform  a biopsy in case of 
suspected progression.
4.73.8 Other
Dinitrochlorobenzene (DNCB) induces a type of delayed hypersensitivity reaction 
after topical application. DNCB was generally successful in six patients. However, 
recurrences developed, side effects were serious and histopathology was 
disturbed by the therapy.219
Bleom ycin is a topical used chem otherapeutical agent and was used in one study, 
and yielded a poor response, with five out of twelve patients progressed to 
invasive carcinom a and only two patients responded.220
lndole-3-carbinol is a natural substance derived from the breakdown of 
glucosinolates, which is present in large concentrations in cruciferous vegetables 
and has been shown to be anti-carcinogenic and anti-oestrogenic. Its use in the 
treatm ent of uVIN has been studied in one uncontrolled randomised phase II trial. 
It significantly improved sym ptom s but, of nine of ten patient who agreed to 
undergo biopsy post treatment, eight biopsies confirmed residual high-grade uVIN.221
4.8 Malignant potential
Generally, the malignant potential of uVIN is considered to be low in comparison 
with dVIN. This opinion is mainly based on the malignant progression in treated 
patients. An example of vulvar SCC adjacent to untreated uVIN is shown in Figure 7. 
The rate of invasion after various prim ary treatm ents ranges from 1.4% to 
20% .177,180'187,222'228 In the m eta-analysis of van Seters et at., 3,3% (108/3322) of 
patients developed a vulvar SCC during follow up after prim ary treatm ent,181 and 
in the study of Jones et at. 17/405 (4.2%) progression was seen after treatm ent.229 
The rates of malignant transform ation of uVIN are high when compared to the 
rates found in treated CIN lesions: in four studies, only 31/13969 (0.22%) patients 
developed invasive cervical SCC after treatm ent for CIN lesions.230'233 
The first study on the malignant potential in untreated VIN 3 lesions, showed
malignant progression in 7/8 cases. However, in the above mentioned 
m eta-analysis vulvar SCC developed in 9% (8/88) of untreated uVIN patients.181 
Jones et al. described 10/63 (15.8%) women who developed invasive disease 
before treatm ent of uVIN.229 Advanced age, raised lesions, radiotherapy, and an 
immune compromised state are known risk factors for progression of uVIN.234 
No differences in progression rate could be found between uni- and multifocal 
lesions.181
Two strikingly different patterns of invasive vulvar SCC in women previously 
treated for uVIN were found. In one group (2.0%), invasion occurred within seven 
years of treatm ent (median 2.4 years). Close examination of these cases points to 
progression of inadequately treated uVIN, as invasion occurred either at the site 
of previous treatm ent and/or there was histological evidence of previous positive 
surgical margins. In the second group (1.8%) invasion occurred many years after 
treatm ent of uVIN (median 13.8 years). In all of these cases, the SCC developed at 
some distance from the previously treated uVIN lesions, thus representing 'de 
novo' tum ours. These late-occurring SCCs appear to represent lesions arising in 
an HPV induced 'field of risk'.229
In contrast to progression to invasive carcinom a, also spontaneous regression of 
uVIN has been described in 14 women 15-27 years of age. All women had 
m ultifocal, pigmented lesions.235 In the review of van Seters et al 1.2% of the 
patients showed spontaneous regression, all were younger than 35 years. In 17 
patients, regression was related to giving birth.181 An im provem ent of the immune 
com prom ised state, e.g., by refrain ing from the use of immune suppressants 
could also lead to spontaneous regression of uVIN. From our own clinical 
experience, cessation of sm oking greatly improves the signs and sym ptom s of 
uVIN.
4.9 Recurrence
The relapsing and recurring nature of uVIN is likely to represent an ongoing battle 
between viral and immune factors in the natural control of this disease.47 
Recurrence rates of uVIN lesions, even after extensive surgical procedures, are 
common. A number of studies has reported the influence of surgical margins 
status on recurrence rates. Surgical m argins are often positive, irrespective of the 
type of operation perform ed.147 In two large reviews recurrences were significantly 
lower after free surgical m argins than after involved surgical m argins.181229 
Two other studies could not confirm  surgical m argins as a risk factor for 
recurrence.177,236
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Figure 7 C lin ica l p ictures of usual VIN w ith ad jacent vu lvar SCC.
A) Th e  patient had been treated  fo r vu lvar itch ing fo r m onths before she visited  our outpatient 
c lin ic. B) Th e  left labium  m inus show s w hite, flat, w a rty  lesions, ad jacent to  an u lcerative  lesion 
tha t show ed to  be vu lvar squ am o us cell carcinom a upon b iopsy. C) B ecause of the  size of the 
tu m o u r (>4cm  diam eter) the  patient w as not e lig ib le  fo r the  sentin el node stud y protocol and 
in gu in o fem o ra l lym ph node d issectio n , com bined  w ith a w id e  local excision , w as p erform ed.
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The presence of positive surgical margins rarely predicts the developm ent of 
invasive SCC (occurring in 27% of patients with a recurrence and in 24% of patients 
w ithout recurrence),226 and therefore it is stated that local excision (instead of 
vulvectom y) can be perform ed because of the low risk of developing invasive 
SCC. Consecutive local resections can better preserve the anatom y and function 
of the vulva than prim ary extensive surgery.179 In the opinion of van Seters et a i, 
the extent of excision should not be enlarged to obtain free surgical margins 
hoping to diminish the chance of progression to invasive vulvar SCC. Besides, in 
patients that show progression, mostly the invasion is superficial (<lm m ), leaving 
WLE w ithout inguinofem oral lymph node dissection as a treatm ent option, with 
excellent survival rates.181218
O ther factors associated with recurrence are HIV positivity,237 use of immune 
suppressants and multifocal lesions.238 p53 gene mutation may play a role in uVIN 
pathogenesis, independent of high-risk HPV infection and may predict recurrence 
or progression to vulvar SC C.222 Irrespective of margin status, the m ajority of 
recurrences were observed within the first three years of follow -up, em phasising 
the fact that careful follow -up of these women is essential.177 
Concerning sym ptom s of uVIN, only patients with unifocal uVIN lesions benefited 
from the extensive removal of affected skin, while sym ptom s in other extensively 
operated patients recurred. In contrast, 75% of the patients who underwent 
restricted surgery benefited from their therapy, even after long-term follow up. 
The recurrences of sym ptom s in extensively operated patients were not always 
due to uVIN or scar form ing, but were also caused by the psychological and sexual 
distress of the surgery.218
4.10 Prevention
Prevention would be the best 'treatm ent' for uVIN lesions. Prophylactic 
vaccination of healthy individuals against the aetiological agent protects against 
acquisition of the disease, but confers some risk to otherwise healthy women 
and requires m assive program m es to vaccinate a sign ificant fraction of the 
population.210 W ith the aim to prevent cervical carcinom a, recently two 
prophylactic vaccines have been introduced to prevent infections with high-risk 
HPV subtypes (HPV 16 and 18). The main public health goal of the introduction of 
an HPV vaccine is to reduce the incidence of cervical carcinom a and its precursor 
lesions. The secondary goal is reduction of the incidence of other HPV-associated 
cancers and benign and prem alignant conditions caused by HPV.239 The studies on 
HPV-vaccines have dem onstrated that prevention of HPV-infection and CIN is
successful, with persistent effects up to five and a half years,240 with sustained 
antibody levels through five and a half years.241 The question rises w hether these 
vaccines have a role in the prevention of uVIN and vulvar SCC. Preliminary results 
show a promising efficacy; Paavonen et al. state that the quadrivalent HPV vaccine 
(Gardasil®) prevents HPV 16 and 18- related vaginal intraepithelial neoplasia 
(VAIN) and uVIN for at least two years post-im m unisation.242 In a combined 
analysis of three randomised clinical trials with a mean follow  up of three years, 
the vaccine was 97% effective in preventing uVIN associated with HPV16 and 18 
in a population that was naive to these viruses at the time of first vaccination, and 
100% effective in a population that was naive throughout completion of the 
vaccination regimen. Vaccine efficacy in the intention-to-treat population, which 
included women who could already have acquired HPV 16 or 18 infection and 
those with vulvar HPV-related disease prior to vaccination, was 71%.207 
Approxim ately 30% of all vulvar SCCs and up to 94% of uVIN lesions are caused by 
infection with HPV. The m ajority of the HPV positive tum ours contain HPV 16 and/ 
or 18. Although the incidence of vulvar SCC in younger women is increasing, it 
remains a rare neoplasm and uVIN lesions have a low progression rate into 
invasive carcinoma after treatm ent.181 When the prom ising results for CIN are 
also true for uVIN, a very large part of the HPV induced VIN lesions and SCCs 
might be prevented by vaccination against HPV 16 and/or 18. It is im portant to 
vaccinate girls before infection with HPV occurs, so before their first sexual 
intercourse.
In several countries the costs for the vaccines are covered by the health care 
insurances and in other countries mass vaccination already started, e.g., in Germany 
and Austria. In the Netherlands the governm ent will soon make a decision w hether 
the vaccination will be incorporated in the vaccination program m e or will be 
covered by the health care insurances.
5. Conclusion
In the absence of HPV, vulvar SCC can develop in a background of LS, dVIN or 
both. A variety of medical treatm ents for LS exist, with derm atocorticosteroids as 
the treatm ent option of first choice. It is unknown w hether the medical treatm ent 
of LS decreases the risk of vulvar SCC developm ent. Patients with LS should be 
follow ed at least once a year. In case of d ifficu lty with symptom control, clinical 
evidence of localised skin thickening or uncertainty of the diagnosis (when dVIN
cannot be excluded), follow-up should take place in a specialised clinic. In contrast 
with the non-surgical approach to LS, the treatm ent of dVIN, which is often 
present in a background of LS, should be surgical to prevent progression to 
invasive vulvar SCC.
uVIN is an entity with a growing interest because of the increasing incidence, 
recurrent character and the young age of women with this condition. uVIN is 
associated with HPV infection in about 90%; mainly HPV 16 and 18 are involved. 
The therapy used to be a radical vulvectom y, but nowadays the extent of the 
surgical procedure has been reduced to a local excision of the lesions. Moreover, 
to further limit the role of surgery, several medical, mostly antiviral, agents have 
been proposed. Some of these agents, such as im iquimod, show prom ising results, 
but randomised controlled trials are needed to confirm  the often-prelim inary 
findings. The first results of HPV vaccination-studies in HPV naive women are 
prom ising. Vaccination can potentially prevent around one third of all vulvar SCC 
and the m ajority of uVIN lesions.
Considering the burden of disease, risk of malignancy, and long lasting need for 
treatm ent and follow -up, vulvar prem alignancies deserve attention in training 
programmes, clinical studies and patient care.
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Abstract
Purpose: High risk (hr) human papillom avirus (HPV) plays a role in the developm ent 
of a subset of vulvar squamous cell carcinom as (SCC). Uncertainty exists about 
the true impact of HPV in this tum our type as conflicting reports have been 
published with diverging prevalence rates. This study was perform ed to fine tune 
the role of hrHPV infection in vulvar SCC developm ent in relation to clinical 
prognosis.
Experimental design: 130 vulvar SCCs of patients with known survival data were 
analysed for histology of the adjacent lesion (differentiated (d) or HPV-associated 
usual (u) vulvar intraepithelial neoplasia (VIN)), in relation to p l6 INK4A expression 
as marker of HPV activity, and presence and integration of hrHPV-DNA.
Results: uVIN was present adjacent to vulvar SCC in 25/130 cases. uVIN-associated 
SCCs had high p l6 INK4A expression and 24/25 SCCs contained integrated hrHPV 
DNA. dVIN was found adjacent to 105/130 vulvar SCCs. hrHPV was detected in 11 
(10.5%) dVIN-associated vulvar SCC, but correlated with high p l6 INK4Aexpression 
in only one case. Integration of viral DNA was never observed in dVIN associated 
SCCs which suggests that a causal relationship of hrHPV in dVIN-associated 
tum ours is highly unlikely. The Disease Specific  Survival (DSS) of the dVIN- 
associated vulvar SCC patients was significantly worse compared to patients with 
a uVIN-associated tumour.
Conclusions: hrHPV is causally associated with the development of uVIN-associated 
SCCs, which comprise 19% of all vulvar SCCs, but not with dVIN-associated vulvar 
SCCs. dVIN-associated vulvar SCCs have a significantly worse prognosis.
62
Introduction
The association between Human Papilloma Virus (HPV) and vulvar squamous cell 
carcinom a (SCC) oncogenesis is less straightforw ard than for cervical carcinom as, 
which are causally associated with HPV in nearly 100% of the cases.243 In previous 
work, we have dem onstrated that vulvar SCCs may develop via two different 
pathways, with their own specific prem alignant lesions.12 The first and most 
common pathway occurs in elderly women and mainly leads to keratinising SCC, 
often in a background of lichen sclerosis (LS) and differentiated vulvar intrae- 
pithelial neoplasia (dVIN). The second pathway of vulvar SCC occurs in younger 
women. This type of carcinom a is associated with w arty or basaloid VIN, currently 
referred to as usual VIN (uVIN).
HPV has been found in a subset of vulvar SCCs, suggesting a causal relationship. 
The exact im pact of HPV in this tum our type is uncertain as diverging prevalence 
rates have been published. Sixteen studies com prising 1181 vulvar SCC patients 
dem onstrated on average 35% HPV positivity, and 25% positivity for HPV 16 and/ 
or i s . 2'35'46'50'169'171'244-253 in the United States, a higher percentage HPV positivity 
was found (63.2%) than in European countries (34.7%).254 However, HPV-DNA 
presence alone does not per se  indicate viral involvem ent in the carcinogenic 
process.255 Infection with HPV is an early event in the m ulti-step process of vulvar 
carcinogenesis and HPV integration into host cell genome seems to be related to 
the progression of vulvar dysplasia.167 Viral integration generally disrupts the E2 
region, resulting in enhanced expression of E6 and E7. E6 and E7 have the ability 
to bind and inactivate p53 and pRb, w hich prom otes rapid progression through 
the cell cycle w ithout a p53-m ediated control of DNA integrity. High p l6 INK4A 
expression is caused by the functional inactivation of pRb and may be used as a 
readout for active HPV.256 257
W ith the aim to fine tune the etiologic role of HPV in vulvar SCC oncogenesis we 
used the histology of the adjacent VIN lesion in relation to p l6 INK4A expression and 
HPV integration. As a consequence, the number of vulvar SCCs that may be 
prevented by the current HPV vaccines can be indicated more accurately and it 
can be determined w hether the two different pathways of vulvar SCC lead to 
different survival patterns.
Ch
ap
te
r 
3 
% 
Th
e 
et
io
lo
gi
c 
ro
le
 
of 
HP
V 
in 
vu
lv
ar
 
sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a 
fin
e 
tu
ne
d
Methods
Patients
Between 1988 and 2005, 167 patients were treated with a curative intent for 
prim ary vulvar SCC at Radboud University Nijmegen Medical Centre, the 
Netherlands. Tissue sam ples of the prim ary tum ours of all patients were available 
for assessm ent of the adjacent VIN lesion (i.e,. into uVIN, which is >90% HPV 
related and dVIN, which is not HPV related258), p l6 INK4A staining as molecular 
marker for HPV activity,249 the presence of HPV by short fragm ent PCR and DNA In 
Situ Hybridisation (ISH) to dem onstrate the physical status of HPV as HPV 
integration is a key event in carcinogenesis.259
In 28 specim ens, am plification of the housekeeping ß-globin gene by PCR failed, 
and these were not included in the study. Five tum ours did not have sufficient 
material for im m unohistochem ical analysis and in four tum ours we were not able 
to classify the adjacent VIN lesion, due to a massive inflam m atory response or 
ulceration. A total number of 130 patients were available for the study. Clinico- 
histopathological characteristics and follow -up data were obtained from medical 
charts (Last date of follow -up: August 1st 2008).
Histology of the adjacent VIN lesion
Based on the specific criteria established for the histopathological characteristics, 
prem alignant lesions flanking vulvar SCC were classified as dVIN, with or w ithout 
the presence of LS, and uVIN.45260 All slides were re-evaluated by an expert 
gynaecopathologist (JB).
pl6'NK4ft expression
Tissue sections (4|im) of the archival paraffin-em bedded tissue sam ples adjacent 
to that used for H&E slides to assess the adjacent VIN lesion were mounted onto 
SuperFrost glass slides (M enzel-Gläser, Braunschw eich, Germany) and dried 
overnight at 37°C. The sections were dewaxed in xylene and rehydrated through 
graded alcohols. Endogenous peroxidase was blocked with 3% hydrogenperoxide 
in phosphate-buffered saline (PBS; pH 7.4) for 30 minutes. Slides were rinsed 
three tim es in PBS for 5 minutes, and antigen retrieval perform ed with boiling 
citrate buffer (0.01 M; pH 6.0) for 10 minutes. After cooling down to room 
tem perature (RT), slides were briefly washed in PBS for 10 minutes. Subsequently, 
the slides were preincubated with 20% normal horse serum and then incubated 
with the primary antibody p l6 INK4A (clone JC-8, Immunologic, Duiven, the Netherlands),
diluted 1:200 in PBS with 1% bovine serum album ine (BSA) (overnight). Slides 
were rinsed in PBS (10 minutes) and postantibody blocking was perform ed for 30 
m inutes (horse-anti mouse IgG). Staining was developed with diam inobenzidine/ 
hydrogenperoxide for 5 minutes, intensified with copper sulphate and counter­
stained with M ayer's haem atoxylin. The slides were dehydrated through graded 
alcohols and xylene, and finally mounted with Permount mounting medium 
(Fisher Chemicals, NJ, USA). Negative controls (buffer only) and HPV-positive CIN 
3 lesions served as p l6 INK4Apositive controls in each run.
Interpretation of p l6 INK4A: nuclear and cytoplasm ic p l6 INK4A staining were both 
considered as a positive reaction. The results were reported in a semi quantitative 
fashion: negative (-) if <5% of the cells had nuclear or cytoplasm ic staining, slightly 
positive (1+) if 5 to 25% of the cells were stained, moderately positive (2+) if 
staining was present in 25 to 75% of the cells, and markedly positive (3+) if >75% 
of the cells showed nuclear or cytoplasm ic sta in ing.247 249
HPV presence and genotyping
DNA was isolated from form alin fixed paraffin-em bedded tissue sections (6|im) 
with the EZ1 robot (with the DNA tissue kit of Qiagen) according to standard 
procedures261 and used for PCR analysis. A negative w ater control was included 
with each batch of 10 samples. Broad-spectrum  HPV DNA am plification was 
perform ed using a short PCR fragm ent (SPF-PCR) assay. The SPF-PCR system 
am plifies a 65 bp fragm ent of the L I  open reading frame, allow ing the detection 
of at least 43 HPV types. Subsequent HPV genotyping was perform ed via a reverse 
hybridisation line probe assay (LiPA), allow ing sim ultaneous typing of the 25 
HPV-genotypes. The combined SPF-PCR-LiPA system for detection and genotyping 
of HPV has been described in detail elsew here.261
Physical status of HPV by In Situ Hybridisation(ISH)
The ISH procedure for HPV16/18 and HPV31/33 on 3 |j.m thick paraffin sections 
was perform ed as described previously.262 263 In brief, tissue sections were 
pretreated with proteolytic reagents, hybridised, and the biotinylated DNA-DNA 
hybrids were immunohistochemically detected by the peroxidase-labelled avidin- 
biotin-com plex (ABC-PO). For detection of HPV16/18/31/33 DNA sequences, ISH 
was follow ed by an im m unohistochem ical detection method utilizing catalysed 
reporter deposition (CARD) signal am plification, which enables the detection of 
low copy numbers. Only a punctate signal in the nuclei was considered to 
represent viral integration.264 265
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Statistical methods
Clinical data were entered in a com puterised database and analysed using SPSS 
softw are (version 16.0.1 for W indows, SPSS). Disease Specific Survival (DSS) was 
defined as the time from the date of prim ary treatm ent to the date of death due 
to vulvar SCC or last date of follow  up. Differences in DSS between the tum ours 
were investigated using Kaplan-M eier statistical method. x2and Student's t test 
were used to calcu late d ifferences in clin icohistopathological characteristics. 
For all tests a significance level of p<0,05 was chosen.
Results
Histopathological review of vulvar SCC slides showed 25 (19.2%) cases of uVIN 
adjacent to vulvar SCC, and 105 cases (80.8%) of dVIN (of which in combination 
with LS in 59 cases) (See Figure la  and Id  for representative H&E slides of uVIN 
and dVIN). LS as a so litary adjacent lesion was present in three cases and was 
considered to belong to the dVIN-associated type.28'30 37
To investigate w hether the tum our tissues displayed HPV activity, we performed 
p l6 'NK4A staining (Figure lb -c  and le -f). N inety-one tum ours (70%) showed a 
p l6 'NK4A expression pattern in which less than 5% of the tum our cells displayed 
cytoplasm ic, and/or nuclear p l6 INK4A positivity. In four tum ours 5-25% positive 
cells were observed. 25-75% and more than 75% positive cells were observed in 
nine and 26 tum ours, respectively and were considered a true positive result. All 
25 uVIN-associated tum ours displayed high p l6 INK4Aexpression (more than 25% 
positive tum our cells), compared to only 10/105 (9.5%) dVIN-associated tum ours 
(Figure 2).
All vulvar SCCs were analysed for presence of HPV DNA. Forty-five of the 130 
tum ours (34.6%) tested positive for HPV, of which 33 (25.4%) for hrHPV types. Of 
the hrHPV types, HPV 16 was most common and present in 18 of the 33 tum ours 
(54.5%) as the only HPV type, and in two tum ours (6%) a combination with HPV 16 
and another HPV type was found. HPV 33 was the second most common type and 
detected in seven of the 33 HPV-positive tum ours (21.2%). HPV 18 was present in 
two tum ours as the so litary subtype, and in combination with HPV 16 and 54 in 
one additional tum our (Table 1).
In 24 out of 25 (96%) uVIN-associated tum ours hrHPV DNA was detected, whereas
11 (10.5%) dVIN-associated tumours were found positive for hrHPV DNA (Figure 2).
Figure 1 Exa m p le s  o f V IN  le s io n s  a d ja ce n t to  v u lv a r  sq u a m o u s ce ll ca rc in o m a s  (SCC), SC C s  
a sso c ia te d  w ith  both ty p e s  o f V IN  and its p l 6 INK4A e x p re ss io n .
Su b d iv is io n  o f v u lv a r  SC C s  w a s a m o n g  o th e r th in g s  based  on th e  h isto lo g y  o f th e  a d ja ce n t 
VIN  le s io n  and p l6  INK4As ta in in g . uVIN  (a) a s s o c ia te d  tu m o u rs  (b) sh o w e d  > 25%  p l 6 INK4A 
e x p re s s io n  in a ll c a se s(c ) . d V IN  (d) a s s o c ia te d  tu m o u rs  (e) d isp la y e d  < 2 5 %  p l 6 INK4A 
e x p re ss io n  (f) in 9 0 .5 %  o f th e  SC C s.
However, of those 11 dVIN associated hrHPV positive tum ours only one single 
tum our displayed high p l6 INK4A expression. The rem aining 10 dVIN hrHPV positive 
sam ples were all p l6 INK4A negative, suggesting that the HPV found in these dVIN- 
associated tum ours was not active. As p l6 INK4Aexpression is linked to HPV activity 
the physical status of hrHPV DNA by ISH for HPV types 16, 18, and 33 was 
dem onstrated. Twenty-three uVIN-associated SCCs were positive for HPV 16, 18, 
or 33. One tum our was positive for HPV 58. All 23 HPV 16, 18, and 33 positive 
uVIN-associated SCCs were analysed, together with all dVIN-associated SCCs that 
tested positive for HPV DNA and/or displayed high p l6 INK4A expression. Integration 
was observed in all 23 HPV 16-, 18-, or 33 positive uVIN-associated SCCs (See 
Figure 3a for a representative slide of a tum our positive for HPV 31/33 by ISH).
Of these, 17 were positive for HPV 16 and/or 18. However, none of the p l6 INK4A 
expressing and/or HPV 16-, 18-, or 33 DNA containing dVIN-associated vulvar 
SCCs displayed HPV integration (See Figure 2 & 3b for a representative slide of a 
tum our negative for HPV 16/18 by ISH), suggesting a non significant clinical 
presence of hrHPV in dVIN-associated SCCs.
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SCC
n=130
Adjacent VIN lesion
uVIN
n-25
dVIN
n-105
p l6 WMA immunostaining
>25%
n=25
£25%
n=95
>25%
n=10
High risk HPV DNA
Integrated HPV 16,18.33
Absent Present Absent
n=l n=24 n=85
Present
n-10
Absent
n=9
Present
n=l
--------1--------------------1--------------------1----------
n=0 ** n=0 n=-0
Figure 2 Sc h e m a tic  o v e rv ie w  o f h isto lo g y  of th e  a d ja ce n t V IN  le s io n , p l 6 INK4A e xp re ss io n , 
h rH P V  p re se n ce  and in te g ra tio n .
A ca u sa l re la tio n  b etw e e n  hrH PV  and v u lv a r  S C C  is o n ly  p la u s ib le  fo r  u V IN -a sso c ia te d  SC C s. 
In d V IN -a sso c ia te d  v u lv a r  SC C s  p o sitiv e  fo r  hrH PV  o r w ith  h igh  p l6 INK4A e x p re ss io n , th is  w as 
not a cco m p a n ie d  by H PV in te g ra tio n .
* O f th e  24 u V IN -a sso c ia te d  SC C s, 23 w e re  p o sitiv e  fo r  16, 18, or 33 and a va ila b le  fo r 
in te g ra tio n  a n a lys is .
** O f th e  te n  H P V -p o s it iv e  d V IN -a sso c ia te d  SC C s  w ith  low  p l 6 INK4A e x p re ss io n , s ix  w ere  
p o s it iv e  fo r  H PV 16, 18, or 33 and a va ila b le  fo r  in te g ra tio n  a n a lys is .
Number Percentage
HPV negative 85 65.4
Low risk HPV types 12 9.2
54 1 91.7
X 11 8.3
High risk HPV types 33 25.4
16 18 54.4
16, 18, 54 1 3
16, 58 1 3
18 6.1
33 7 21.2
52 1 3
52, 66 1 3
53 1 3
58 1 3
Table 1 O v e rv ie w  o f HPV ty p e s  in 130 v u lv a r  SC C s.
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Figure 3 Exa m p le s  o f tu m o u r ce lls  p o s it iv e  or n eg a tive  fo r  ISH fo r  HPV ty p e s  16/18 and 
3 1/33.
In te g ra tio n  a n a ly s is  w as p e rfo rm e d  to  f in e  tu n e  th e  e t io lo g ic  ro le  o f H PV in v u lv a r  SC C s. 
A ll u V IN -a sso c ia te d  SC C s  sh o w e d  H PV in an in te g ra te d  fo rm  (a, p o sitiv e  fo r  HPV 31/33), 
w h e re a s  none o f th e  H PV p o s it iv e  or h igh p l6 INK4A e x p re ss in g  d V IN -a sso c ia te d  SC C s  had 
H PV in te g ra te d  (b).
W ith the aim to find out w hether there are differences in disease specific survival 
(DSS) between the two types of vulvar SCCs, the DSS of all vulvar SCC patients and 
subdivided between uVIN and dVIN associated vulvar SCCs was determined. In 
addition, DSS for vulvar SCCs subdivided between hrHPV positive and negative 
was established. For all vulvar SCC patients, five year DSS rate was 77% (Figure 
4a). A subdivision between u- and dVIN showed a five year DSS rate of 70% for 
dVIN-associated SCC patients. Survival for uVIN-associated SCC patients was 
significantly better with a five year DSS rate of 100% (log rank p=0.012) (Figure 
4b). A subdivision between hrHPV positive or negative did not result in a different 
DSS (log rank p=0.646) (Figure 4c). Stratification for uVIN, HPV negative dVIN, and 
HPV positive dVIN revealed an unexpected worse survival of the latter (Figure 
4d). Sim ilarly, stratification for HPV p o sitive /p l6 INK4A positive (24 uVIN and one 
dVIN), HPV positive/p l6  INK4A negative (10 dVIN) and HPV negative (94 dVIN and 
one uVIN) vulvar SCCs dem onstrated reduced DSS for the HPV po sitive /p l6 INK4A 
negative subset (Figure 4d insert). As such, the lack of a difference in DSS between 
HPV positive and HPV negative tum ours (Figure 4c) can be explained, but why 
these HPV p o sitive /p l6 INK4A negative dVIN-associated SCC carry a poor DSS 
remains elusive.
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Figure 4 D ise a se  s p e c if ic  su rv iv a l cu rve s .
Five  ye a r D ise a se  S p e c if ic  S u rv iv a l (D SS) fo r  all v u lv a r  SC C  p a tie n ts  is 77%  (a). Su b d iv is io n  
b etw e e n  th e  v u lv a r  SC C s  based  on h isto lo g y  o f a d ja ce n t VIN  le s io n , d e m o n stra te d  a b e tte r 
D SS fo r  u V IN -a sso c ia te d  tu m o u rs  th a n  d V IN -a sso c ia te d  tu m o u rs  (p = 0 .0 1 2 ) (b). F ive ye a r 
D SS fo r  u V IN -a sso c ia te d  tu m o u rs  is 100% , w h e re a s  D SS fo r  d V IN -a sso c ia te d  tu m o u rs  is 
7 0 % . Based  on h rH P V  p o s it iv ity , no s ig n if ic a n t  d iffe re n c e s  co u ld  be d e m o n stra te d  
(p = 0 .6 4 6 ) (c). T h is  w as m ain ly  due to  th e  a ttr ib u tio n  of h rH P V  p o s it iv e  d V IN -a sso c ia te d  
SC C s  (F ig u re  4d ), or H PV p o sitive , p l6 INK4A n e g a tive  (in se rt) w ith  a w o rse  D SS. W hen  all 
u V IN -a sso c ia te d  tu m o u rs  m ay be p re ve n te d  by v a cc in e s  in th e  fu tu re , th e  d ise a se  s p e c if ic  
s u rv iv a l o f v u lv a r  SC C  p a tie n ts  w ill s lig h t ly  d e cre a se  fro m  7 7 %  to  70%  (a and b).
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Discussion
HPV detection by PCR alone results in an overestimation of the percentage vulvar 
SCCs that are causally associated with HPV. We dem onstrated the presence of 
hrHPV in 26.9% of the vulvar SCCs, but our more detailed analysis dem onstrated 
a plausible causal relationship between hrHPV and vulvar SCC carcinogenesis only 
in uVIN-associated vulvar SCCs (19.2%). In dVIN-associated SCCs the detected 
HPV was not found integrated or activated and thus was not considered to be 
causally involved. Thirteen percent of the vulvar SCCs were considered to be 
caused by HPV 16 and/or 18. In addition, the uVIN-associated vulvar SCCs had a 
better DSS than dVIN-associated vulvar SCCs.
To assess the extent of the aetiological role of HPV in the carcinogenic process, 
we established histology of adjacent VIN lesion, p l6 INK4A overexpression, and 
determ ination of HPV integration status. Since dVIN is not associated with HPV,258 
it is unlikely that the tum our directly adjacent to this dVIN lesion is caused by 
HPV. In our study, a subdivision based on adjacent VIN lesion resulted in two 
clearly perceptible groups of vulvar SCCs (Figure 2). High p l6 INK4Aexpression was 
observed in 9.5% dVIN associated SCCs and suggested active HPV involvem ent 
but only in one tum our the high p l6 INK4A expression was accom panied by hrHPV 
presence. However, although p l6 INK4A overexpression is strongly related to active 
HPV infection as a result of functional inactivation of pRb, it may also occur as an 
endogenous response towards abnormal cell proliferation due to an eroded 
checkpoint function.247 249 p l6 INK4A thus is an indicator that a carcinogenic cascade 
has commenced but may also be expressed in HPV-independent tum ours where 
its overexpression may counteract signals that abnorm ally drive cell proliferation, 
a checkpoint function that is eroded in prem alignant and tum our cells.266 
Furtherm ore, the observation that integration of HPV was not observed in 
HPV-positive dVIN-associated tum ours supports our suggestion that HPV did not 
contribute to the developm ent of this tum our type. However, we cannot rule out 
that that episomal HPV does not have an oncogenic potential. Viral integration is 
not a prerequisite for oncogenic activity, as a proportion of HPV-16-positive 
cervical tum ours contains episomal HPV DNA either alone or in coexistence with 
integrated HPV sequences.267 268 In contrast with dVIN-associated tum ours, uVIN- 
associated tum ours were causally associated with hrHPV; all expressed high 
p l6 'NK4A expression and the HPV types found were integrated in the genome.
The analysis of the presence and integration of hrHPV, expression of p l6 INK4A, and 
histology of the adjacent lesion indicated that it is very unlikely that hrHPV is
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causally related to the developm ent of dVIN-associated vulvar SCCs. When 
perform ing a survival analysis for dVIN and uVIN-associated SCC, we found a 
significantly worse DSS for dVIN (Figure 4b). Unexpectedly, we found reduced DSS 
for HPV positive dVIN compared to HPV-dVIN-associated vulvar SCCs (Figure 4d). 
We cannot provide an explanation why presence of HPV, that most likely did not 
induce the dVIN-associated vulvar SCC, is associated with poor DSS. The low 
sample number of HPV positive dVIN ( n = ll)  compared to HPV negative dVIN 
(n=94) may have influenced this finding. Further retrospective studies using 
sam ples from other centres are needed to determine w hether the poor DSS of 
HPV positive dVIN is actually a real finding or a chance occurrence. Stratification 
based on p l6 INK4A expression did not result in a different allocation of sam ples in 
the three subsets because the sample set contains only one HPV p o sitive /p l6 INK4A 
positive dVIN and one HPV negative uVIN-associated vulvar SCC and therefore 
DSS curves were highly com parable to uVIN, HPV positive dVIN and HPV negative 
dVIN.
In this study we dem onstrate that with HPV DNA detection alone the number 
of vulvar SCCs with a c lin ica lly  relevant infection is overestim ated. This has 
im plications for the protective role of HPV vaccines for vulvar SCCs. There is 
increasing evidence that the recently introduced vaccines against HPV 16 & 18 
will significantly reduce the incidence of cervical carcinom a and its prem alignan­
cies.242269 This has led to the im plication of HPV vaccination in nationwide vaccine 
program m es in most European countries. Although most studies have focused on 
the impact these vaccines will have on cervical cancer, limited research has been 
perform ed on how the vaccines may affect vulvar SCC incidence. Still, in Septem ber 
2008, the Food and Drug Adm inistration (FDA) approved one vaccine (Gardasil®) 
to be used to prevent some cancers of the vulva and vagina.270 In our detailed 
analysis it appears that only uVIN associated (25/130) vulvar SCCs are causally 
associated with hrHPV. Of those uVIN associated vulvar SCCs, 17 (13% of all vulvar 
SCCs) were HPV 16/18 positive and will possibly be prevented by the current HPV 
vaccines. We dem onstrate that the uVIN-associated vulvar SCC have a more 
favourable prognosis compared to dVIN-associated vulvar SCCs. Vaccination may 
therefore prevent a small subset of vulvar SCC with relatively good prognosis, 
w ithout broadly affecting vulvar SCC incidence and survival rates. Currently, HPV 
vaccines covering more hrHPV types are under developm ent, and most, if not all, 
uVIN-associated carcinom as may be prevented by these vaccines in the future. 
As this strategy elim inates the tum ours with a relatively good prognosis, five 
year survival for vulvar SCC patients could slightly decrease from 77% in the pre­
vaccination era to 70% after the possible prevention of all uVIN-associated vulvar 
SCCs (Figure 4 a-b).
In conclusion, hrHPV is causally associated with the developm ent of uVIN- 
associated vulvar SCCs. Although hrHPV was found in 10.5% of dVIN-associated 
vulvar SCCs, it does not seem to be causally associated with tum our developm ent. 
Integration of HPV 16 or 18 was observed in 17 uVIN-associated vulvar SCCs (13%), 
which may be prevented by HPV vaccines in the future. This is lower than 
previously supposed and leaves the m ajority of the vulvar SCCs with w orst DSS 
unsolved.
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Abstract
Objective: The purpose of the present study is to investigate the trends in 
incidence of both usual (u) and differentiated (d) vulvar intraepithelial neoplasia 
(VIN) separately, their malignant potential and the relation with other HPV related 
anogenital lesions in the Netherlands during a 14 year period.
Methods: The incidences of both types of VIN and vulvar SCC were retrieved from 
the Nationwide Netherlands Database of Histo- and Cytopathology. Population 
data were retrieved from the Database of Statistics Netherlands.
Results and Conclusions: In the study period the incidence of uVIN and dVIN 
increased, while the incidence of vulvar SCC remained stable. The overall 
percentage of uVIN patients that were later diagnosed with vulvar SCC was 5.7%, 
which was significantly lower than the percentage for dVIN patients (32.8%). 
In addition to this 5.6 fold increased conversion rate, the time of progression 
from dVIN to SCC developm ent was significantly shorter than that of uVIN 
(p=0.005). Percentage of uVIN patients that were later diagnosed with SCC 
significantly increased with age (p=0.005) whereas the time to SCC significantly 
shortened with age (p=0.05). Forty-one percent of uVIN patients had a past, 
concom itant or future HPV associated lesion of the lower genital tract, which is in 
contrast to the 3% for dVIN patients. In short, an increase in diagnoses of both 
uVIN and dVIN has not led to an increase in vulvar SCC incidence. The m alignant 
potential of dVIN is higher than for uVIN. For uVIN the malignant potential 
increases with age.
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Introduction
Vulvar squamous cell carcinom a (SCC) is the fourth most common gynaecological 
type of cancer with an annual incidence of 2-3 per 100.000 w om en.44271 Vulvar 
SCC usually arises from prem alignant vulvar intraepithelial neoplasia (VIN). In 
general, there are two different types of VIN, i.e., differentiated VIN (dVIN) and 
usual VIN (uVIN) that both can progress towards vulvar SC C.23 W hereas uVIN is 
causally related with human papillom avirus (HPV) infection, dVIN is HPV 
unrelated.2
dVIN is a recently recognised, but d ifficu lt to diagnose entity for c lin icians as 
well as p atho logists.3 45 dVIN is found adjacent to SCC in 70-80%  of vulvar SCCs, 
but so litary dVIN lesions are rare. This may be caused by a relatively brief 
intraepithelial phase before progression to invasive carcinom a,5 154 156 and suggests 
a high malignant potential of dVIN. dVIN is often seen in a background of lichen 
sclerosuis (LS) and occurs in elderly women (mean age 65).272 The aetiology of SCC 
via LS and dVIN is largely unknown. The HPV-associated (mainly HPV 16 and 18) 
uVIN mainly leads to non-keratinising vulvar SCC and it prim arily affects younger 
women around the age of 45 .51 uVIN lesions are seen adjacent to approxim ately 
20-30%  of the vulvar SCCs. M ulticentric intraepithelial or invasive squamous 
neoplasia (of cervix, anus or vagina) occur in approxim ately 53-66%  of uVIN 
patients.50 51 Most of these lesions are cervical (intraepithelial) neoplasias, as in 
most countries, as well as in the Netherlands, w ell-organised mass screening 
program m es exist for the prevention of cervical carcinom a. In contrast to the 
presumed high malignant potential of dVIN, SCC percentages of 3- 5% were found 
in patients treated for uVIN.51'161'181'229
The incidence of uVIN is increasing w orldw ide,52'55 161 162 181'271'273 which is in 
concordance with the increase in HPV prevalence. Despite the increase in uVIN, 
no increase in the overall incidence of SCC of the vulva has been seen.52 53 271 In 
some publications, an increase in SCC incidence in young women was reported, 
possibly due to the younger age of first sexual intercourse and the increasing 
incidence of HPV infections.54'57 Since the introduction of the new nomenclature, 
the incidence of uVIN and dVIN lesions has not been studied separately. The aim 
of the present study is to investigate the trends in incidence of both types of VIN, 
their malignant potential and the relation with other HPV related anogenital 
lesions in the Netherlands during a 14 year period.
Materials and Methods
Data concerning the incidence of VIN and vulvar SCC were collected via PALGA, 
the Nationwide Netherlands Database of Histo- and Cytopathology,274 which has 
national coverage from 1991 onwards. Analogous with other studies concerning 
the incidence of cancer and using cancer registry data,275'277 we calculated the 
incidence of VIN and vulvar SCC.
All patients with a prim ary VIN lesion diagnosed between January 1st, 1992 and 
December 31st, 2005 in the Netherlands were selected and a total number of 2935 
patients were retrieved. We excluded patients with a first diagnosis of VIN 
diagnosed before 1992 with a recurrent lesion between 1992 and 2005. For all 
patients, the first report that mentioned VIN or vulvar SCC was included. For 
every pathology-report, all VIN lesions were subdivided into u- or dVIN. We based 
this subdivision on the conclusion drawn by the pathologist and additional 
indications mentioned in the reports (Figure 1). In the analyses we adopted the 
new International Society for Study of Vulvovaginal Disease (ISSVD) classification3 
(we did not include VIN 1 lesions, and grouped VIN 2 and 3 together as uVIN). 
We only included solitary VIN lesions, {i.e., not adjacent to vulvar SCC). VIN lesions 
that progressed to vulvar SCC within three months were excluded, as these were 
considered 'missed invasion'. A total number of 1893 patients was available for 
analyses, including 1826 uVIN patients and 67 dVIN patients.
For each patient with VIN, prior and subsequent pathology reports of vulvar 
biopsies or excisions were available and when a vulvar SCC occurred more than 
three months after the first histological diagnosis of VIN, it was scored as 
malignant progression. In addition, the pathology reports contained all histological 
reports of biopsies or excisions of the fem ale lower anogenital tract.
Vulvar SCC
The PALGA database revealed 4648 patients with vulvar cancer between January 
1st, 1992 and December 31st, 2005 in the Netherlands. We excluded patients with 
a non-squam ous vulvar carcinom a and patients with a first diagnosis of vulvar 
SCC diagnosed before 1992 with a recurrent lesion between 1992 and 2005. For 
all patients, the first report that mentioned vulvar SCC was included. The total 
number of primary vulvar SCC patients was 2701.
VIN, usual type 
VIN, classic type
• VIN, basaloid type
Morbus Bowen, bowenoid papulosis
• VIN NOS with presence of high-risk HPV/ 
kollocytosis
VIN NOS with high p l6 ,NMA expression
Usual VIN
• VIN, differentiated type
• VIN, simplex type Differentiated
• VIN NOS with Lichen Sderosus \ \ / IM
• VIN NOS high-risk HPV negative / V I  IN
Figure 1 H isto lo g ica l d ia g n o se s  th a t su p p o rt  th e  d ia g n o s is  o f usual or d iffe re n tia te d  V IN . 
V IN  NO S: V IN  not o th e rw ise  sp e c if ie d .
Population data
Population data in order to calculate European standardised rates of the 
Netherlands were obtained from the Database of Statistics Netherlands (http:// 
w w w .cbs.nl/).
Statistical analysis
Incidences of both types of VIN and vulvar SCC were calculated per 100.000 
person years (European Standardised Rate, ESR). Age was categorised into 15-year 
strata (15-29, 30-44, 45-59, 60-74, over 75 years of age). Differences between the 
incidences over time were calculated using the univariate general linear model. 
The Student's t test was used to compare the mean ages and tim es to SCC 
developm ent. A significance level of p<0.05 was chosen.
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Results
In the study period, 2701 patients were identified with vulvar SCC, 1826 patients 
with solitary uVIN and 67 patients with solitary dVIN. The median age of patients 
with uVIN (47.8 years) and dVIN (67.0 years) differed significantly (p<0.001). 
The median age at diagnosis of vulvar SCC patients was 70.4 years, which is 
significantly higher compared to uVIN, but comparable with dVIN.
In order to determ ine trends in incidence of vulvar SCC, uVIN and dVIN, their 
incidences over the 14 year study period were calculated (Figure 2). The incidence 
of uVIN alm ost doubled from 1.2/100.000 patients in 1992 to 2.1/100.000 patients 
in 2005 (p<0.001). The incidence of dVIN increased nine-fold from 0.013/100.000 
patients to 0.121/100.000 patients (p=0.019). In contrast, the incidence of vulvar 
SCC remained unchanged from 2.6/100.000 patients in 1992 to 2.5/100.000 
patients in 2005 (p=0.670). To determine the age with highest incidence rate of 
vulvar SCC, uVIN and dVIN, the age specific incidences were calculated (Figure 3). 
A gradual and strong increase in vulvar SCC incidence was observed starting at 
the age of 60. uVIN showed a bimodal peak incidence at the ages of 4 0-4 4  and at 
75-79. dVIN has the highest prevalence at the age of 75-79. Of all prem alignant 
lesions, uVIN was diagnosed in 98.9% of all VIN lesions in 1992, which decreased 
to 94.5% in 2005, despite the overall increase in uVIN incidence (Figure 2). 
Conversely, the diagnosis of dVIN increased in this time period to 5.5% of all VIN 
lesions in 2005, with a significant increase in especially the last three years of the 
study period.
With the objective to study possible differences in the incidence of m alignant 
progression from VIN to vulvar SCC the incidence of SCC more than three months 
after the initial diagnosis of VIN was determined. The overall percentage of 
uVIN patients subsequently diagnosed with vulvar SCC was 5.7% (104 patients). 
The risk of a subsequent diagnosis of SCC significantly increased with the age of 
diagnosis of uVIN, beginning with 2.7% for the age group 15-29 and increasing to 
8.5% for the group >75 years of age (p=0.005) (Figure 3). In addition, the time 
between diagnosis of uVIN and SCC significantly shortened with increasing age; 
50 months for the 15-29 age group and 25 months for the >75 age group (Figure 4).
8 0
3,0
-  —  dVIN
-------- uVIN
— —  vulvar SCC
year
Figure 2 O verview  of incidence vu lvar SCC, uVIN and dVIN for all patients.
The incidence of vulvar SCC rem ained stable  w hereas the incidences of both types of VIN 
increased.
go
;o
*0 c
—  dVIN
------uVIN
------vulvar SCC
Age categories
Figure 3 Age specific  incidence for vu lvar SCC, u- and dVIN from  1992-2005.
A gradual and strong increase in vulvar SCC was found. uVIN show s a bim odal peak 
incidence at the ages of 40 -4 4  and 75-79. dVIN has the highest prevalence at the age of 
75-79. Left y-axis: uVIN and dVIN incidence; right y-axis: vu lvar SCC incidence.
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15-29 30-44 45-59 60-74 >75
Age categories
Figure 4 Percentage of patients with uVIN that subsequently diagnosed with vu lvar SCC.
15-29 30-44 45-59 60-74 >75
Age categories
Figure 5 Tim e from  usual VIN to vulvar SCC developm ent.
The tim e from  uVIN to vu lvar SCC sign ifican tly  decreases with increasing age.
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The number of dVIN patients that were subsequently diagnosed with SCC was too 
small to give a trend over a 14 years study period (22 patients) but the overall 
percentage of dVIN lesions with subsequent diagnosis of SCC was 32.8%. The 
median time from uVIN towards SCC was 41.4 months (range 3 - 156 months), 
w hereas the median time from dVIN to SCC was significantly shorter: 22.8 months 
(range 3 - 8.4 months) (p=0.005). Th irty  percent of all SCCs after diagnosis of uVIN 
developed within one year of follow  up after the diagnosis of uVIN.
The database contained additional inform ation about previous, concom itant or 
subsequent intraepithelial neoplasia of the cervix, vagina and/or anus (CIN, VAIN 
and/or AIN, respectively). Forty-one percent of patients with uVIN had an 
associated HPV induced lesion of the lower fem ale anogenital tract, com prising 
cervical, anal, and vaginal (pre) neoplasia or com binations of those (Table 1). 
This percentage remained stable from 1992-2005. We found that the most 
common type was a CIN lesion or cervical carcinom a (33.5% of all uVIN patients). 
In contrast, epithelial abnorm alities of the genital tract were observed in only 
two of the 67 patients diagnosed with dVIN.
VAIN AIN AIN,
VAIN
CIN CIN,
AIN
CIN,
AIN,
VAIN
CIN,
VAIN
No
multicentric 
HPV associated 
lesion
1826
uVIN
45
(2.5%)
89
(4.9%)
7
(0.7%)
471
(25.8%)
93
(5.1%)
10
(0.6%)
37
(2.0%)
1074
67
dVIN
2
(2.9%)
0 0 0 0 0 0 65
Table 1 Overview  of prevalence of previous, concom itant or subsequent m ulticentric HPV 
associated intraepithelial neoplasias or invasive carcinom as.
Discussion
During the 14 year study period the incidence of uVIN and dVIN increased 
significantly, while the incidence of vulvar SCC remained stable. In the recent 
years vulvar prem alignant lesions have gained more public awareness, and a more 
liberal use of biopsies may have led to the observed increase in incidence 
worldwide.52'55 161 162'271'273 Increased awareness not only contributes to the doubling 
in uVIN diagnoses, but also it may result in removal of these lesions at an early
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stage of disease before these become invasive. In addition, the m alignant 
potential of uVIN lesions is considered to be low: about 3% to 5% of all uVIN 
patients progress towards SCC,161181229 and is in line with our data (5.7%).
O ther studies reported im pressive increases in uVIN incidence, up to 400%  
increase.52'55 161 162 271 Some of those also reported an increase in vulvar SCC in 
young patients,52 54'57 but in this study incidence of vulvar SCC under the age of 44 
remained stable. There are several differences between these previous 
publications and this study. First, we excluded recurrent VIN lesions; in addition, 
we excluded patients with a VIN lesion that developed into a vulvar SCC within 
three months, because it is most likely that the diagnosis of (micro) invasive SCC 
w as missed. Furtherm ore, we used a different statistical method; the above 
m entioned studies mostly studied two cohorts and compared them with a %2 test. 
Our data give an overview  of the trends over a 14 year period, and we have 
calculated w hether there was an increase or decrease over those years. Finally, 
the incidence of HPV related lesions of the lower fem ale genital tract may not 
show an increase as found in several other countries, possibly due to a limited 
increase in HPV prevalence. For example, the incidence of adenocarcinom a in situ 
lesions of the cervix has not increased in the Netherlands, which is in contrast 
with the incidence in the United States of Am erica.277
The overall percentage of dVIN patients subsequently diagnosed with vulvar SCC 
was 32,8%, which was significantly higher compared to uVIN patients (5.7%). 
Furtherm ore, the time period between diagnosis of VIN and SCC was significantly 
shorter for dVIN than for uVIN patients (22.8 compared to 42 months). dVIN is a 
recently recognised, and difficult to diagnose lesion due to the high degree of 
cellular differentiation, absence of w idespread architectural disarray, nuclear 
pleomorphism  and diffuse atypia.4 Default from the assum ption that about 75% 
of the vulvar SCC is HPV unrelated (2075 SCCs in this study) and have dVIN as 
prem alignant lesion (67 solitary dVIN lesions in this study), the incidence of 
so litary dVIN may be extrem ely underreported. This may be explained by the fact 
that dVIN as a solitary lesion, or even adjacent to SCC, easily may be mistaken for 
benign derm atosis or epithelial hyperplasia.45 It is thought that dVIN has a short 
intraepithelial period and a rapid progression towards SCC and therefore is less 
likely to be found w ithout the presence of a carcinom a.5 154 156 The percentage of 
32.8% would probably even be higher and the time to SCC shorter when invasion 
w ithin the three months after dVIN were included. It is unlikely that dVIN is a new 
lesion that som ehow developed in the past few years. We presume that of all 
lesions previously diagnosed as benign derm atosis or epithelial hyperplasia, a
large proportion would currently be diagnosed as dVIN. As such, trends in 
increased incidence of dVIN in the past years are merely a reflection of increased 
diagnosis of dVIN as a newly described entity rather than a truly increased 
incidence. Currently, w ell-defined histopathological features and im m unohisto- 
logical stainings exist to recognise dVIN more easily.1'4'545 This is reflected in the 
increased diagnosis of dVIN as a solitary lesion in the last three years of the study. 
A large study on the incidence of dVIN either as a solitary lesion or adjacent to 
SCC is needed to elucidate this point.
A bimodal peak incidence of uVIN incidence was observed at 40-44 and 75-79 
years of age (Figure 3). As the incidence of SCC strongly increases with age, the 
time from uVIN to vulvar SCC is much longer for the patients aged 40-44 than for 
patients aged 75-59. For uVIN patients we found that the percentage of uVIN 
patients that are subsequently diagnosed with vulvar SCC increased with the age 
of uVIN diagnosis. In addition, the time from uVIN towards the diagnosis of SCC 
was significantly shorter for patients in the older age group. This has not been 
described before but is in line with two reports on recurrence of CIN after 
treatm ent.278 279 This finding may possibly be explained by altered im m unity for 
elderly women compared to younger women. In young women uVIN may reflect 
the im m aturity of the immune system and a hindered elim ination of HPV. In older 
women uVIN may reflect a failure of the immune system to suppress HPV resulting 
in recurrent uVIN lesions and possibly vulvar SCC. In their review, van Seters et al. 
found that the patients with uVIN who were subsequently diagnosed with SCC 
often had im m unosuppressant treatm ent,181 which is supportive for a role for the 
immune system. Another explanation may be that older women are less likely to 
perform  self examination of the vulvar region than younger women.
Forty-one percent of uVIN patients had a past, concom itant or future HPV- 
associated lesion of the fem ale lower anogenital tract, whereas dVIN patients 
hardly presented these types of lesions. In two other reports, percentages of 
53% 50 and 67% (concerning a sm aller number of patients)51 were found, which are 
higher than reported in this study. In contrast to the study of Hampl et al.50 we did 
not include vulvar condylom as as an associated HPV induced vulvar lesion. Vulvar 
condylom as are merely caused by low-risk HPV 6 and 11, which is in contrast to 
the high-risk HPV types that are associated with uVIN, CIN, VAIN and AIN. As a 
result, the malignant potential of vulvar condylom as is thought to be negligible. 
CIN lesions were the most frequently found associated lesions, which is not 
unexpected as in the Netherlands women aged 30 -  60 years of age are screened 
for cervical abnorm alities every five years. The m ajority of HPV associated lesions
of the fem ale lower genital tract may be prevented by the current HPV 16-18 
vaccines that have been introduced recently and implemented in national 
vaccination programmes, as the m ajority of these HPV lesions are caused by these 
HPV types. The m ulticentricity of the HPV induced lesions argues to examine the 
entire lower fem ale genital tract for possible HPV induced lesions, once a lesion 
is found.
In conclusion, this study has dem onstrated that an increase in both types of VIN 
has not led to an increase in the incidence of vulvar SCC. In addition, dVIN lesions 
are rarely seen as a solitary lesion, but are diagnosed more often in the last years 
of the study, most likely as a result of recently established histopathological 
criteria. The malignant potential of dVIN is higher than for uVIN. For uVIN, the 
malignant potential increases with age.
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Abstract
Background: Vulvar lichen sclerosus (LS) is thought to be the precursor lesion of 
HPV unrelated vulvar squam ous cell carcinoma (SCC). It remains unclear why only 
2-5% of all LS lesions progress to SCC. It has been proposed that differentiated 
vulvar intraepithelial neoplasia (dVIN) is the direct precursor lesion. However, 
dVIN is only recently recognized as a separate entity and is a d ifficult diagnosis 
which may easily be missed or mistaken for a benign derm atosis. The aim of this 
study was to test the hypothesis that of all lesions that have been diagnosed as 
LS in the past, a part might currently be diagnosed as dVIN and to identify 
histopathological differences between LS lesions with and w ithout progression to 
vulvar SCC.
Methods: All LS slides were revised by two expert gynaecopathologists, who 
were unaware of the course of the patient. The presence of hyperkeratosis, 
parakeratosis, dyskeratosis, hyperplasia, basal cellular atypia of keratinocytes, 
(atypical) mitoses, oedema, hyalinisation and subepithelial inflamm ation were 
docum ented. Furtherm ore, the presentation of the rete ridges and basal cell layer 
were examined and the epithelial thickness counted.
Results: After revision of LS biopsies w ithout progression (n=61), 58 were 
reclassified as LS. In contrast, revision of LS biopsies with progression yielded 
concordant diagnoses in 18/60 cases (30%). Im portantly, 25/60 (41.7%) lesions 
were reclassified as dVIN. Median time from dVIN to vulvar SCC was significantly 
shorter (27.5 months) than from LS to vulvar SCC (83.8 months) (p<0.001). LS that 
did progress to SCC, but that did not meet the criteria for dVIN, more often 
showed parakeratosis (p=0.004), dyskeratosis (p<0.001), hyperplasia (p=0.048) 
and basal cellular atypia (p=0.009) compared to LS w ithout progression.
Conclusion: dVIN diagnosis has been frequently missed and is associated with 
rapid progression to SCC. Patients with LS with dys- and parakeratosis, hyperplasia 
and/or basal cellular atypia should be kept under close surveillance as these 
lesions also tend to progress to SCC.
90
Introduction
Vulvar squam ous cell carcinom a (SCC) is the fourth most comm on type of 
gynaeco logical cancer and affects the external fem ale genitalia. It accounts for 
approximately 3-5% of all gynaecological malignancies, with an incidence rate of 
1-2/100,000.10 Vulvar SCC is a disease that occurs in the 6th-7th decade of life, and an 
increase in incidence is to be expected due to the ageing of w om en. Vulvar SCC 
treatm ent has a great im pact on the quality of life because of the extensive 
surgery that is often required.9 Im provem ents for the patients are established 
by ind ividualization of treatm ent (e.g., the Sentinel Lymph Node technique15) 
and prevention of the disease by more insight in and treatm ent of the associated 
prem alignancies.
There a re two different pathways I eading to vulva r SCC with their own prem alignant 
lesions; the most common pathway, that accounts for approxim ately 80% of all 
SCCs, is HPV-independent,280 but its aetiology is still unknown. These, mostly 
differentiated keratinizing, SCCs often arise in Lichen Sclerosus (LS) and it has 
therefore been suggested that LS is the precusor lesion of SC C.28'29'281 LS is a 
chronic inflam m atory skin disease and mainly affects the fem ale anogenital 
area.76258 The classical histological findings of LS are a thinned epiderm is and/or 
loss of rete ridges, hyperkeratosis, oedema and/or hyalinization, and a chronic 
band like inflam m atory cell infiltrate of the derm is58 (Figure 1), but there are a lot 
of variations to these classical histological characteristics, leading to a myriad of 
lesions that may be classified as LS. Although LS is considered a prem alignant 
condition, only 2-5% of the patients with LS ultim ately develop a vulvar SC C.2930 
Currently, no molecular markers have been proven to identify LS lesions that are 
at risk to develop vulvar SCC. It has been hypothesized more recently, that 
differentiated Vulvar Intraepithelial Neoplasia (dVIN) is the direct precursor of 
vulvar SCC. dVIN (Figure 2A) is often found directly adjacent to SCC and is 
characterized by a thickened epithelium  that is typically associated with elongation 
and anastom osis of rete ridges (Figure 2B). Dys- and parakeratosis are usually 
present (Figure 2 C & D), associated with prom inent intercellular bridges (Figure 
2B). The basal keratinocytes are large and pleom orphic with a relatively large 
amount of eosinophilic cytoplasm . Keratin pearl form ation within the rete ridge 
may be seen. The nuclear chrom atin is vesicular rather than coarse, and the nuclei 
have prom inent nucleoli (Figure 2E), usually most prom inently in the basal and 
parabasal keratinocytes.58 Although dVIN is seen adjacent to approxim ately 80% 
of vulvar SCCs,280 it is seldom diagnosed as a solitary lesion.282 This discrepancy
C
ha
pt
er
 
5 
Di
ffe
re
nt
ia
te
d 
vu
lva
r 
in
tr
ae
pi
th
el
ia
l 
ne
op
la
sia
 
is 
of
te
n 
fo
un
d 
in 
le
sio
ns
, 
pr
ev
io
us
ly 
di
ag
no
se
d 
as 
lic
he
n 
sc
le
ro
su
s, 
th
at
 h
av
e 
pr
og
re
ss
ed
 
to 
vu
lva
r 
sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a
may be explained by underdiagnosis; dVIN may easily be missed or mistaken for a 
benign derm atosis, such as lichen simplex chronicusand squamous hyperplasia.4'545 
In addition, it has been proposed that dVIN has a relatively short intraepithelial 
phase before progression towards vulvar SCC282 which makes it more difficult to 
diagnose isolated dVIN. It has been hypothesized that dVIN may develop from LS 
and carries a higher malignant potential than LS does.5 28'36148'283'284 We hypothesize 
that of all lesions that have been diagnosed as LS in the past, a part would 
currently be diagnosed as dVIN.
Figure 1 Classical cases of lichen sclerosus (LS). A: Typical exam ple of LS with a thinned 
epiderm is and loss of rete ridges, hyperkeratosis, hyalinization, and a chronic band like 
inflam m atory cell infiltrate  of the derm is
B: Lichen sclerosus with atypia, C: Lichen sclerosus with hyperplasia. Original m agnification. 
A-C: lOOx.
The term inology and criteria for the diagnosis LS have been subject to quite some 
revisions in the past 40 years and this unevitably has led to diagnoses of LS that 
would currently be classified differently, including dVIN. Before the 1975 ISSVD 
classification285 of vulvar dystrophies, confusing terms such as 'kraurosis', 
'leukoplakic vulvitis' and 'atrophic vulvitis' were used. The term 'vulvar dystrophy' 
replaced all of these terms. In 1987, the term 'non-neoplastic epithelial disorders 
of the vulva' was introduced to replace 'dystrophy', listing LS, squamous 
hyperplasia and other derm atoses.286 In 2005, Regauer proposed the term 'early' 
LS, to be set apart from 'atrophic' LS120, suggesting there clearly are two types of 
LS, each with its own histopathological criteria, but this subdivision has not gained
w orldwide acceptance.
It is currently unknown which LS lesion carries risk of malignant progression. This 
is in part due to the wide variety of histopathological entities that have been 
collectively diagnosed as LS in the past. The first aim of this study was to test the 
hypothesis that of all lesions that have been diagnosed as LS in the past, a part 
would currently be diagnosed as dVIN. The second aim was to determine whether, 
in retrospect, there are histopathological differences between LS lesions that did 
and did not progress to vulvar SCC. Recognition of the LS at risk for SCC 
developm ent would greatly help to select patients who need close follow-up.
Figure 2 Differentiated VIN.
Low pow er overview  of dVIN (A) w ith the five  m ost im portant h istop ath o lo gica l 
ch a ra cte ristics  that can be recognized in a H&E stain: e longated rete ridges with 
anastom osis (B), d isord erly  basal cell layer and d yskeratosis(C ), p arakeratosis (D), 
prom inent nucleoli (E), and atyp ica l m itoses, indicated by arrow s (F).
O riginal m agnifications: 50x (A), lOOx (B,D), 200x (C,E) and 400x (F).
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Patients and Methods
Patient selection
Lichen scierosus without progression
Patients with LS who were not diagnosed with a subsequent vulvar SCC were 
selected from the outpatient clinic at the departm ent of Obstetrics and 
Gynaecology of the Radboud University Nijmegen Medical Centre (RUNMC), the 
Netherlands. We used the nationwide Netherlands database of Cyto- and 
Histopathology (PALGA)287 to confirm  that these patients did not develop a vulvar 
SCC with a minimum follow  up of ten years.
Lichen scierosus with progression
Patients with vulvar SCC who were treated at the departm ents of Obstetrics and 
Gynaecology of the RUNMC or the University Medical Centre Groningen between 
January 1st 1988 and December 31th 2008 were selected for this study. W ith the 
use of PALGA, all prior vulvar biopsies with the diagnoses 'Lichen scierosus (et 
atrophicus)' and 'vulvar dystrophy' were retrieved. When m ultiple prior biopsies 
were available from different moments, the most recent biopsy was included for 
this study (with a minimum interval between the biopsy and vulvar SCC of three 
months). In case m ultiple biopsies were taken at the same time, the lesion with 
the most severe dysplastic characteristics was selected.
The haem atoxylin and eosin (H&E)-stained slides were retrieved and reviewed by 
two expert gynaecopathologists (JB and HH) independently and unaware of the 
course of the patient. D iscrepancies were resolved in a consensus m eeting with 
these two gynaecopathologists. In the analyses, we categorised the diagnoses 
vulvar dystrophy and LS together, because in earlier days the term vulvar 
dystrophy was used for the same entity as LS. Concordance between the original 
and revised diagnosis was calculated.
Collected data
The patients' age, time of diagnosis of SCC and time to progression were obtained 
from medical charts and electronic patient files. All slides were scored on the 
presence of hyperkeratosis, parakeratosis (Figure 1C and 2D), dyskeratosis (Figure 
2C), hyperplasia (Figure 1C), basal cellular atypia (Figure 1 B), presence of mitotic 
figures (Figure 2F), oedema, hyalinization (Figure 1A) and presence of subepithelial 
inflamm ation (Figure 1A). In addition, we examined the presentation of the rete 
ridges (Figure2B), the basal cell layer (Figure 2C) and the epithelial thickness.
Statistical analysis
Calculations were perform ed using Statistical Package for Social Sciences 16.0 
(SPSS, Chicago, IL).
Descriptive statistics were used to reproduce study results as percentages, 
means, m edians and standard deviations. Chi-Square tests were used to identify 
significant differences between LS with and without progression. The Independent- 
Sam ples t-Test was used to compare the age for two groups. P-values less than
0.05 were considered to be statistically significant.
Results
Lichen sclerosus without progression
Sixty-one patients with LS w ithout progression and a minimal follow up of ten 
years were retrieved from the pathology archives of the RUNMC. Median age at 
the time of the diagnosis was 59.5 (range 16-83 years) Three biopsies did not fulfil 
criteria for LS and were excluded. In 58 of the 61 cases (95%), the diagnosis was 
not changed.
Lichen sclerosus with progression
During the study period 1988-2008, 273 patients with vulvar SCC were treated in 
Nijmegen and 548 patients were treated in Groningen. In Nijmegen, 33 cases that 
sufficed the criteria of a prior biopsy with 'Lichen sclerosus(et atrophicus)' or 
'vulvar dystrophy' were identified and 72 in Groningen. Of these 105 cases, a 
total number of 60 biopsies were received from the pathology archives of the 
RUNM C/ University Medical Centre Groningen and the referring hospitals in the 
surrounding areas. We did not receive 35 biopsies we requested from the hospitals 
where the biopsies were taken and ten biopsies were excluded from analysis for 
different reasons (poor quality H&E staining, or slides with too little tissue to 
review). The study population consisted of 60 LS patients with progression to 
vulvar SCC. Median age at the time of diagnosis of LS was 64.6 (range 30-90) 
years. These patients were older compared to LS patients w ithout progression 
(p<0.001).
All biopsies were revised and scored. In total, diagnoses of 42 biopsies were 
changed by the two expert gynaecopathologists (70%). Tw enty-five of the 60 
(41.7%) lesions previously diagnosed as LS, but that did progress to SCC, were 
reclassified as dVIN (Figure 2). The biopsies that were changed into dVIN mainly
C
ha
pt
er
 
5 
Di
ffe
re
nt
ia
te
d 
vu
lva
r 
in
tr
ae
pi
th
el
ia
l 
ne
op
la
sia
 
is 
of
te
n 
fo
un
d 
in 
le
sio
ns
, 
pr
ev
io
us
ly 
di
ag
no
se
d 
as 
lic
he
n 
sc
le
ro
su
s, 
th
at
 h
av
e 
pr
og
re
ss
ed
 
to 
vu
lva
r 
sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a
came from the original diagnosis categories of LS with an associated lesion such 
as an HPV induced lesion (VIN 1, 3, Morbus Bowen, Buschke Lowenstein), or from 
LS with hyperplasia, atypia or both. The highest percentage of concordance 
between the original and changed diagnoses was achieved for 'simple' LS w ithout 
an associated lesion (42.9%). The original and revised diagnoses are given in Table 1. 
Of all biopsies, six were not classified as LS/dVIN. Twenty-nine biopsies were 
diagnosed as LS, of which one was classified as early LS (categorized as LS),120 and 
three were classified as LS with hyperplasia (Figure 1C). Five LS biopsies had basal 
cellular atypia (Figure IB ), and two biopsies were classified as LS with hyperplasia 
and basal cellular atypia. These seven biopsies did not comply with other criteria 
for dVIN.
Differences in the time to progression into vulvar SCC between LS and dVIN 
biopsies were calculated. For this analysis, the six biopsies w ithout LS or dVIN 
were excluded. The time to progression for dVIN (27.5 months) was shorter than 
for LS (83.8 months) (p=0.001) (Table 2). The number of lesions in the subcategories 
of LS were too small to calculate differences in tim es until progression.
Histopathological differences between lichen sclerosus with and without 
progression
For this com parison, only biopsies were included that were indeed classified as LS 
after revision (29 with progression, 58 w ithout progression). LS biopsies with 
progression showed more often dyskeratosis (31% vs. 0% p<0.001) and 
parakeratosis (48.3% vs. 19% p=0.004) than LS biopsies w ithout progression. 
In addition, LS biopsies with progression more often had hyperplasia (24.1% vs. 
8.6% p=0.048) and basal cellular atypia (20.7% vs. 3.4% p=0.009). The other 
histopathological characteristics did not differ between both groups (Table 3).
96
Diagnosis after revision
Original
diagnosis Total LS
LS with 
hyperplasia
LS
with
atypia
LS with 
hyperplasia 
and atypia dVIN Other
Concordance
n(%)
Lichen
sclerosus
42 18 4 3 1 10 6 18/42 (42.9)
LS with HPV 
related lesion
5 1 4 0/5
LS with atypia 4 4 0/4
LS with 
hyperplasia
9 1 1 7 0/9
Total 60 19 4 6 2 25 6 18/60 (30)
Table 1 Overview  of original and diagnoses after revision.
Diagnosis after revision
1
Median age 
(range)
Median time 
to vulvar SCC 
(months) 
(range)
Lichen sclerosus 29 64.6 (30-90) 83.8(9-230)
-  Lichen sclerosus 19 67.6 (52-79) 61 (9-200)
-  Lichen sclerosus with hyperplasia 3 51.8(30-54) 98.6(13-135)
-  Lichen sclerosus with atypia 5 59.1 (53-64) 115 (91-231)
-  Lichen sclerosus with hyperplasia and atypia 2 69.7 (65-73) 30 (26-35)
Differentiated VIN 25 64.4 (42-90) 27.5 (5-144)
No Lichen sclerosus, no differentiated VIN 6 64 (54-72) 31.4 (4-63)
Table 2 LS with progression; diagnoses after revision by two expert gynaecopathologists.
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Histological features LS without progression 
(N= 58)
LS with progression 
(N = 29)
P value
Number % Number %
Hyperkeratosis
No
Yes
21
37
(36.2)
(63.8)
11
18
(37.9)
(62.1)
.875
Parakeratosis
No
Yes
47
11
(81)
(19)
15
14
(51.7)
(48.3)
.004
Dyskeratosis <0.001
No 58 (100) 20 (69)
Yes 0 (0) 9 (31)
Rete ridges .235
Normal 2 (3.4) 5 (6.9)
Reduced 51 (87.9) 21 (82.8)
Widened 4 (6.9) 0
Merged 1 (1.7) 1 (3.4)
Elongated and merged 0 1 (3.4)
Widened and merged 0 1 (3.4)
Epithelial thickness .332
(cells) 1 (1.7) 1 (3.4)
<5 27 (46.6) 10 (34.5)
5-9 24 (41.4) 11 (37.9)
10-14 5 (8.6) 4 (13.8)
15-19 1 (1.7) 3 (10.3)
>20
Hyperplasia .048
No 53 (91.4) 22 (75.9)
Yes 5 (8.6) 7 (24.1)
Dysplasia .213
No 57 (98.3) 27 (93.1)
Yes 1 (1.7) 2 (6.9)
Basal cellular atypia .009
No 56 (96.6) 23 (79.3)
Yes 2 (3.4) 6 (20.7)
Mitotic figures .510
No 49 (84.5) 26 (89.7)
Yes 9 (15.5) 3 (10.3)
Basal cell layer
Normal
Disorderly
52
6
(89.7)
(10.3)
27
2
(93.1)
(6.9)
.600
Oedema
No
Yes
22
36
(37.9)
(62.1)
11
18
(37.9)
(62.1)
1.000
Hyalinisation
No
Yes
12
46
(20.7)
(79.3)
2
27
(6.9)
(93.1)
.099
Inflammation at
epithelial-dermal
junction
Absent
Focal
Diffuse
22
12
24
(37.9)
(20.7)
(41.4)
9
5
15
(31)
(17.2)
(51.7)
.658
Inflammation .647
subepithelial 25 (43.1) 14 (48.3)
Bandlike 33 (56.9) 15 (51.7)
Not bandlike
Intraepithelial
presence .759
inflammation cells 24 (41.4) 13 (44.8)
No 34 (58.6) 16 (55.2)
Yes
Table 3 Overview  of original and diagnoses after revision.
Discussion
In this study we found that 41.7% of LS biopsies, taken from patients who showed 
progression into vulvar SCC, showed the histological characteristics of dVIN. 
In the majority of cases dVIN was found in biopsies of which the original diagnosis 
was LS with an HPV induced lesion or with hyperplasia and/or atypia. In addition, 
we found that LS biopsies with dys- and parakeratosis, hyperplasia and atypia 
may be regarded as LS with an elevated risk of vulvar SCC developm ent.
By revising numerous biopsies which were earlier classified as LS, we show that a 
substantial part nowadays would be diagnosed as dVIN. Remarkably, most 
revisions were made when the original report mentioned LS with an associated 
lesion (an HPV induced lesion, hyperplasia and/or atypia) (Table 1). Most 
concordance was achieved for 'simple' LS lesions w ithout an associated lesion. 
The histological diagnosis of dVIN is d ifficult; the recognition of dVIN is hindered 
by a high degree of cellular differentiation combined with an absence of 
w idespread architectural disarray, nuclear pleomorphism  and diffuse nuclear 
atypia.4 The atypia in dVIN lesions is strictly confined to the basal and parabasal 
layers of the epithelium .4 58 In addition, despite dVIN was first described in the 
1960s by Abell as a highly differentiated form of vulvar carcinom a in situ (CIS),288 
until more recently, the entity has not gained wide attention because its existence 
as a clinicopathological entity has long been questioned.42 Since more insight is 
gained that vulvar SCCs originate from two different pathways, each with its own
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prem alignant lesions,12 dVIN has been designated the direct precursor of the HPV 
independent pathway. Earlier, all VIN lesions were classified as being HPV related, 
which explains the high incidence of LS with HPV induced lesions, which turned 
out to be dVIN instead of the nowadays so-called usual VIN (uVIN) lesions.3 
In addition to the d ifficult histopathological diagnosis, it is thought that the 
intraepithelial period of dVIN is short, all being reasons why dVIN has been seldom 
diagnosed as a solitary lesion. In this study, we show that dVIN is not as rare as a 
solitary lesion as previously thought, but there is significant underdiagnosis. 
The recognition of dVIN is of utmost im portance because the malignant potential 
of dVIN is thought to be high,282 and therefore treatm ent differs between LS 
(topical superpotent corticosteroid ointm ent127) and dVIN (surgical excision258). 
After exclusion of the lesions that were changed into dVIN, we found that LS 
biopsies with progression more often showed dys- and parakeratosis, hyperplasia 
and basal cellular atypia in com parison with LS biopsies w ithout progression. 
It has been suggested that hyperplasia, dysplasia or cellular atypia are precursor 
features linking progression of vulvar LS to vulvar SCC30'31'3637 and that squamous 
cell hyperplasia with atypia might represent a step in the carcinogenesis towards 
vulvar SCC.151 Although the numbers of LS lesions with atypia or hyperplasia were 
small in our study, it may be recommended that these patients require a more 
careful follow  up because they have a higher risk to develop vulvar SC C .37 
The characteristics of dys- and parakeratosis have not been associated with 
progression towards vulvar SCC before, but were not included in the analyses of 
the earlier studies. In our study, dysplasia was not a characteristic of LS biopsies 
with progression. We hypothesize that in the studies that have defined features 
linking progression of LS to SCC, also dVIN lesions may have been included, and 
therefore dysplasia was found to be associated with progression. Patients with 
progression were significantly older at the time of the biopsy, which has also been 
associated with malignant progression in other studies,3137 but the difficu lty is 
that it is unknown for how long the patients have been suffering from LS at the 
time of the biopsy.
From this study, we cannot draw strong conclusions regarding the m alignant 
potential of dVIN because we have not included dVIN lesions without progression. 
In the LS group w ithout progression, no dVIN lesions were found. In an earlier 
study, we saw that 32.8% of solitary dVIN lesions progressed to vulvar SC C.282 
In that study, we only used the reports in the PALGA database; we did not revise 
the VIN lesions. Now that we dem onstrate that dVIN is more often present in its
solitary form than previously thought, its high malignant potential should be 
appreciated. The median time between dVIN biopsies and vulvar SCC developm ent 
in this study was 27.5 months, which is comparable with the 22.8 months in our 
other study.282 In total, we have identified 92 (67282 and 25 (this study) solitary 
dVIN lesions with and w ithout progression, which is still rather a small number to 
draw strong conclusions from.
This study has several lim itations; the first is the possible different localization of 
the biopsies and the subsequent SCC. We do not have access to these data of 
patients as this is poorly recorded. The concept of field cancerization is plausible, 
because in most patients the greatest part of the vulva is affected by LS. But it is 
unknown w hether different types of LS were present in one patient at the same 
time. In addition, there is a large time range between LS lesions and vulvar SCC 
developm ent, the longest being 19 years.
In total, 821 patients were treated for a vulvar SCC during the study period, and 
of only 105 patients a biopsy of LS or vulvar dystrophy was identified. We used 
PALGA,274 which has national coverage from 1992 onwards, so it may be that more 
biopsies were taken before 1992 that we did not retrieve. However, the majority 
of vulvar SCC patients do not have a recorded and histopathologically proven 
history of LS, but suffer from LS, either asym ptom atic or unnoticed.29'3133'35 This 
may result in delayed diagnosis by both patients and doctors. In our vulvar clinic, 
the policy is to biopsy every women with a suspicion of LS, because this diagnosis 
has the consequence of a lifelong follow  up (at least yearly).
In conclusion, we found that in patients with progression, the original diagnosis 
LS often was changed into dVIN. When adhering to strict criteria (elongated rete 
ridges with anastom osis, a disorderly basal cell layer, dys- and parakeratosis, 
prom inent nucleoli and atypical mitosis) the diagnosis of dVIN should be more 
easy to make, especially when the patient is suffering from LS as well. We conclude 
that dVIN suffers from underdiagnosis rather than from rarity. When the diagnosis 
LS with an HPV associated lesion, atypia or hyperplasia is made by a pathologist, 
the diagnosis dVIN should at least be considered by both the pathologist and the 
gynaecologist/derm atologist. Furtherm ore, when the diagnosis dVIN cannot be 
established, but when LS with dys- and/or parakeratosis, hyperplasia and basal 
cellular atypia is diagnosed, close follow up of the patient is warranted as these 
LS lesions are at increased risk for malignant progression. A prospective study 
and translational research are needed to confirm  our hypothesis that patients 
with LS lesions with dys- and/or parakeratosis, hyperplasia and basal cellular 
atypia are at risk to develop vulvar SCC.
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Abstract
Aims: The m olecular pathogenesis of HPV-unrelated vulvar squamous cell 
carcinom a (SCC) is not well known. W hether malignant progression of lichen 
sclerosus (LS) and differentiated vulvar intraepithelial neoplasia (dVIN) to vulvar 
SCC could be accom panied by altered DNA content has not been studied 
extensively.
Methods & results: DNA-content in isolated nuclei of m icrodissected normal 
vulvar epithelium (n=2), LS (n=9), dVIN (n=13), solitary dVIN (n=6) and SCC (n=17) 
from 26 patients, was measured via DNA image cytom etry. p53 expression was 
determ ined by im m unohistochem istry on consecutive tissue sections. Th irty-e ight 
percent of dVIN lesions (5/13) and 65% of SCCs (11/17) were DNA aneuploid or 
tetraploid. In lesions that contained dVIN and adjacent SCC, the ploidy status of 
dVIN did not exceed that of SCC. We observed a strong correlation between high 
p53 expression and DNA aneuploidy. This relation was also present at the level of 
single nuclei, measured by sequential image cytom etry of p53-im m unohisto- 
chem istry followed by DNA image cytom etry on form alin-fixed tissue sections. 
Sim ilarly, we found p53-positive non-proliferating cells with increased DNA 
content in the superficial com partm ent of 6 solitary dVIN that were not associated 
with SCC, indicating ascending aneuploid cells from the basal compartm ent.
Conclusions: DNA ploidy m easurem ents suggest that dVIN has a higher m alignant 
potential than LS, and thus is a more likely precursor of SCC. Furtherm ore, high 
p53 expression correlates with increased DNA content and aneuploidy, but it 
requires further research to unveil a possible causal relation.
1 0 6
Introduction
Vulvar cancer is the fourth most common gynaecologic cancer and accounts for 
approxim ately five percent of the m alignancies of the fem ale genital tract.289 
Based on etiologic characteristics, two separate pathways that lead to vulvar 
squamous cell carcinom a (SCC) can be distinguished.2 About a third of all vulvar 
SCCs develops through a high-risk human papillom avirus (HPV)-dependent 
pathway in which premalignant stages of vulvar SCC are usual vulvar intraepithelial 
neoplasia (uVIN)-lesions that mainly affect younger women. However, the 
m ajority of vulvar SCCs arise in the absence of HPV, predom inantly in older 
women with lichen sclerosus (LS). LS is a chronic inflam m atory disease of the 
vulvar skin and mucosa characterised by markedly thinned epithelium  with loss of 
rete ridges, culm inating in architectural changes of the vulva and can give rise to 
severe itching. D ifferentiated VIN (dVIN) is thought to play a role in this HPV-inde- 
pendent pathway as a prem alignant lesion with a high malignant potential 
although the m olecular pathogenesis remains elusive.2 Women with LS have a 
two to six percent lifetime risk to develop vulvar SC C.258 dVIN is seen relatively 
infrequently in its pure form and is com m only identified as an ulcerative or 
verrucous lesion, adjacent to invasive SCC, often in a background of LS. dVIN can 
be a d ifficult histological diagnosis as the atypia is confined to the basal cell layers 
w hereas the rest of the epithelium shows normal m aturation.58 The possible 
malignant progression of LS via dVIN and subsequently rapidly to vulvar SCC, may 
be caused by m itotic defects and consequently chrom osom e m issegregation and 
instability.
DNA aneuploidy, a frequently identified genom ic abnorm ality, can occur in the 
earliest stages of m alignant transform ation, although it is unknown w hether DNA 
aneuploidy is a cause or consequence of malignant progression.290 Impaired 
functioning of cell cycle checkpoint proteins contributes to proliferation of cells 
with impaired genom ic integrity. To prevent survival of aneuploid cells, cell cycle 
checkpoint proteins block cell proliferation after abnormal division.291 In normal 
skin, only a small percentage of cells divides and has a tetraploid status. Due to 
increased proliferation, the percentage of tetraploid cells increases and may 
result in the developm ent of aneuploid cells when loss of function of the cell cycle 
regulator proteins occurs.291 The tum our suppressor protein p53 is a key regulator 
of m aintaining normal diploid status292 and halts cell division and/or eliminates 
cells that have acquired irreparable DNA dam age.293 A relationship between high 
p53 expression, m orphological variability of nuclei and DNA aneuploidy in breast
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1 0 8
carcinom as was dem onstrated by Haroske and co-w orkers294 more than a decade 
ago, but has not been studied in vulvar carcinom as and their precursor stages 
before.
In vulvar SCCs, ploidy has been studied mostly in relation to prognosis. It has 
been reported that aneuploidy in vulvar SCC varies from 13% to 83%, but no 
relation with prognosis has been described so far.169295 300 Aneuploidy in vulvar LS 
varies from 0% to 33% of the cases.31'169'300'301 The relation between the expression 
of cell cycle proteins and ploidy status of vulvar lesions has not been extensively 
studied. Lerma et al. concluded that p53 expression is a late event in m alignant 
progression as 72% of the mainly HPV-negative SCCs were aneuploid and only 
56% of the SCCs showed p53-overexpression.169 Recently, high p53 expression in 
the basal cell layers of LS has been postulated as a marker for increased likelihood 
to progress to vulvar SC C.39
The aim of this study was to analyse ploidy in different groups of HPV-negative 
vulvar lesions to test the hypothesis that in LS, dVIN, and SCC, increased DNA 
content abnorm ality is associated with an increased malignant potential of the 
histological entity. In addition, we evaluated the correlation between aneuploidy 
and the expression of p53 with the intention to shed light on the potential 
malignant conversion of LS and dVIN towards SCC.
Methods
Sample Selection
Form alin-fixed and paraffin-em bedded tissue sections of 28 patients who 
underwent a local excision or (partial) vulvectom y because of a (pre-) malignancy 
of the vulva, were random ly selected from the archives of the Departm ent of 
Pathology, Radboud University Nijmegen Medical Centre. All tissue sections 
were collected between 1996 and 2009. All original H&E-stained slides were 
re-exam ined by an expert gynaecopathologist (JB), and all lesions were classified 
according to WHO criteria.58 Tissues were obtained according to local ethical 
guidelines and approved by the local regulatory committee.
The median age of all patients was 71.5 years (range 37-90 years). From most 
patients, more than one type of lesion was present in the excised tissue and the 
total number of lesions available for analysis was 47: two sam ples of normal 
epithelium , nine LS lesions, 13 dVIN lesions, and 17 sam ples with SCC. In addition, 
6 solitary dVIN not associated with micro- or m acro-invasive SCC were included in
this study. See Table 1 for an overview  of the lesions and tissue composition. 
In the tissue sections with LS and dVIN, and 1 dVIN lesion, m icro-invasive vulvar 
SCC was present in the tissue, but was too small for ploidy analysis (Table 1). 
All patients with SCC had LS in the excised material; when it was present in the 
same tissue block, both entities were analysed.
Lesions were tested for high risk HPV DNA using a broad-spectrum  HPV detection/ 
genotyping assay (SPFlO-LiPA) and were all HPV-negative. The combined 
SPF-PCR-LiPA system for detection and genotyping of HPV has been described in 
detail elsew here.261'302
Lesion Number of
Patients Samples
LS only 1 1
dVIN (adjacent to microinvasive SCC) 1 1
dVIN (without adjacent (micro) invasive SCC 6 6
SCC only 5 5
LS+dVIN (all adjacent to (micro)invasive SCC) 3 6
LS+SCC 2 4
LS+dVIN+SCC 3 9
dVIN+SCC 5 10
N+SCC 1 2
N+dVIN+SCC 1 3
Total 28 47
Table 1 Num ber of patients and sam ples 
LS = lichen sclerosus (n=9)
SCC = squam ous cell carcinom a (n=17) 
dVIN = differentiated VIN (n=19)
N = normal epithelium  (n =2)
Tissue dissection and isolation of nuclei for Feulgen staining
From each paraffin-em bedded tissue block, a 50 |j.m thick section was cut and 
dewaxed through xylene and rehydrated through graded alcohol. The tissue 
sections were washed three tim es in dem ineralised water and phosphate- 
buffered saline (PBS), before m icrodissection of the different epithelial lesions. 
Excised tissue was digested with pepsine (Sigma Aldrich, 2 ml 0.5%(w/v), p H l,5) 
for 60 minutes at 37°C. After complete tissue dissolution, 2 ml of PBS was added
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to stop the reaction. The suspension was passed through a 50 |j.m Celltrics filter, 
and spinned down for 10 min at 150g. The pellet of nuclei was collected and 
counted using a Coulter Counter. Subsequently, the suspension was centrifuged 
again and the pellet was re-suspended in PBS to a dilution of 200.000 nuclei per 
ml. A cytospin of 20.000 nuclei was prepared (100 |J.I,10 min, lOOg), followed by 
fixation in Bohm fixative (60 min at room tem perature (RT)), rinsed with methanol 
and air-dried. For ploidy measurement, Schiff-Feulgen staining was perform ed as 
described elsew here.303
Ploidy examination with Q-path DNA software
Image cytometry with Q-path DNA software (Leica Imaging Systems Ltd. Cambridge, 
UK) was performed to determine DNA ploidy of isolated nuclei. For each analysis 
DNA content of 4000 nuclei was calculated autom atically. Images of overlapping 
nuclei were m anually excluded from the analysis. Ploidy status was determined 
according to the consensus criteria of the European Society for Analytical Cellular 
Pathology (ESACP).304 306 In each sample, lym phocytes were identified by their size 
and roundness and included as an internal control for true diploid status.
p53 and MIB1 im munohistochem istry
Four-micrometer-thick sections of formalin-fixed paraffin-embedded tissue blocks 
were mounted onto SuperFrost slides and dried overnight at 37°C. The sections 
were dewaxed in xylene and rehydrated through graded alcohols. Following 
quenching of endogenous peroxidases, slides were rinsed three times in PBS (pH 
7.4) for 5 minutes, and antigen retrieval perform ed with boiling sodium citrate 
(0.01 M; pH 6 .0 ,10  minutes). After cooling down to RT, tissue sections were rinsed 
in PBS for 10 minutes and subsequently incubated with a prim ary m onoclonal 
antibody towards p53 (clone DO-7 (Neomarkers), 1:1000 in PBS containing 1% 
(w/v) bovine serum albumine (BSA)) for lh  at RT. Subsequently the slides were 
rinsed in PBS (10 minutes) and post antibody blocking was perform ed for 15 
minutes (Powervision Plus, Dako SA, Glostrup, Denmark). This was followed by 
incubation with polym eric-horse-radish peroxidase conjugated goat-anti-rabbit 
IgG, (30 minutes, RT). Staining was developed with diam inobenzidine (DAB) in the 
presence of H20 2, counterstained with M ayer's haem atoxylin, dehydrated in 
ethanol and xylene, and finally mounted with Permount (Fisher Chemicals, NJ, 
USA). Negative controls (buffer only) and positive controls were included in each 
analysis.
Because the atypical cells in dVIN are located in the basal parts of the epithelium , 
nuclear p53-positivity in the lower one-third of the epithelium  was estimated. 
In the SCCs and LS lesions, the percentage of p53-positive cells in the entire lesion 
was estim ated.
MIB1
MIB1 im m unohistochem istry was performed as has been described in detail 
elsew here.153
Combined p53 im munohistochem istry and DNA image cytom etry
Tissue sections (7 |j.m) mounted on Superfrost slides were stained for p53 as 
described above, but developed with the water soluble 3 am ino-9-ethyl-carbazol 
(AEC) instead of DAB, and mounted with Imsol w ithout coverslips. Images of 
representative areas were digitised and stored in 24 bit RGB using a 3CCD camera 
(Sony 950P, Sony, Japan) attached to a Zeiss AxioPhot m icroscope (Carl Zeiss, 
Germany) with 20x objective (Plan Neofluar, NA=0.5; specim en level pixel size
0.64x0.64 |j.m2). Subsequently, p53 stained sections were washed in dem ineralised 
w ater (37°C, 1 hour), followed by an overnight w ash-step in dem ineralised water 
to remove all traces of Imsol. After a brief third wash with dem ineralised water, 
tissue sections were submerged in Bohm fixative (60 min, room temperature), 
rinsed with methanol, air-dried and Schiff-Feulgen staining was perform ed. This 
procedure removes all p53 staining as well as the haem atoxylin counter staining. 
Contours of nuclei in stored p53 images were extracted and shown as an overlay 
in the live camera image, to facilitate acquisition of exactly the same locations in 
the Feulgen stained sections. Images of the Feulgen stained sections were 
acquired using the same camera and m icroscope setup, using a band pass filter 
(5 6 5 . 5 + /-2 0 n m ). Recognition of nuclei in images from Feulgen stained specim ens 
was initially perform ed by applying a region growing algorithm  on manually 
indicated seed points. If required, results of region growing were interactively 
corrected. Integrated optical density (IOD) of both Feulgen and p53 staining were 
calculated for 500 to 1000 nuclei in each specim en. To obtain an internal reference 
for diploid Feulgen IOD and for p53 negativity, approxim ately 200 nuclei in the 
tissue stroma were measured in each specimen. When comparing the p53-negative 
basal regions with the superficial p53-positive regions, the operator manually 
identified the basal and superficial regions.
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Statistical analyses
To determine the correlation between DNA ploidy and sem i-quantitative scoring 
of p53 expression, Chi-square tests were perform ed. To compare ploidy status of 
p53-positive versus p53-negative cells, the IODp53 and IO D Feu|gen distributions 
for these groups were compared using the two sample Kolm ogorov-Sm irnov test. 
Statistics were perform ed using SPSS softw are (SPSS Inc, Chicago, II, USA).
Results
Ploidy Analysis
DNA content of various entities of vulvar (pre-) m alignancies was perform ed by 
DNA image cytom etry on isolated nuclei from m icrodissected tissues (Figure 
1A-D). The ploidy status of all sam ples is sum marised in Table 2. Both normal 
epithelium  sam ples were DNA diploid. DNA hypoploidy was observed in one out 
of nine LS lesions (11%), whereas the other eight LS sam ples were DNA diploid. 
Five of the 13 analysed dVIN lesions (38%) were DNA aneuploid. From the 17 
carcinom as, nine were DNA aneuploid tum ours (53%), and two tum our sam ples 
(12%) were DNA tetraploid. The rem aining six tum our samples (35%) were DNA 
diploid. For lesions in which both dVIN and SCC were present, the ploidy status of 
dVIN never exceeded the ploidy status of the associated SCC.
Hypoploid Diploid Aneuploid Tetraploid Total
LS 1 8 - - 9
dVIN - 8 5 - 13
SCC - 6 9 2 17
N - 2 - - 2
Total 1 24 14 2 41
Table 2 Ploidy-status versus type of lesion.
N: normal epithelium
LS: lichen sclerosus
dVIN: d ifferentiated VIN
SCC: squam ous cell carcinom a
112
A dVIN SCC LS
A n e u p lo id  Aneuploid
Figure 1 A nalysis of DNA ploidy and p53 expression in tissue containing LS, dVIN and SCC.
A) H&E staining of the com posite lesion (constructed of three im ages, as shown by the 
dashed dividing lines, original m agnification 1.25x). The black rectangles represent the 
excised areas for ploidy analysis.
B) H&E stained detail of dVIN lesion with nuclear atypia and the presence of m itotic figures 
in the basal cell layers. Hyperkeratosis and dyskeratosis are present and rete ridges 
elongated. C) H&E stained detail of SCC. D) In the H&E stained section of LS, flattened and 
m ildly hyperkeratotic epithelium  is present. Loss of rete ridges is clearly visible. There is 
little cellu lar or nuclear atypia. A zone of hyalinised derm is and subepithelial oedema of 
variable thickness is present. The characteristic band-like infiltrate of lym phocytic cells is 
located beneath this zone.
E) Im m unohistochem istry revealed nuclear p53-posititivity in dVIN, most prom inent in the 
basal cell layers with suprabasal extension. In this section, p53-postivity of the lower one 
third of the epithelium  is estim ated at 80%. F) Approxim ately 75% of the cells of the invasive 
nests of the SCC are positive for p53. G) p53-negative LS lesion.
Original m agnification B-G: 50x
Each histogram  (H-J) d isplays the ploidy condition of the vulvar lesion beneath it. The x-axis 
in the ploidy histogram  represents the integrated optical density (IOD) of the nuclei 
population, whereas the y-axis identifies the num ber of nuclei in the specific population. 
dVIN (H) was aneuploid with a 2A-peak (aneuploid peak) shown next to a 2C-peak (diploid 
peak). Tetraploidy in an SCC lesion (I), identified with a 4C-peak (tetraploid peak) higher 
than the 2C-peak. Diploid LS lesion (J).
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p53 expression
Subsequently, consecutive tissue slides of the sam ples described above were 
subjected to p53 expression analysis by im m unohistochem istry (Figure 1E-G). 
Results are sum marised in Table 3. In all 13 dVIN present in com posite lesions 
p53-positivity was confined to the lower one-third of the epithelium  (Figure IE ), 
som etim es with suprabasal extension. In the SCCs, p53 expression (Figure IF )  
varied from 5% to 95% (median 75%) positive cells (Table 3). In LS, the percentage 
of p53-positive (Figure 1G) did not exceed 30%. In the composite lesions that 
contained dVIN and SCC, the percentage of p53-expressing cells in dVIN was less 
or comparable to p53 expression by the corresponding SCC in all but one case 
(i.e., patient XVII in Table 3).
Patient Diagnosis Ploidy-status" p53-expression*
1 LS Diploid 10%
dVIN Diploid 10%
II LS Diploid 2%
dVIN Diploid 1%
III dVIN Diploid 10%
SCC Diploid 5%
IV LS Diploid 0%
dVIN Aneuploid NA
V LS Diploid 10%
SCC Aneuploid 75%
VI SCC Diploid 40%
VII dVIN Aneuploid 75%
SCC Aneuploid 80%
VIII dVIN Diploid 5%
IX SCC Diploid 0%
X LS Hypoploid 30%
XI SCC Diploid 30%
XII LS Diploid 2%
dVIN Aneuploid 80%
SCC Tetraploid 75%
XIII dVIN Diploid 25%
SCC Diploid 50%
XIV SCC Tetraploid 20%
XV LS Diploid 5%
dVIN Diploid 50%
SCC Aneuploid 80%
XVI N Diploid 0%
dVIN Diploid 80%
SCC Aneuploid 90%
XVII dVIN Aneuploid 100%
SCC Aneuploid 70%
XVIII LS Diploid 30%
dVIN Aneuploid 75%
SCC Aneuploid 85%
XIX dVIN Diploid 90%
SCC Aneuploid 95%
XX LS Diploid 20%
SCC Diploid 65%
XXI N Diploid 0%
SCC Aneuploid 95%
XXII SCC Aneuploid 95%
Table 3 A nalysis of DNA ploidy and p53 expression in com posite vulvar lesions.
p53 expression and DNA ploidy
In order to determine a possible correlation between the percentage of 
p53-positive cells and DNA content in a tissue entity, both results were combined. 
This revealed that the high percentage of p53-expressing cells in the lower 
one-third of the epithelium  (dVIN) or the entire lesion (SCC or LS or normal tissue) 
significantly correlated with aneuploidy determined by Feulgen staining on 
isolated cells (Table 4, chi-square=27.6, p<0.001). N inety-three percent (14/15) of 
all non-diploid lesions displayed more than 70% of p53-positive cells. In contrast, 
in 92% of the DNA diploid cases (22/24), p53 expression was observed in less than 
70%. As such, we subjectively set the cut-off value for high p53 expression at 
70%. Despite high p53 expression in two dVIN lesions adjacent to an aneuploid 
SCC (case XVI and XIX) DNA content was determined to be diploid, whereas the 
H&E staining displayed the typical features of dVIN.58 Case XIX is shown in Figure 2. 
Collectively, these data suggest a positive correlation between high percentage 
of p53-positve cells and altered DNA content in tissue specimens.
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1 1 6
Figure 2 dVIN of case XIX.
A: H&E sta in ing  of a diploid dVIN lesion adjacent to an aneuploid carcinom a with elongated 
and bridging rete ridges. B) Detail of the boxed area in A show ing atypia in the basal layer. 
C) A consecutive tissue section stained for p53 expression dem onstrates more than 70% of 
the cells w ithin the lower one-third com ponent positive for p53. D) Detail of the boxed 
area in C. Original m agnifications: A ,C:50x, B,D:200x.
p53 <70% p53 >70% Total
Diploid 22 2a 24
Non-diploid l b 14 15'
Total 23 16 39
Table 4 Ploidy-status versus high p53-expression 
a both dVIN lesions, b SCC, * p<0.001 (Chi-square test)
Combined ploidy analysis and im munohistochem istry
The above described correlation was derived from two different approaches, 
which made it im possible to determine the relation between DNA-content
aberration and p53 expression in individual cells. To overcom e this problem, we 
subjected tissue sections to sequential p53 im m unohistochem istry and Feulgen 
DNA staining (Figure 3AB), and measured the staining intensity in between these 
two staining methods. The integrated optical density (IOD) of p53 in p53-negative 
stromal nuclei reached a maximum value of 1.6. Visual inspection of p53 staining 
confirm ed that higher values corresponded to p53-positive nuclei. Therefore, 
p53-positivity was defined as IOD IODp53>1.6. Mean values of IODFeu|gen of 
p53-negative nuclei in each tum our specim en is presented as a dotted line 
(Figure 3C, top panels), which allows easy visualisation of the shift in the 
distribution of I OD Feu|gen towards increased intensity in p53 expressing cells 
(Figure 3C, middle panels). Com parison of the Feulgen IOD distribution of 
p53-negative versus p53-positive epithelial nuclei showed a significant difference 
for all patients assessed (p<0.001). When all IOD values for p53 and Feulgen are 
presented as a scatter plot (Figure 3C, bottom panels), a positive trend between 
both lODs can be observed in all sam ples that display high levels of p53 expression 
(i, ii, and iii). Thus, compared to p53-negative nuclei, p53-positive nuclei displayed 
an increased DNA content.
DNA ploidy, p53 expression and cell proliferation in solitary dVIN
Expression of p53 was not observed in the superficial layers of dVIN and could 
imply that aneuploidy is confined to the lower layers. We have therefore analysed 
the relationship between DNA ploidy and p53 expression in single cells of 6 
solitary dVIN samples in more detail and sum marised the results in Table 5. The 
frequency plot of sample 2 is shown in Figure 4. Compared to the DNA content of 
normal reference cells within the stroma (DNA Index (D l)= l), the lower one-third 
component of dVIN (basal epithelium ) contains nuclei with increased DNA content 
(DI>1: 27.5%; Figure 4 lower left panel). Because of the effect of truncation of 
nuclei within (relatively thin) tissue sections, ploidy patterns show asym m etric 
(right skewed) distribution. In contrast, the upper one-third component 
(superficial epithelium) only contains 4.7% nuclei with a DI>1. This indicates that 
the superficial component indeed contains a low percentage of cells with an 
abnormal DNA content.
In all sam ples, the basal layers contained significantly more p53+ cells (Table 5A). 
Sim ilarly, DNA content was significantly higher in the basal component compared 
to the superficial component for all sam ples (Table 5A). Strongly increased DNA 
content in the superficial layer was also observed in two of the six samples 
analysed (i.e,. sample 1 and 5). When com paring DNA content between p53
C
ha
pt
er
 
6 
Hi
gh
 
le
ve
ls 
of 
p5
3 
ex
pr
es
si
on
 
co
rr
el
at
e 
wi
th
 
DN
A 
an
eu
pl
oi
dy
 
in 
(p
re
-) 
m
al
ig
na
nc
ie
s 
of 
th
e 
vu
lv
a
Ill IV
•M 121
IOD,F e u lg e n
1 1 8
Figure 3 p53 sta in ing  intensity correlates with DNA content.
Sequentia l sta in ing  for p53 (A) and DNA (B) was perform ed on tum our tissue and the 
respective IOD values determ ined on selected cells. Yellow asterisks indicate the region of 
inflam m atory cells from  which cells were selected to serve as a diplo id and p53 negative 
internal control. The frequency d istribution (C) of IODpeu|gen values of p53 negative 
(IO D p53<1.6, top panels) and p53 positive (IO D p53>1.6, m iddle panels) nuclei from  four 
d ifferent patients (i-iv) are presented as histogram s and dem onstrates a sh ift tow ards 
increased DNA content when p53 expression is increased. Dotted line: mode IODpeu|gen of 
p53-negative nuclei. Scatterplots of IODpeu|gen and IOD p 5 3  (IC)Da||>0, bottom  panels) 
reveals a sim ilar positive correlation between p53 stain ing intensity and DNA content in 
individual cells. O riginal m agnification A,B:50x
negative and p53 positive cells in the basal com partm ent, for all cases a strongly 
significant increase was observed for the number of cells with DI>1 (Table 5B). 
W ith the exception of sample 3, such a relationship was not found for cells in the 
superficial component due to the low number of p53-postive cells.
We have previously shown that the lower com partm ent of dVIN is highly 
proliferative153 and which also contributes to increased DNA content in this study. 
Therefore, we have analysed MIB-1 expression in the 6 solitary dVIN lesions and 
found a mean percentage of positive cells of 43.1% (95% Cl 18.1% - 68.1%) in the 
basal com partm ent compared to 2.1% (95% Cl 1.1-4.8%) in the superficial 
com partm ent. The low abundance of proliferative cells in relation to the 
percentage of cells with DI>1% in the superficial component, indicates that DNA 
content is in part due to aneuploidy.
All cells
4.7%
jmru-
p53- p53 +
27.5%  
—>
Figure 4 DNA ploidy histogram s for one exam ple case (case 2). Upper panels show data 
from  the sup erfic ia l com partm ent; lower panels for the basal com partm ent. Panels on the 
left show data for all cells, m iddle and right panels distinguish between p53 negative and 
p53 positive cells, respectively. The percentages shown inside individual graphs indicate 
the percentages of cells with DI>1 (indicative for aneuploidy).
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Sol dVIN p53 positive cells (%) Cells with Dl >1* (%)
Basal** Superficial *** P Basal Superficial P
1 20.0 9.8 0.003 47.4 21.7 <0.001
2 72.9 27.2 <0.001 27.5 4.7 <0.001
3 41.4 9.4 <0.001 3.9 5.2 <0.001
4 30.9 3.3 <0.001 16.6 7.8 0.003
5 4.1 0.6 <0.001 20.7 10.6 <0.001
6 34.9 12.9 <0.001 26.4 8.7 <0.001
Table 5A p53 positivity and DNA content in so litary  dVIN.
Sol dVIN Basal compartment** 
Percentage cells with Dl >1
Superficial compartment*** 
Percentage cells with Dl >1
1 43.9 61.0 <0.001 20.2 35.7 NS
2 4.8 35.9 <0.001 3.5 7.8 NS
3 1.6 7.1 <0.001 3.5 21.6 <0.001
4 8.4 34.9 <0001 6.9 33.3 NS
5 19.7 44.0 <0.001 10.7 0 NS
6 21.8 35.0 <0.001 9.3 5.0 NS
Table 5B DNA content in relation to p53 expression and localisation within dVIN. 
* Dl (DNA in d e x)= l: DNA content of norm al reference cells w ithin the strom a.
** Basal com partm ent: the lower one-third com ponent of dVIN.
*** Su p erficia l com partm ent: the upper one-third com ponent of dVIN.
Discussion
In this study we dem onstrate that DNA aneuploidy in vulvar lesions correlates 
with high expression of p53 in tissue at the cellular level, which has not been 
described before. Based on a higher percentage of DNA aneuploid cases among 
dVIN than in LS, we believe that at least a subset of dVIN lesions is a prem alignancy 
with a higher malignant potential compared to LS.
O u rfin d in g o fa la c k o fD N A a n e u p lo id y in L S is  coherent with the results published 
by Scurry et al.i0° They perform ed cytom orphom etric analysis on 20 LS sam ples 
and found that 50% of those sam ples were diploid, and that the other 50% were
hypoploid. The authors concluded that the occurrence of hypoploidy in LS reflects 
reduced m itotic activity that relates to a loss of DNA.300 We only found one out of 
nine LS lesions to be DNA hypoploid and have described previously that the 
proliferative activity in LS is comparable to that in other vulvar prem alignancies.153 
However, the absence of DNA aneuploidy in all but one hypoploid LS in our study 
suggests that LS has less malignant potential than dVIN. Recently, Raspollini et al. 
showed that high MIB1 and p53 labelling indices in LS might identify those vulvar 
LS cases with a high likelihood of evolving into SC C.39 However, these high-risk LS 
lesions show histological features that resemble the criteria for dVIN.36The results 
of our study suggest that these so called 'atypical LS' might be non-diploid dVIN 
lesions.
The atypia in a dVIN lesion is confined to the lower one-third of the epithelium 
(Figure IB ) .45 However, the entire epithelium  of the dVIN lesion was m icrodissected 
and used for DNA image cytom etry. Therefore, samples were 'contam inated' with 
p53-negative cells and could have resulted in an underestim ation of DNA 
aneuploidy in dVIN. Furtherm ore, in situ quantification of DNA dem onstrated 
that increased DNA content in the superficial layers was observed which cannot 
be explained by mitotic activity as MIB1 positivity in these layers was low. 
However, it is unlikely that all dVIN lesions would have been DNA aneuploid, as 
DNA diploid SCCs were found, and as there were no patients with a DNA aneuploid 
dVIN lesion next to a DNA diploid SCC. From these observations we conclude that 
aneuploid cells predom inantly reside within the basal com partm ent of dVIN, but 
that m igration towards the superficial com partm ent can occur.
It remains unclear how p53 could contributes to the developm ent of vulvar SCC 
from dVIN. Lerma et al. concluded that p53 expression is a late event in m alignant 
progression as 72% of their SCCs were DNA aneuploid and only 56% of the SCCs 
showed p53-overexpression (which was defined as >10% of the tum our cells)169, 
but they do not provide sim ultaneous results on ploidy status and p53 expression 
in individual lesions. In vulvar SCCs, ploidy has been studied m ostly in relation to 
prognosis and no results on ploidy status of VIN lesions exist. Despite the limited 
number of cases in our study, the percentage of DNA aneuploidy in vulvar SCC 
(9/17, 53%) is in line with the percentages found in previous reports of 13% to 
83%.169'295'300 The causal relationship between high p53 expression in vulvar 
epithelium  and DNA aneuploidy remains elusive. Possibly, destabilisation of 
chrom osom es due to centrosom e am plification contributes to the cancer 
susceptibility phenotype associated with mutation (resulting in over-accumulation 
of p53) or stabilisation of p53.291 In this study, im m unohistochem ical detection of
C
ha
pt
er
 
6 
NJ
 
Hi
gh
 
le
ve
ls 
of 
p5
3 
ex
pr
es
si
on
 
co
rr
el
at
e 
wi
th
 
DN
A 
an
eu
pl
oi
dy
 
in 
(p
re
-) 
m
al
ig
na
nc
ie
s 
of 
th
e 
vu
lv
a
p53 expression could not be correlated with p53 mutation because no antibody 
can discrim inate between either forms.
Rolfe et al. found that p53 m utations develop in LS and squamous hyperplasia, 
and are intrinsic to the clonal evolution that leads to vulvar SC C.307 Our immuno- 
histochem ical data supports this hypothesis, although we were unable to directly 
correlate im m unohistochem ical detection of p53 with p53 m utational status due 
to insufficient high quality DNA in the m icrodissected tissue. Further correlative 
studies of p53 expression with mutational status in vulvar dVIN and SCC are 
warranted.
It has been suggested that loss of function of cell cycle regulator genes influences 
chrom osom e segregation, leading to DNA aneuploidy.291'293'308 The absence of 
p l6 'NK4A in cells generates supernum erary centrosom es, which can eventually lead 
to the production of aneuploid daughter cells as a result of unequal segregation 
of the genom ic material during m itosis.309 In our study, we were unable to 
correlate the role of p l6 INK4A and p l4 ARF to DNA aneuploidy since the staining of 
p l6 INK4A-expression was not different in DNA diploid and DNA aneuploid cases 
(data not shown).
In conclusion, a high percentage of p53 expressing cells in vulvar lesions appears 
to be a surrogate marker for DNA aneuploidy. DNA aneuploidy was observed in 
vulvar lesions in which more than 70% of the epithelial cells expressed p53. 
Furtherm ore, high levels of p53 expression correlate with increased DNA content 
in individual cells. For dVIN, both adjacent to vulvar SCC and solitary, increased 
p53 expression and DNA ploidy are found in the basal cells compared to the 
superficial com partm ent, although ascending aneuploid cells can also be detected. 
The observation that the degree of aneuploidy in dVIN is higher compared to LS, 
but less or equal compared to SCC, suggests that dVIN has a higher m alignant 
potential than LS. The mechanism of oncogenesis and the progression of LS to 
dVIN remains elusive.
122
1C
ha
pt
er
 
6 
NJ
 
Hi
gh
 
le
ve
ls 
of 
p5
3 
ex
pr
es
si
on
 
co
rr
el
at
e 
wi
th
 
DN
A 
an
eu
pl
oi
dy
 
in 
(p
re
-) 
m
al
ig
na
nc
ie
s 
of 
th
e 
vu
lv
a

Chapter
Specific intraepithelial localisation of mast 
cells in differentiated vulvar intraepithelial 
neoplasia and their possible contribution to 
vulvar squamous cell carcinoma development
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I. O tte-Holler 
L.F.A.G. M assuger 
J.A. de Hullu 
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Histopathology, 2010;57(3):351-362
Abstract
Aim: The aetiology of vulvar squamous cell carcinom as (SCC) that are not causally 
associated with high risk human papillom avirus remains largely elusive. The aim 
of this study was to analyse the inflam m atory response in its presumed precursor 
lesions, lichen sclerosus (LS) and differentiated vulvar intraepithelial neoplasia 
(dVIN), and provide evidence that dVIN is a likely precursor of vulvar SCC.
Methods and results: Im m unohistochem ical analyses for CD4, CD8, CD20, CD68, 
S100, and tryptase positive immune cells was perform ed and quantified in LS 
(n=7), dVIN (n=19), SCC (n=11), and normal vulvar tissue (n=8). The subepithelial 
inflam m atory response in dVIN and SCC was comparable, but absent in LS. 
Abundant intraepithelial mast cells were observed in dVIN only, and was confirmed 
by electron microscopy, toluidine blue staining and cKIT expression. Adjacent 
keratinocytes displayed increased proliferation as determined by MIB-1 positivity. 
Electron m icroscopy revealed intraepithelial m ast cell degranulation. Intrae­
pithelial mast cells were not or infrequently observed in vulvar hyperplasia (n=13), 
condylom ata acum inata (n=5), keratinocytic intraepiderm al neoplasia of 
sun-exposed skin (KIN, n=15), epidermal hyperplasia of head and neck (n=12), and 
psoriasis (n=3).
Conclusions: These data indicate that dVIN can be recognized by intraepithelial 
mast cells and that this might promote the progression of dVIN to SCC.
126
Introduction
Vulvar squamous cell carcinom a (SCC) accounts for approxim ately 3-5% of all 
gynaecological m alignancies and 1-2% of all carcinom as in women, with an 
incidence rate of 1-2/100.000.10258 Vulvar SCC can develop via two different 
oncogenic pathways.1'2 Approxim ately 20% of all vulvar SCCs are associated with 
usual vulvar intraepiderm al neoplasia (uVIN) and are caused by an infection with 
oncogenic Human Papillom avirus (HPV).280 The aetiology of HPV-negative vulvar 
SCCs is unknown. These tum ours com m only arise in a background of lichen 
sclerosus (LS).2 D ifferentiated vulvar intraepiderm al neoplasia (dVIN) is often 
found adjacent to this type of tumour. Cellular atypia and architectural disarray in 
dVIN is confined to the basal and suprabasal layers.1'345 Intriguingly, the normal 
keratinocyte differentiation programme appears intact as the developm ent of a 
term inally d ifferentiating epiderm is is not impaired and is thus a d ifficult to 
recognise entity by non-expert pathologists. So litary dVIN lesions are rare,282 
which might be caused by under diagnosis due to its histological resem blance to 
epidermal hyperplasia and/or by a relatively brief intraepithelial phase prior to 
invasive carcinom a.5 154 156 Alike SCC, but in contrast to LS, an often strong 
inflam m atory response can be observed directly at the epiderm al-derm al junction 
of dVIN. These observations contributed to our hypothesis that the developm ent 
of HPV-negative SCC follows a gradual progression from LS to dVIN to carcinoma.
Progression of a prem alignant lesion towards an invasive tum our concurs with a 
persistent stromal response. Recruitm ent of immune cells can be observed in or 
around developing neoplasm s that regulate different aspects of tum our 
developm ent (e.g., fibroblast activation and the early angiogenic response) by 
providing am ongst others soluble growth and matrix rem odelling enzym es.310 
This stromal response creates a m icroenvironm ent that can support neoplastic 
progression.310'312 Recruitm ent of B-cells and deposition of im m unoglobulins 
appear key events in the initial stromal response towards a developing neoplasm .312 
Sim ilar to a wound healing response, mast cells are among the first cells of the 
innate immune response at the damaged site. Under normal conditions mast cells 
are pre-stationed in tissues and continuously monitor their m icroenvironm ent 
for signs of distress. When tissue hom eostasis is disturbed, mast cells instantly 
release soluble m ediators that induce m obilisation and infiltration of immune 
cells (e.g., macrophages and T-cells) into damaged tissue as well as activate 
vascular and fibroblast responses in order to orchestrate elim ination of invading
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organism s and initiate local tissue repair.313 On the other hand, mast cells 
accum ulate at the periphery of prem alignancies, where they initiate the early 
events of neoplastic progression, i.e., fibroblast activation, extracellu lar matrix 
rem odelling and activation of angiogenesis.314315
In orderto  find sim ilarities and differences in the composition ofth e  inflam m atory 
response in vulvar prem alignant stages (LS and dVIN) and vulvar SCC that can 
support our hypothesis, we have quantified a subset of inflam m atory cells, i.e., 
T-cells (CD4 and CD8), B-cells, dendritic cells, macrophages and mast cells. These 
analyses revealed a sim ilarity between the com position of the inflam m atory 
response in dVIN and SCC. Furtherm ore, we dem onstrate intraepithelial 
localisation of mast cells in dVIN, which was not observed in other benign or 
prem alignant epidermal hyperplasia nor in vulvar SCC. This suggests that mast 
cells might be involved in malignant conversion of dVIN to SCC.
Material and Methods
Human tissues
Form aldehyde-fixed and paraffin-em bedded tissue containing normal vulvar 
tissue (n=8), LS (n =7), dVIN (n=19), HPV-negative vulvar SCC (n=11 ), uVIN (n=8), 
vulvar hyperplasia (n=13), condylom ata acuminata (n=5), keratinocytic intrae­
pidermal neoplasia of sun-exposed skin (KIN, n=15), epidermal hyperplasia of 
head and neck (n=12), and psoriasis (n=3) were obtained from the pathology 
archives o fth e  Radboud University Nijmegen Medical Centre. In this set of vulvar 
samples, all SCCs arose in a background of LS and contained dVIN at its border. 
Three out of 19 dVIN were solitary and not associated with a SCC. For electron 
microscopy, fresh 4 mm biopsies of clinical suspect dVIN lesions were obtained 
from vulvectom ies and split in two. One half was processed for H&E staining and 
the other fixed in 2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate 
buffer (pH 7.4). All specim ens were re-evaluated by expert pathologists (JB and 
KMH). Tissues were obtained according to local ethical guidelines and approved 
by the local regulatory committee.
Immunohistochemistry
Tissue sections (4 |j.m) on Superfrost slides (M enzel-Gläser, Braunschweig, 
Germany) were deparaffinised in xylene, rehydrated through graded alcohols and 
rinsed three tim es in phosphate-buffered saline (PBS; pH 7.4) for 10 minutes.
Following a sodium -citrate antigen retrieval step (0.01 M, pH 6.0, 95°C, 10 minutes), 
tissue sections were pre-incubated with 20% normal goat serum in PBS and 
subsequently incubated overnight at 4°C with antibodies towards CD8 (mouse 
monoclonal, clone C8/144B, 1/80, Dako, Glostrup Denmark), CD20 (mouse 
monoclonal, clone L2 6 ,1/300, Dako), CD68 (mouse monoclonal, clone K P 1 ,1/4000, 
Dako), S100 (rabbit polyclonal, 1/2000, Dako), ortryptase (mouse monoclonal clone 
AA1, 1/400, Dako). For detection of CD4 (mouse monoclonal, clone BC/1F6, 1/10, 
Biocare Medical, Concord CA, USA), antigen retrieval was performed by incubating 
tissues in TRIS-buffered EDTA (Im M , pH 9.0) at 95°C for 10 minutes. All antibodies 
were diluted in PBS containing 1% bovine serum albumine (BSA). Slides were rinsed 
in PBS for 10 minutes and incubated with biotinylated anti-rabbit IgG or anti-mouse 
IgG (Vector, Burlingame, CA) for 30 minutes at room temperature (RT). A biotin-avid in 
peroxidase or alkaline phosphatase complex was generated according to standard 
procedures (Vector). Peroxidase was visualised with 3-amino-9-ethylcarbazole 
(AEC, ScyTek, Logan, UT), or 3,3'-diam inobenzidine (DAB, Sigma-Aldrich) and briefly 
counterstained with Mayer's haematoxylin. Slides were dried and mounted with 
Permount (Fisher Scientifc, Fairlawn, NJ, USA). Negative controls (buffer only) were 
included in each analysis.
For Ki67/Tryptase double staining, the sodium-citrate antigen retrieval step and 
incubation with normal serum was followed by incubation with monoclonal 
mouse-anti Ki67 (clone M IB-1,1:100, Dako) overnight at 4°C. After washing the slides 
with PBS for 10 minutes, tissue sections were incubated with biotinylated anti-mouse 
IgG (Vector), an avidin-peroxidase complex (Vector) generated and visualised with 
DAB. Subsequently, the tryptase staining protocol (AEC) was performed.
Immunofluorescence
After deparaffinisation and rehydration, tissues were left in PBS overnight at 4°C. 
Follow ing sodium -citrate antigen retrieval, tissues were incubated with the 
mouse monoclonal antibody towards tryptase (1/400) and rabbit polyclonal 
antibody towards CD117 (1/200, Dako) overnight at 4°C. After extensive wash 
steps with PBS, tissues were incubated with A lexa488-conjugated goat-anti- 
rabbit (Invitrogen, 1/200) for 30 minutes TRYP at room tem perature in the dark. 
Follow ing extensive wash steps with PBS, tissues were incubated with Alexa594- 
conjugated rabbit-anti-m ouse CD117 (Invitrogen, 1/200, 30 m inutes room 
temperature), washed extensively with PBS, incubated with 4,6'-diam ino-2- 
phenylindole (DAPI, 80 ng/ml in PBS, 30 seconds), and mounted with Vectashield 
(Vector).
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Toluidine blue
The toluidine blue staining protocol for mast cells was perform ed according to 
standard procedures. Briefly, follow ing deparaffinisation and rehydration, tissues 
were incubated 0.1% Toluidine blue (Sigm a-Aldrich) for 2-3 minutes, rinsed in 
running tap w ater for 2 minutes, quickly dehydrated through graded alcohols and 
xylene, and mounted with Permount.
Cell quantification
Specifically stained cells within the epithelium  and adjacent stoma were counted 
manually by two observers independently (HvdN, LvK) in 4-8  non-overlapping 
fie ld s at 40x m agnification and expressed as a percentage of all inflam m atory 
cells in the respective tissue component. The sub-epithelial component (i.e., 
stroma) was defined as the dermal component within 100-150 |j.m from the 
epiderm al-derm al interface in which a direct interaction of inflam m atory cells 
with the epidermal component is likely. For LS, this implies that the characteristic 
band-like infiltrate under the broad hyalinised zone of superficial derm is was not 
included in the analysis.
In order to determine the amount of tryptase-positive cells in various epithelia, 
cells were counted m anually in 4-8  non-overlapping fields of which the epidermal 
surface area was measured using KS400 image analysis software (Karl Zeiss, 
W eesp,The Netherlands).153 316 Subsequently, epidermal mast cells were expressed 
as number of cells per mm2.
Electron microscopy
Processing of tissue samples for electron m icroscopy was perform ed as described 
previously.317 After presence of dVIN was confirm ed in H&E, the glutaraldehyde- 
fixed tissue fragments were postfixed in cacodylate-buffered 1% 0 s 0 4 for 2 hours, 
dehydrated, and embedded in Epon 812 (Merck, Darmstadt, Germany). Ultrathin 
sections were cut on an ultratome (Leica, Reichert Ultracuts, W ien, Austria), and 
contrasted with 4% uranyl acetate for 45 min and subsequently with lead citrate 
for 4 min at room temperature. Sections were examined in a Jeol 1200 EX2 
electron m icroscope (JEOL, Tokyo, Japan).
Statistical analysis
Data were analysed using SPSS softw are (version 16.0.1 for W indows, SPSS) and 
box plots generated. Because the percentages of cells in stroma and epithelium, 
and mast cells per mm2 epithelium were not normally distributed, nonparametric
M ann-W hitney tests w ere perform ed to com pare means between groups. 
A probability value of <5% was considered statistically significant.
Results
Profiling of the inflammatory response
Im m unohistochem ical analyses were perform ed to determ ine the localisation 
and am ount of T-helper cells (CD4), cytotoxic T-cells (CD8), B-cells (CD20), 
m acrophages (CD68), dendritic cells (S100), and mast cells (tryptase) (Figure 1) in 
LS (n=6), dVIN (n =7) and HPV-negative vulvar SCC (n=5)
W hereas the mean amount of all inflam m atory cells in the sub-epiderm al 
component of LS is low (11 ± 3 cells per high power field (HPF, average of 4-8 non­
overlapping fields at 40x), it is highly increased in both dVIN and SCC (88 ± 31 and 
84 ± 32 cells per HPF, respectively). To gain insight in sim ilarities and differences 
in the com position of these infiltrates, specific cell types were expressed as mean 
percentage of the total amount of cells (Figure 2 A). W ithin the stromal component, 
the percentage of CD4-positive cells in SCC was significantly increased compared 
to LS and dVIN (p=0.04, M ann-W hitney, 2-tailed), and indicated an altered 
CD4:CD8 ratio in SCC compared to LS and dVIN.
In LS, CD20-positive B-cells were localised to the patchy infiltrate in the mid 
dermal region, whereas these were also diffusely dispersed within the 
subepiderm al derm is in dVIN and SCC. In dVIN, the percentage of B-cells in 
sub-epiderm al infiltrate of dVIN was 2-fold increased (p=0.04) compared to that 
of SCC. Furtherm ore, an increased number of m acrophages was observed in LS 
compared to dVIN and SCC (p=0.01).
W ithin the epithelium  of LS, a higher percentage of CD8-positive cells was 
observed compared to dVIN (p=0.2) and SCC (p=0.03). Furtherm ore, the LS 
epithelium  contained significantly more dendritic cells than dVIN (p=0.04). 
Intriguingly, a high percentage of mast cells were detected within the epithelium 
of dVIN, not in LS (p=0.005) and infrequently in SCC (p=0.01). Intra-epithelial 
m acrophages were observed in dVIN and SCC, but not in LS (p=0.01).
Vulvar hyperplasia w ithout cellular or nuclear atypia does not confer a risk for 
neoplastic progression. We therefore compared the inflam m atory response in 
vulvar hyperplasia with dVIN (Figure 2B).
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Figure 1 Detection of im m une cells in vulvar lesions.
A diffuse distribution of CD 4-positive  T-helper cell (A) and CD 8-positive cytotoxic T-cells 
(B) w ithin the strom al com ponent SCC (*) and adjacent dVIN (D) was observed. CD20-positive 
B-cells (C) predom inantly localised in clusters. D68-positve  m acrophages (D) were also 
found in these clusters and throughout the strom al com ponent. S lO O -positive  dendritic 
cells (E) and tryp tase-positive  mast cells (F) were detected within the strom a and 
epithelium .
Inserts in A-F: high power m agnification of specific stain ing. Scale bar A: 100 nm.
No sign ificant d ifferences were observed in the com position of the strom al 
inflammatory response, but the ratio CD4/CD8 was smaller in vulvar hyperplasia 
com pared to dVIN, albeit not sign ificantly  d ifferent (0.5±0.2 and 0.9±0.5, 
respectively). The epithelial infiltrate in hyperplasia consisted predominantly out
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Figure 2
A. Error bar plot of the percentage (mean ± SEM) of T-helper cells (CD4), cytotoxic T-cells 
(CD8), B-cells (CD20), dendritic cells (DC), mast cells (MC), and m acrophages (Mf) within 
the sub-ep iderm al and intraepithelia l inflam m atory infiltrate  of LS (n=7), dVIN (n=19) and 
SCC ( n = ll ) .  * p<0.05 (M ann-W hitney); ** p<0.03; *** p<0.01.
B. Sim ilar error bar plot, now com paring the inflam m atory response in benign vulvar 
hyperplasia (n=13) and prem alignant dVIN (n=19).
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of CD8 positive cells (55%±9), whereas these cells contributed to 22%±9 of stromal 
epithelial cells in dVIN. However, no differences were observed in absolute number 
of CD8 cells per high power field. Strikingly, cells of the innate immune response 
(mast cells, and macrophages) were detected in dVIN, but not in hyperplasia.
To validate that the tryptase-positive cells were indeed mast cells, additional 
stainings were perform ed. An im m unofluorescent analysis for tryptase and the 
mast cell marker cKIT (CD117) revealed that all tryptase-positive cells within the 
stroma and epithelium  of dVIN also expressed cKIT (Figure 3A-B). Using toluidine
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Figure 3 Tryp tase-p ositive  cells w ithin the epithelium  are mast cells.
Double im m unofluorescence for tryp tase  (A, green) and the mast cells m arker CD117 (B, 
red) dem onstrated that all tryp tase-positive  cells express CD 117. Conversely, CD117-positive 
but tryp tase-negative  cells (arrows) can be observed. Toluidine blue stain ing of a dVIN (C) 
dem onstrated the typ ica l reddish granual appearance of intrae pit he I ia I (D) and strom al (E) 
134 mast cells. Dotted line in D and E indicates the basem ent m em brane. Arrow head indicates
a m itosis, e: epithelium , d: derm is. Scale  bar A: 12.5 nm; D, E: 25nm.
blue, intraepithelial mast cells were readily identified by their typical granular 
reddish appearance (Figure 3C-D). The amount of toluidine blue cells was 
approxim ately 50% less compared to tryptase im m unohistochem istry (data not 
shown) and suggested mast cell degranulation. Collectively, these data demonstrated 
intraepithelial localisation of mast cells in dVIN.
High infiltration of mast cells in dVIN, but not in other cutaneous epidermal 
abnormalities
The identification of mast cells within the epithelium  of dVIN suggested that this 
could be a marker for this prem alignancy. Therefore, we have analysed the 
amount of intraepithelial mast cells per mm2 in different types of epidermal 
abnorm alities (Figure 4).
Figure 4 Q uantification of intraepithelia l mast cells in cutaneous epithelia.
Box plot of the am ount of mast cells per mm2 epithelium  in vulvar epithelium  (norm al, 
n=8; hyperplasia, n=13; LS, n=7; usual VIN (uVIN), n=8; dVIN, n=19; vu lvar SCC, n = l l ;  
condylom ata acum inata, n=5), hyperplasia of head and neck (H&N) epithelium  (n=12), 
keratinocytic intraepiderm al hyperplasia of skin (KIN, n=15), and psoriasis (n=3). *** 
p<0.001, M ann-W hitney com pared to any other entity.
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Intraepithelial mast cells were not detected in normal vulvar epithelium  (n=8) 
and LS (n=7). Mast cells were detected in two of 13 epidermal hyperplasias, but 
the density in these two cases was very low (0.05±0.02/mm2). Mast cells were not 
always detected in HPV-associated uVIN (n=8, 2.5±3.2/m m 2), vulvar SCC (n=11, 
5.7±6.3/mm2) and condylom ata acuminata (n=5, 0.3±0.7/mm2). In contrast, a high 
number of intraepithelial mast cells was observed in all dVIN, albeit at different 
densities (n=19, 64.1±30.1/m m 2; p<0.001, M ann-W hitney test compared to any 
other entity). In dVIN, 80% of the intraepithelial mast cells were confined to the 
first three layers of basal epithelium  (Figure 5). In non-vulvar epidermal 
abnorm alities, a limited number of intraepithelial mast cells was infrequently 
detected in psoriasis (n=3, 0.8±1.7/mm2), epidermal hyperplasia of the head and
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Figure 5 Intraepithelial mast cell in dVIN predom inantly localise to the basal com partment. 
Representative im ages of two different dVIN lesions (A, C) contain ing a high am ount of 
tryp tase -po sitive  intraepithelia l mast cells (brown) that predom inantly localise to the 
basal com ponent. B and D are high power m agnifications of the areas indicated in A and C, 
136 respectively. Intraepithelia l (arrows) and strom al (arrowheads) mast cells are indicated.
Scale  bar A, C: 100 nm; B, D: 25 nm.
neck (n=12, l,9±1.6/m m 2), and cutaneous keratinocytic intraepiderm al neoplasia 
(KIN, n=15, 0.2±0.4/m m 2).
Intraepithelial mast cells and keratinocyte proliferation
Degranulation of mast cells can stim ulate cell proliferation. Intriguingly, intrae­
pithelial mast cell staining was accom panied by a focal and diffuse tryptase 
staining of keratinocytes suggesting release of pro liferatio n-in ducin g tryptase. 
Occasionally, we observed keratinocyte mitosis adjacent to intraepithelial mast 
cells (Figure 6A), but could not dem onstrate a significant correlation between the 
abundance of mitotic figures and presence of mast cells (data not shown). 
To investigate this in more detail, a double im m unohistochem ical staining for 
tryptase and the proliferation marker Ki67 was perform ed using the m onoclonal 
antibody MIB-1. The latter identifies all cells that are not in the GO phase of the 
cell cycle, and thus identifies all proliferative cells in addition to those in M-phase. 
These analyses indicated M IB l-po sitive  keratinocytes in close proxim ity of in­
traepithelial mast cells (Figure 6B & C) and supports previous observations that 
mast cells can increase keratinocyte proliferation.318'320 However, MIB-1 positive 
keratinocytes also were observed in the absence of mast cells (Figure 6D), 
indicating that intraepithelial localisation of mast cells is not a prerequisite for 
keratinocyte proliferation.
Intraepithelial mast cells are predominantly degranulated
The observations that the intensity of tryptase staining of intraepithelial mast 
cells was reduced compared to that of stromal mast cells (Figure 6C) and that a 
local diffuse tryptase staining of the epiderm is could be observed (Figure 6A) 
suggested mast cell degranulation. To confirm  that the content of the granules of 
intraepithelial mast cells could be released, electron m icroscopy was perform ed 
on 5 dVIN biopsies to study the stromal and intraepithelial mast cells in dVIN 
biopsies in detail. Dermal mast cells were readily identified by their characteristic 
granules with different electron densities. (Figure 7A). In contrast, the electron 
density of intraepithelial mast cell granules (Figure 7B-E) was strongly reduced 
and suggested a release of their contents into the epidermal environm ent. 
The electron m icrographs further indicated that the basement membrane of the 
epithelium  infiltrated with mast cells remained intact (Figure 7E) and is in line 
with the observation that migration of inflam m atory cells across basement 
mem branes is proteolysis independent.321
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Figure 6 Increased keratinocyte proliferation adjacent to i nt raep it he I ia I mast cells. 
dVIN (A) in which m itotic figures (blue arrows) can be observed adjacent to DAB-stained 
tryp tase -po sitive  intraepithelia l mast cells (w hite arrows). A derm al mast cells is indicated 
by an arrow head. D iffuse tryptase  sta in ing  in close proxim ity of mast cells can be detected 
(asterisks). Sequentia l sta in ing  for Ki67 (brown) and tryptase  (red) (B-D) revealed 
pro liferating (brown) keratinocytes adjacent to mast cells (B,C), but intraepithelial 
localisation of mast cells is not a prerequisite for high keratinocyte proliferation (D). In 
general, the intensity of tryptase sta in ing  of derm al mast cells (arrow heads) is stronger 
com pared to that of intraepithelia l mast cells (arrows). Counterstain ing was not perform ed. 
Dotted line in B-D indicates basem ent m em brane. Scale b a rA -D : 12.5 nm.
138
Figure 7 The num ber of e lectron-dense granules of intraepitheIiaI mast cells is reduced. 
Electron m icrographs of a derm al (A) and intraepithelial (B-E) mast cell. The characteristic 
scala of granules with varying electron density can be observed in a derm al mast cell (A). 
In contrast, the granular content of an intraepithelial mast cell (boxed area in B) is strikingly 
d ifferent (C, enlargem ent of indicated area in B). Arrow  head in B indicates melanin 
deposits. Sim ilarly, the intraepithelial mast cell in panel D (b lack box), does contain 
granules (E) albeit not electron dense (arrows). The basem ent m em brane (arrow heads) in 
close proxim ity of the intraepithelia l mast cell (F, w hite box in D) appears intact (arrow 
heads). O riginal m agnifications A: 6000x; B, D: 2000x, C, E: 6000x; F:10.000x.
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Discussion
140
The aetiology of HPV-independent vulvar SCC is unknown. The suggested brief 
intraepithelial phase of dVIN before progression to invasive carcinom a5154156 
urges for the identification of cellular and/or m olecular m arkers and better 
understanding of its biology. By profiling the inflam m atory response in LS, dVIN 
and SCC we have started to provide support for the gradual progression model 
that states that SCC evolves from dVIN. Furtherm ore, we dem onstrate that 
intraepithelial localisation of mast cells could be marker for dVIN, and that this 
could promote keratinocyte proliferation.
Mast cells within the epithelium of dVIN are readily observed by im m unohisto- 
chem ical staining for mast cell tryptase. These cells also proved positive for the 
mast cell marker cKIT/CD117. However, less intraepithelial mast cells were 
observed when dVIN lesions were stained with toluidin blue. Since this staining 
highlights the content of mast cell granules, and electron m icroscopic analysis of 
intraepithelial mast cells revealed a reduced electron density of these granules, it 
allowed to conclude that mast cell degranulation occurs within the epiderm is of 
dVIN. Our findings that mast cells hardly infiltrate the proliferative epithelium  of 
vulvar, cutaneous and mucosal hyperplasia, condylom ata acuminata, uVIN and 
SCC indicates that the epidermal localisation of mast cells in dVIN is not merely a 
m arker of epithelial proliferation.
Degranulation of m ast cells can have a wide variety of e ffects in skin. The 
contribution of dermal mast cells to cutaneous m alignancies has been well 
described.322 Their infiltration into the epithelium and subsequent degranulation 
potentially alters keratinocyte hom eostasis. Mast cell tryptase is a mitogen for 
keratinocytes. It can activate protease-activated receptor (PAR)-2 on keratinocytes 
and increase their proliferation in vitro.319,320 In atopic derm atitis, mast cells 
likewise infiltrate the intraepithelial component and correlate with increased 
keratinocyte proliferation.318 Furtherm ore, mast cell chymase can activate 
pro-IL18 that is produced by keratinocytes.323 324 In transgenic mice, high levels of 
I L I 8 in the epithelium  contributes to the developm ent of atopic derm atitis-like 
inflam m atory skin lesions.325 Once activated, keratinocytes release inflammatory, 
chem otactic and growth prom oting cytokines, and cytokines regulating humoral 
and cellular im m unity.326 The subsequent strong inflam m atory response alters 
tissue hom eostasis and can promote m alignant progression of initiated cells.311 
It remains elusive why mast cells migrate into the epithelium of dVIN, but not as 
prom inent in other vulvar epidermal abnorm alities. We did not find a correlation
between the amount of stromal and intraepithelial mast cells, which suggests 
that mast cells within dVIN is not a spill-over of an increased concentration of 
stromal mast cells. Furtherm ore, the amount of stromal mast cells in SCC is 
com parable to that of dVIN but m igration into the epidermal component of the 
tum our is limited. This indicates a preferential m igration of mast cells into dVIN. 
Mast cells have also been observed in the epiderm is of atopic derm atitis,318 
bronchial epithelium in asthm a,327 and mucosa of chronic and stress-induces 
inflam m atory bowel disease.328 In all of these examples, recruitm ent and 
activation of mast cells depends on the presence of an irritating agent, from 
which could be concluded that also for dVIN a noxe could exist. However, there is 
no evidence of the presence of, e.g., a m icroorganism  or irritating agent that 
could be involved in the aetiology of dVIN.
dVIN and its associated SCCs comm only arise in the background of LS. Also for LS, 
the cause remains elusive.258 Although LS can be asym ptom atic, most patients 
experience itching and burning sensations. The latter provokes scratching and 
subsequent dam aging of the already atrophic skin. Clinically, these 'unstable' LS 
often present as erythem atic lesions. Histological examination of these lesions 
frequently shows solitary dVIN or m icro-invasive SC C,258 although exact numbers 
are unknown. This raises the possibility that scratching and damaged skin might 
induce mast cell recruitm ent and activation that leads to the induction of a 
chronic inflam m atory response that can support neoplastic progression of 
initiated cells.
In summary, we have dem onstrated that mast cells specifically infiltrate the 
epidermal component of dVIN and mainly localise to the basal and suprabasal 
layers in which atypia is found. Our data suggest that identification of intrae­
pithelial mast cells by tryptase im m unohistochem istry aids in diagnosis dVIN and 
requires further studies. The m ajority of intraepithelial mast cells have released 
the content of their granules. This appears to correlate with increased proliferation 
of the adjacent keratinocytes and suggest that mast cells could promote the 
neoplastic progression of dVIN towards SCC. The mechanism by which mast cells 
are triggered to infiltrate the epidermal component of dVIN and why they are not 
found in the adjacent SCC remains elusive.
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Chapter 8
General discussion
144
Is dVIN a border phenomenon or a precursor lesion?
Because dVIN is rare ly seen in its so l i ta ry  fo rm , is has been argued tha t  dVIN is a 
bo rder phenom enon o f  HPV-negative vu lvar SCC, instead o f  being a precursor 
lesion.42 In Chapter 4 we have shown th a t  a lthough dVIN was seldom diagnosed in 
its so l ita ry  fo rm , it does occur. Sol itary dVIN was more o f ten  diagnosed in the  last 
th ree  years o f  the  study, re f lec t ing  more knowledge o f  patholog is ts  and cl inicians 
to  recognize this  lesion. Moreover, in Chapter 5 we describe tha t,  a f te r  revision, 
so l ita ry  dVIN is m ore  o f ten  found in biopsies previously  diagnosed as LS in patients 
tha t  la ter developed a vu lvar SCC. Based on these studies, we have concluded 
tha t  dVIN is not solely a bo rde r  phenom enon o f  the  HPV-negative vu lvar SCC, but 
at least also a precursor lesion.
Does dVIN suffer from underdiagnosis or from rarity?
dVIN is a diff icu lt  diagnosis, both clinically and histopathologically. Clinically, it 
appears mostly  as subtle erosive lesions in a background o f  LS. In LS, areas of 
erythema often occur, which are diff icu lt  to  discern f rom  dVIN. Histopathologically, 
the recognit ion o f  dVIN is hindered by a high degree o f  cellular d i fferentia tion 
combined w ith  an absence o f  widespread arch itectura l disarray, nuclear po ly­
morphism and diffuse nuclear atyp ia.4The atypia in dVIN is str ic t ly  confined to the 
basal and supra basal layers o f  the ep ithe l ium .458 In Chapter 4 we describe tha t  o f  all 
VIN lesions diagnosed in the Netherlands between 1992 and 2005, only a m inor i ty  
were dVIN, in comparison to  the HPV induced usual VIN. Its incidence had increased 
in the  more recent years, and because it is unlikely tha t dVIN is a new lesion tha t  
somehow developed in the past few  years, this is merely  a ref lection o f  more 
knowledge about dVIN o f  both gynaecologists and pathologists. In Chapter 3, we 
dem onstra te tha t  dVIN is found adjacent to  80% o f 130 vulvar SCCs, which strongly 
reflects the gap between the incidence o f  the solitary diagnosis and the incidence 
o f  dVIN adjacent to a vulvar SCC. We presume that o f  all lesions previously diagnosed 
as benign dermatosis (such as LS) or epithelial hyperplasia, a large propo r t ion  would 
current ly  be diagnosed as dVIN. Indeed, in Chapter 5 we have revised LS slides of 
patients w ho were la ter diagnosed w i th  vulvar SCC, and it appeared tha t  dVIN was 
present in 42% o f  these patients, previously diagnosed as having LS. From this 
study, we have hypothesized tha t  dVIN will  be more often diagnosed as a solitary 
lesion w i th  the current we ll-def ined histopathological features and acquaintance o f  
the lesion by both gynaecologists and pathologists.
146
Still, the re  is a large gap be tween the  num ber o f  so l ita ry  dVIN lesions and dVIN 
lesions found adjacent to  vu lvar SCC. Besides the  d i f f ic u l t  diagnosis, th is  could be 
a t t r ib u te d  to  the  short  in traep ithe l ia l phase o f  dVIN. In Chapter 4 we found tha t  
the  t im e be tween the  diagnosis o f  dVIN and subsequent vulvar SCC was 22.8 
months. This was the  f i rs t  t im e  th a t  this  assumed 'short  in traep ithe l ia l phase' was 
quan t i f ied .  In Chapter 5, the  t im e  f rom  dVIN to  SCC was comparable w i th  tha t  
study, being 27.5 months. In the  upcom ing years, the  gap be tween so l ita ry  dVIN 
and dVIN adjacent to  vu lvar SCC wil l  p robably  d imin ish. This may be achieved by 
paying more a t ten t ion  to  dVIN by both clinicians and patholog is ts  and this  may 
eventua lly  lead to  more insight in the  true  biological behaviour o f  dVIN and an 
earl ier de tec t ion  o f  dVIN, which, a f te r  p roper t re a tm e n t  (surgical excision), may 
lead to  a decrease o f  HPV-negative vu lvar SCCs. This early  de tec t ion  w i l l  be o f  
great im portance  in the  fu tu re  because the  incidence o f  HPV-negative vu lvar SCC 
is though t  to  increase in the  upcom ing years due to  the  ageing o f  society. M ost 
w om en  w i th  vulvar SCC present w i th o u t  a h is tory  o f  LS, however, these patients 
o f ten  su f fe r  f rom  e ither  asym ptom at ic  or unnoticed LS,29'31'33’35 leading to  a delay 
in diagnosis by both patients and doctors. These pat ien ts never have been treated, 
wh ich may suggest, a l though evidence is lacking, th a t  t re a tm e n t  w i th  top ical cor­
ticoste ro ids may have some preventive e f fec t  in vu lvar SCC deve lopm ent.123 
The an t i - in f lam m ato ry  effectiveness o f  these top ical cort icoste ro ids  may be the 
exp lanat ion fo r  this  possible effect.
In conclusion, dVIN is seldom diagnosed as a so l ita ry  lesion, bu t this  is mere ly  
a t t r ib u ta b le  to  underdiagnosis  ra the r  than to  rarity .
Is LS or dVIN the direct precursor of HPV-negative vulvar SCC?
Because LS as well  as dVIN are seen adjacent to  HPV-negative vu lvar SCC, both 
are considered prem alignant lesions. In w h a t  way vulvar SCC arises f rom  LS and 
dVIN still has to  be c larif ied. Review o f  the  published l i te ra tu re  on LS and SCC as 
pe r fo rm ed  in Chapter 2 i l lustrates conspicuous associations be tween these tw o  
entit ies. O ther itchy condit ions (e.g., eczema, psoriasis) do not show such a 
re lat ion w i th  vulvar carcinogenesis. O ther malignancies than SCCs (e.g., basal cell 
carcinoma) are rare ly associated w i th  LS. Remarkably, LS has on ly a link w ith  
cancer when present on the  genita l area (vulva, penis329); only tw o  case reports  
have been published abou t skin cancer arising in extragen ita l LS.330 331 Carlson 
found  a compiled f requency  o f  vulvar SCC aris ing in LS o f  4.5%, based on case 
repor ts  and re trospect ive  stud ies.31 However, th is  percentage o f  4.5% was
h indered by the  poo r ly  de f ined  te rm in o lo g y  w h ich  had been used fo r  LS. 
In addit ion , mainly sym ptom at ic  w om en were  included in those studies. As the 
incidence o f  asym ptom at ic  LS is unknown, a b e t te r  es t imate o f  the  real malignant 
po tent ia l  o f  LS cannot be given. All together,  the  coexistence o f  LS and vu lvar SCC 
has been shown, bu t w i th o u t  i l lustra t ive evidence o f  vu lvar SCCs aris ing f rom  LS. 
The topograph ica l association w i th  most vu lvar SCCs arising w i th in  f ie lds o f  LS 
has been the  most com pel l ing  evidence l inking these tw o  conditions.
As described in Chapter 3, we found  tha t  dVIN was more o f ten  found  (102 cases) 
adjacent to  a vu lvar SCC than LS (62 cases). The percentage o f  47.7% (62/130) o f  
LS being present adjacent to  vu lvar SCC may be biased by the fac t  tha t  we only 
searched fo r  adjacent lesions in the  same slide tha t  conta ined the tum our.  LS may 
be more o f ten  present when also slides are revised wh ich are m ore distal f rom  
the tum our.  However, in most i f  no t all cases, dVIN was present adjacent to  the 
vu lvar carcinoma and in be tween LS and the  tum our, suggesting tha t  dVIN but 
no t  LS is the  d irec t  p recursor lesion.
In Chapter 5 we have stud ied LS lesions w i th  and w i th o u t  subsequent progression 
to  vu lvar SCC. In LS biopsies w i th  progression, in 42% dVIN was found a f te r  
revision. The median t im e be tween LS biopsy and vu lvar SCC deve lopm ent was 
83.8 months, whereas this  was sign if icant ly  sho r te r  fo r  dVIN (27.5 months), 
ind ica t ing a h igher malignant po tent ia l fo r  dVIN than fo r  LS, also suggesting tha t  
dVIN is the  d irec t  precursor lesion.
In Chapter 6 and 7 we have s tud ied LS in the  carcinogenic  cascade leading to 
vu lvar SCC in more detail .  In Chapter 6 we stud ied DNA aneuplo idy, a f requen tly  
iden t i f ied  genomic abnorm ali ty ,  which can occur in the earliest stages o f  malignant 
t rans fo rm a t ion .  DNA aneuplo idy was not found in LS, making it unlike ly to  be a 
prem alignant lesion. In contrast, DNA aneup lo idy  was found in 38% o f  dVIN 
lesions and in 53% o f  tu m o u r  samples, indicating tha t  dVIN has a h igher malignant 
po tent ia l  than LS. The percentage o f  p53 expression cells in LS tu rned  ou t to  be 
30% or lower. On the o ther  hand, this  p53 expression was higher than in normal 
t issue (although l im ited  in num ber in our study). p53 is a key regulator o f  
main ta in ing  a normal d ip lo id status and an increased expression may indicate 
tha t  the  skin has d i f f icu lt ies  w i th  main ta in ing this  d ip lo id  status in LS. The am ount 
o f  p53 expressing cells increased w i th  increasing p lo idy status. These increasing 
percentages o f  aneup lo idy  and p53 expression suggest an increasing malignant 
po tent ia l  f rom  LS to  dVIN and vu lvar SCC.
In Chapter 7, a s im i la r i ty  be tween the com posit ion  o f  the  in f lam m ato ry  response 
in dVIN and SCC was shown, wh ich was d i f fe re n t  f rom  tha t  in LS. The mean
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am oun t o f  in f lam m ato ry  cells in the  subepithe lia l com ponen t o f  LS was low. 
In dVIN the  to ta l am oun t o f  in f lam m ato ry  cells was sign if icant ly  higher, and 
comparable w i th  the  am oun t found  in vu lvar SCC. As progression o f  a premalignant 
lesion is o f ten  accompanied by a pers is tent in f lam m ato ry  s tromal response, this 
challenges the  role o f  LS as the  d irec t  p rem alignant lesion.
W ith  these studies, we have more evidence than based on incidence studies alone 
th a t  dVIN and not LS is the  d irec t p recursor lesion o f  HPV-negative vulvar SCC. 
We have no t found  any s trong evidence tha t  LS is a t rue  prem alignant condit ion.
The microenvironment in LS and dVIN probably contributes 
to vulvar SCC development
In Chapter 7 we have stud ied the  in f lam m ato ry  response in LS, dVIN and SCC, 
w i th  the  aim to  f ind  s im ilar i t ies and d iffe rences in the  com posit ion  o f  it. In general, 
solid tum ou rs  consist o f  bo th malignant cells and a num ber o f  s tromal cell types .332 
Cells in the  s tromal com p a r tm en t  are a dynamic, f lex ib le  asset to  tu m o u r  
deve lopm ent, reorganiz ing and evolv ing in response to  cues f rom  malignant cells 
as the  tu m o u r  advances.333 The s tromal c o m p ar tm en t  consists o f  a subset of 
in f lam m ato ry  cells, subdiv ided be tween the innate and adaptive im m une cells. 
The innate im m une system, also re ferred to  as the f i rs t  line o f  im m une defence 
against in fec t ion ,  consists o f  g ranu locy tes  (neutroph i ls ,  basophils, and 
eosinophils), d e n d r i t ic  cells, macrophages, na tura l k i l le r cells and mast cells). 
W hen tissue homeostasis  is d is rup ted  by an invad ing m ic robe  or virus, 
macrophages and mast cells release chemokines and cytokines, which a t t rac ts  
leukocytes. This acute ac t iva t ion o f  the  innate im m une response activates the 
adaptive im m une response, wh ich comprises B lymphocytes, CD4 T helper cells 
and CD8 c y to tox icT  cells. In chronically  in f lamed tissue, this  may lead to  excessive 
tissue remodell ing, loss o f  tissue arch itec ture , pro te in  and DNA changes by 
oxida tive stress and an increased risk o f  cancer deve lopm ent.  This increased risk 
is caused by the  func t ions  o f  the  in f lam m ato ry  cells, wh ich in f luence pro l i fe ra t ion  
and survival, angio- &  lymphangiogenesis, invasion &  metastasis and im mune 
evasion &  suppression. We found tha t  the  mean am oun t o f  in f lam m ato ry  cells in 
LS in the  sub-ep idermal com ponen t o f  LS is low, wh ich was in con trast to  the 
am oun t found in dVIN and SCC. Intr iguingly, a high percentage o f  mast cells was 
de tected w i th in  the  ep ithe l ium  o f  dVIN, wh ich was absent in LS and scanty in SCC. 
In addit ion, we showed tha t  mast cells were no t  found in o ther  in traep ithe l ia l 
lesions. W ith  the  aim to  unravel the ir  possible func t ion  in the  dVIN ep ithe lium,
we found  tha t  the  mast cells may play a role in kera t inocy te  p ro l i fe ra t ion .  
In addit ion, we found th a t  mast cells in the  ep ithe l ium  were p redom inan t ly  
degranulated, suggesting a release o f  the ir  contents in to  the ep idermal 
env ironm ent.
M ast cells may play a crucial role in angiogenesis. They have been known to 
accumulate around blood vessels dur ing homeostasis334'336 and produce 
pro-angiogenic com pounds.337 338 Recent studies have suggested tha t  mast cells 
play an im p o r ta n t  ro le in the  'angiogenic sw itch ' dur ing tu m o u r  g ro w th .339 At 
early  stages in tu m o u r  deve lopm ent, mast cells d irec t  angiogenesis in the 
develop ing tum our, wh i le  at la ter stages tu m o u r  cells take contro l o f  g row th  and 
angiogenesis and g ro w th  becomes mast ce l l- independent.340 The la t te r  may be an 
explanation why few  mast cells w ere  present in vu lvar SCC, when compared to 
dVIN.
Based on these data, one could hypothesize tha t  the  so-called early LS, as 
suggested by Regauer,120 wou ld  carry a h igher risk o f  malignant progression than 
advanced, a troph ic  LS. We propose a hypothe tica l new model fo r  HPV-negative 
vu lvar carcinogenesis (Figure 1). In 'early ' LS, the  lym phocy t ic  in f i l t ra te  is tagged 
along the  basement m em brane and it is known tha t  prem alignan t progression is 
accompanied by a s tromal response o f  mainly in f lam m ato ry  cells. These 
in f lam m ato ry  cells (mainly cy to tox ic  T cells) may induce tissue remodell ing, loss 
o f  t issue arch itec ture , pro te in  and DNA changes by oxidative stress, the reby  
increasing the  risk o f  dVIN and probab ly  vu lvar SCC deve lopm ent.  'Early' LS may 
also 'regress' in to  'advanced, a troph ic '  LS. In 'advanced' LS the re  is o f ten  an 
oedematous zone beneath the  basement membrane, under wh ich and a bandlike 
lym phocy t ic  in f i l t ra te  is present. The in f lam m ato ry  cells have descended and no 
longer are supposed to  in te ract w i th  the  kera tinocytes o f  the  ep ithe l ium  o f  LS. 
Vulvar SCC, however, is more o f ten  seen in the  advanced stages o f  LS. It may be 
argued tha t  the preneoplast ic  changes already occur in the  earliest stages, when 
early  LS is replaced by dVIN and the re fo re ,  a troph ic  LS is seen adjacent to  dVIN. 
Because LS is o f ten  present on the w ho le  vu lvar area, the re  is a f ie ld  cancerization 
e ffec t.  It is possible tha t  several subtypes o f  LS are present w i th in  the same 
patient, w i th  a d i f fe re n t  malignant po tent ia l.  This may explain why in some areas 
a vulvar SCC develops, whereas in o th e r  areas the  LS remains quiet.
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A lymphocytic in filtra te  is 
tagged along the basement 
membrane, and has the 
ab ility to induce an 
inflammatory response by 
which dVIN may develop 
and may replace early LS.
The inflammatory cells 
descend and an oedematous 
zone develops beneath the 
basement membrane.
From dVIN and the stromal 
response induced by the 
inflammatory cells, tissue 
remodelling, loss of tissue 
architecture, protein and 
DNA changes by oxidative 
stress may occur, by which 
a vulvar SCC develops.
Figure 1 H ypo thes is  o f a new  m ode l fo r  H P V-negative v u lv a r SCC oncogenesis .
What will be the role of HPV vaccines in preventing vulvar 
SCCs?
The in troduc t ion  o f  HPV vaccines has led to  a lo t o f  media a t ten t ion .  The main 
goal o f  the  vaccines is to  prevent cervical (pre) malignancies. Because a subset o f  
vu lvar SCCs is also posit ive fo r  HPV, the  preventive e f fec t  is tho ugh t  not to  be 
applicable fo r  cervical (pre) malignancies only. In a short  period, several reviews 
have been published regarding HPV in fect ions in vulvar SCCs and address the 
possible im pact o f  the  HPV vaccines on the  incidence o f  vu lvar se e ,254'341'344 w i th  
HPV16/18 percentages be tween 32%342 and 57.5%.343 However, as m en tioned  by 
Gil lison et al. HPV de tec t ion  by itse l f  should not be considered as su f f ic ien t  
evidence fo r  a causal re la t ion .342 In Chapter 3 the  role o f  HPV is f ine  tuned; we 
have dem onstra ted  tha t  HPV de tec t ion  alone is no t  su f f ic ien t  to  prove a causal
re la t ion w i th  vu lvar carcinogenesis. We have shown tha t  the re  are vu lvar SCCs 
w i th  dVIN adjacent to  it, wh ich are posit ive fo r  HPV DNA. W ith  in situ hybrid ization 
we have shown th a t  this HPV was no t in tegra ted in to  the genome, and w ith  
p l6 'NK4Aim m unoh is tochem is try  it was dem onstra ted  tha t  the  HPV was no t active 
in most cases. All together,  the re  are HPV posit ive vu lvar SCCs tha t  are unlike ly to 
be caused by tha t  HPV in fect ion . This s tudy has implica tions fo r  the  am oun t o f  
vu lvar SCCs th a t  may be prevented in the  fu tu re ,  wh ich is less than suggested in 
the  reviews mentioned, based on HPV pos it iv i ty  alone. HPV vaccines wil l  have a 
role in the  preven tion o f  uVIN related vu lvar SCCs, bu t no t in the  dVIN related 
vu lvar SCCs.
Future perspectives
We have gained more insight in the  oncogenesis o f  HPV-negative vu lvar SCC, w ith  
special focus on the  role o f  dVIN in this  cascade, bu t the  mechanisms behind this 
oncogenesis remain to  be unravelled. To gain evidence fo r  the proposed hypothesis 
as ou t l ined  above, the  concept o f  early  LS may be subject o f  fu tu re  research. 
Especially, the com posit ion  o f  the  in f lam m ato ry  in f i l t ra te  o f  early  LS may be the 
focus o f  study. It wou ld  be o f  great in terest to  know w hy an early LS lesion e i ther 
progresses towards  dVIN or regresses to  advanced LS. Un fo rtuna te ly ,  mouse 
models o f  vu lvar SCC are not used on a large scale.345 W ith  the  use o f  these 
models, the  carcinogenic cascade o f  early LS, advanced LS, dVIN towards  vulvar 
SCC m ight be m on ito red .
In addit ion, it wou ld  be o f  great in te rest to  know the  genetic  m uta t ions  tha t  occur 
f rom  LS to  dVIN and vu lvar SCC. It has been dem onstra ted  tha t  p53 m uta t ions  are 
shared in both dVIN and vu lvar SCC, which supports  a genetic re lat ionship 
be tween the  tw o .346 The main p rob lem  w i th  this  kind o f  research is tha t  DNA has 
to  be isolated f rom  paraff in  em bedded fo rm a l in  f ixed tissues. LS only has a very 
th in  ep ithe l ium  and dVIN lesions are o f ten  very  t iny  ad jacent to  vu lvar SCC w ith  
the  in f lam m ato ry  in f i l t ra te  d irec t ly  underneath it. We have t r ied  to  isolate enough 
DNA f rom  these lesions, but un fortuna te ly ,  we did no t succeed. Fresh frozen 
tissue w ou ld  be more suitable fo r  DNA iso lat ion and this  kind o f  research. 
Furtherm ore, it wou ld  be very helpfu l when a subgroup o f  LS patients could be 
distinguished w i th  an increased risk o f  m alignant progression. We have access to 
a group o f  LS pat ien ts w i th  and w i th o u t  tow ards  vulvar SCC. In Chapter 5 we have 
focused on the h istopatholog ica l character istics o f  these lesions. Future research
may be focused on the  in f lam m ato ry  in f i l t ra te  as stud ied in Chapter 7 to  f ind  ou t  
w h e th e r  the re  are d if fe rences in the  in f lam m ato ry  in f i l t ra te  be tween them. We 
have dem onstra ted  th a t  mast cells are p rom inen t ly  present in dVIN (Chapter 7), 
bu t the  quest ion remains by wh ich mechanisms mast cells en ter the  ep ithe lium , 
e.g., wh ich cell in LS is responsible fo r  the  a t t rac t ion  o f  mast cells? Furthermore, 
we have dem onstra ted  tha t  mast cells are likely to  play a role in kera tinocyte  
pro l i fe ra t ion ,  bu t  do they also exert  o ther  functions? Also o ther  cells may be o f  
in te res t ;  we have focussed on several in f la m m a to ry  cells, bu t  also o th e r  
in f lam m ato ry  cells (e.g., regu la tory  T cells, in terleukins, natural k il ler cells) may 
be studied. The regulation o f  in f lam m ato ry  reactions in cancer is not fu l ly  
unders tood , bu t  recent research has focused on the  role o f  the  IL-17/IL23 axis. 
IL-17 and IL-23 signall ing could p ro m o te  tu m o u r  g ro w th  and metastasis and 
d i rec t ly  suppress a n t i tu m o u r  im m une responses.347 However, the re  is also 
evidence to  suggest tha t  IL-17, 11-23 and T h l7  cells could assist in the  generat ion 
o f  an t i tu m o r  im m une responses. Well -estab lished tum ou rs  produce high levels 
o f  TGFI5 and IL-6, as both o f  these cytok ines can also act as d i f fe re n t ia t ion  factors 
fo r  T h l7  cells. Tum our-der ived TGFI5 may help the  d i f fe re n t ia t ion  o f  FoxP3+ 
regu la to ryT  cells, thus result ing in im m unosuppression o f  an t i tu m o u r  responses.348 
These in f lam m ato ry  cells may be s tud ied in vu lvar SCC and its precursors as well 
to  establish the  role in vulvar carcinogenesis.
In addit ion, a t ten t ion  is needed to  educate patholog is ts  and gynaecologists to 
b e t te r  recognize dVIN and to  adhere to  a s t r ic t  no m en c la tu re  fo r  vu lvar 
prem alignan t lesions. Both clinically and h is topa tho log ica lly  dVIN is hard to 
recognize. Gynaecologists need to  biopsy every suspicious lesion in a background 
o f  LS and patholog is ts  need to  be t ra ined in the  recogn it ion o f  dVIN. The 
recogn it ion o f  a premalignancy in general may lead to  its t re a tm e n t  and possibly 
the  p reven tion  o f  malignant progression. The incidence o f  the  HPV-negative 
vu lvar SCC may increase due to  the  ageing o f  society, so it is o f  u tm os t  im portance  
th a t  the oncogenic  cascades are be t te r  unders tood and tha t  the  current  knowledge 
is incorpora ted  in daily practice.
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Summary
Chapter 1
Vulvar SCC arises fo l low ing  tw o  d i f fe re n t  pathways. The m in o r i ty  is caused by an 
in fec t ion  w i th  h igh-risk HPV, w i th  usual VIN as prem alignant lesion. The m a jo r i ty  
is HPV independent and arise in a background o f  LS. dVIN is though t  to  be the 
d irec t  precursor o f  this  vu lvar SCC. How LS develops in to  dVIN and eventually 
vu lvar SCC is current ly  unknown.
To be able to  answer the  question: 'w ha t  is the role o f  dVIN in the oncogenesis o f  
vu lvar SCC?' we have several sub questions th a t  are addressed in this  thesis:
1. W ha t  is the  exact role o f  HPV in the tw o  pathways leading to  vu lvar SCC? 
(Chapter 3)
2. W ha t  is the  incidence o f  so l ita ry  dVIN, has this incidence changed in the 
past years and w ha t is its malignant po tent ia l?  (Chapter 4)
3. Can we f ind  d i f fe rences be tween LS biopsies o f  patients w h o  la ter are 
diagnosed w i th  a vulvar SCC and LS biopsies o f  pat ien ts w ho did not 
develop a vu lvar SCC? (Chapter 5)
4. Is the  malignant progression o f  LS and dVIN to  vu lvar SCC accompanied by 
alte red DNA content? (Chapter 6)
5. Can we prov ide  ev idence fo r  the  fac t  th a t  dVIN is a l ikely p recursor o f  
vu lvar SCC based on the  in f lam m ato ry  response? (Chapter 7)
Chapter 2
Chapter 2 is a rev iew about the  vu lvar p rem alignant lesions, LS, dVIN and uVIN. 
The signs and symptoms, malignant po tent ia l,  and t re a tm e n t  op t ions o f  these 
lesions are described.
Chapter 3
W ith  the aim to  f ind  ou t  w h a t  the  exact role o f  HPV is in the  tw o  pathways leading 
to  vu lvar SCC, we have pe r fo rm ed  a s tudy on 130 vu lvar SCC cases fo r  the  presence 
o f  the adjacent VIN lesion, its p l 6 INK4A expression, and HPV DNA presence and 
in tegra tion  in the genome. W ith  the  results o f  th is  s tudy we also wanted to 
est imate the  p rophy lact ic  e f fec t  o f  HPV 16/18 vaccines fo r  vu lvar SCC. We showed 
tha t  HPV presence no t au tom at ica l ly  means a causal re la t ionship w i th  the  tu m o u r  
deve lopm ent.  Based on HPV presence a lone the  preventive e f fec t  o f  HPV vaccines 
is overest imated. Moreover,  we showed tha t  the  dVIN-associated vulvar SCCs had 
a worse disease specif ic  survival (DSS) than the  uVIN-associated vu lvar SCCs,
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wh ile  a comparison be tween HPV posit ive and HPV negative vu lvar SCCs did not 
result  in d i f fe re n t  DSS curves. This was expla ined by a worse DSS fo r  dVIN- 
associated vulvar SCCs th a t  were HPV posit ive. Summarised, HPV found  in dVIN- 
associated vu lvar SCCs is no t  likely to  be causally associated w i th  the  tu m o u r  
deve lopm ent. uVIN-associated vu lvar SCCs may be prevented by vaccines in the 
fu tu re ,  leaving the prob lem  o f  dVIN-associated vulvar SCCs, w i th  w o rs t  DSS 
unsolved.
Chapter 4
It has been though t  tha t  dVIN is underdiagnosed as a so l ita ry  lesion and tha t  its 
malignant po tent ia l is high, but this  has not been s tud ied in detail  before. In 
Chapter 4 we have pe r fo rm ed  a study to  the incidence o f  bo th VIN lesions and 
vu lvar SCC in the  Netherlands f rom  1992 -  2005. O f all VIN lesions, the  vast 
m a jo r i ty  were usual VIN lesions, o f  wh ich the incidence sign if icant ly  increased in 
the  14 years o f  study. Only a m in o r i ty  o f  all VIN lesions were o f  the  d i f fe ren t ia ted  
type, but we found  an increase in incidence, especially f rom  2002 onwards. 
Remarkably, despite an increase in bo th prem alignant lesions, the  incidence o f  
vu lvar SCC remained stable. In contrast to  the 5.7% malignant po tent ia l  o f  uVIN, 
a percentage o f  32.8% was found fo r  dVIN. The t im e  f rom  VIN diagnosis to  vulvar 
SCC deve lopm ent was sho r te r  fo r  dVIN (22.8 months) compared to  uVIN (41.4 
months). We also dem onstra ted  tha t  this  malignant po tent ia l fo r  uVIN increased 
w i th  age, p robably  re f lec t ing  an altered im m u n ity  fo r  e lderly  w om en, re f lec t ing  a 
fa i lu re  o f  the  im m une system to  suppress HPV result ing in recu rren t  uVIN lesions 
and possibly vu lvar SCC. Forty-one percent o f  pat ien ts w i th  uVIN have a previous, 
concom itan t  or subsequent in traep ithe l ia l neoplasia o f  the  cervix, vagina and/or 
anus. From this  s tudy we have concluded tha t  an increase o f  bo th uVIN and dVIN 
has no t led to  an increase in vu lvar SCC incidence, and th a t  dVIN carries a higher 
malignant po tent ia l than uVIN.
Chapter 5
Because only a m in o r i ty  o f  patients w i th  LS wil l  u l t im ate ly  develop vu lvar SCC, we 
compared the LS biopsies o f  pat ien ts w ho w ere  la ter diagnosed w i th  vu lvar SCC 
(both in Nijmegen and Groningen) to  LS biopsies o f  pat ien ts w ho never developed 
vu lvar SCC. All biopsies were  revised by tw o  expert  gynaecopatholog is ts  and 
his topatholog ica l characteristiscs were scored. We found tha t  o f  the  60 LS 
biopsies w i th  la ter progression, in 42% dVIN was found. A f te r  we excluded those 
dVIN lesions, a comparison was made w i th  the  LS biopsies o f  pat ien ts w i th o u t
progression. Para- and dyskeratosis, atypia and hyperplasia were the  h is topa tho- 
logical features linking LS to  vu lvar SCC deve lopm ent.  In addi t ion , pat ien ts w i th  
la ter progression were  s ignif icantly  o lder than pat ien ts w i th o u t  progression at 
the  t im e  the biopsy was taken. The median t im e  to  vu lvar SCC deve lopm ent was 
sign if icant ly  longer fo r  LS than fo r  dVIN lesions. In this study we have shown tha t  
dVIN is no t as rare as previously tho ugh t  but this  it was o f ten  over looked in the 
past.
Chapter 6
In Chapter 6 we have stud ied the  p53 expression and DNA plo idy status in LS, 
dVIN and HPV negative vu lvar SCCs. The aim o f  this  s tudy was to  f ind ou t  w h e the r  
progression o f  LS and dVIN to  vu lvar SCC is accompanied by a ltered DNA content.  
In addit ion, we have taken the  p53 expression o f  these lesions in to account to 
s tudy the  re lat ion be tween the  expression o f  this  cell cycle pro te in  and plo idy 
status. We have found tha t  the m a jo r i ty  o f  LS lesions w ere  dip lo id , re f lec t ing  a 
normal DNA con ten t  in these lesions. Lesions in wh ich both dVIN and vu lvar SCC 
w ere present, the  plo idy status o f  dVIN never exceeded the p lo idy status o f  the 
carcinoma. In all dVIN lesions, the  p53 expression was conf ined to  the  basal and 
suprabasal layers, sometimes w i th  suprabasal extension. We showed a posit ive 
corre la t ion  be tween high percentage o f  p53 posit ive cells and altered DNA 
con ten t  in the  tissues studied. We also have examined this corre la t ion  in indiv idual 
cells, dem onstra t ing  a d i f fe rence in Feulgen In tegrated Optical Density be tween 
p53 negative and p53 posit ive ep ithe lia l nuclei. In so l ita ry  dVIN lesions the  lower 
one- th ird  com ponen t o f  dVIN contains nuclei w i th  increased DNA content,  in 
contrast to  the  upper one- th ird  com ponent,  wh ich contains a low percentage o f  
cells w i th  an abnormal DNA content.  In addit ion, the  basal c o m p ar tm en t  was 
m ore pro l i fe ra t ive  than the  superf ic ia l com partm en t.  All together,  in this study 
we have dem onstra ted  tha t  based on plo idy data and p53 expression, dVIN has a 
h igher malignant po tent ia l  than LS. The mechanism o f  oncogenesis and the 
progression o f  LS to  dVIN still cannot be unravelled w i th  these data.
Chapter 7
Because progression o f  a prem alignant lesion towards  an invasive tu m o u r  concurs 
w i th  a pers is ten t s tromal response, the  purpose o f  the  study in Chapter 7 was to 
analyse the com posit ion  o f  the  in f lam m ato ry  response in LS, dVIN and vulvar 
carcinoma. We studied the  localisation and am oun t o f  T he lper cells, cy to tox ic  T 
cells, B cells, macrophages, dendr i t ic  cells, and mast cells. The mean am oun t o f  all
in f lam m ato ry  cells in the  sub-ep ithe l ia l com ponen t was low in LS, and highly 
increased in dVIN and vulvar SCC. Remarkable was the  high percentage o f  mast 
cells w i th in  the  ep ithe l ium  o f  dVIN, wh ich w ere no t found in LS and only  
in frequen t ly  in SCC. S ignif icantly  more mast cells w ere  found in the  ep ithe l ium  o f  
dVIN compared to  o ther  in traep ithe l ia l or hyperp last ic  lesions. MIB-1 posit ive 
kera tinocytes w ere  observed in close p ro x im ity  o f  in traep ithe l ia l mast cells, but 
we also found MIB-1 posit ive kera tinocytes in the  absence o f  mast cells, suggesting 
th a t  in traep ithe l ia l localisation o f  mast cells is not a prerequis i te  fo r  kera tinocyte  
p ro l i fe ra t ion .  The e lec tron  dens i ty  o f  in t raep ithe l ia l  mast cells was s trong ly  
reduced, suggesting th a t  mast cells have released th e i r  con ten ts  in to  the  
ep idermal env ironm ent.  W ith  this  s tudy we have shown tha t  in traep ithe l ia l 
localisation o f  mast cells could be used as a m arker fo r  dVIN, wh ich may fac il i ta te  
its recogn it ion . We have provided support  fo r  the  gradual progression f rom  dVIN 
tow ards  vulvarSCC. Moreover,  in traep ithe l ia l  m astce l lscan p rom ote  pro l i fe ra t ion .  
From this study it remains elusive why mast cells migrate to  the epithelium of dVIN 
and w h e th e r  they exert  o ther  functions, apart f rom  induction  o f  p ro l i fe ra t ion .
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Samenvatting
Hoofdstuk 1
Het vu lvacarc inoom kan op tw ee  manieren ontstaan. Een klein deel w o rd t  door 
een in fect ie  m et hoog risico HPV veroorzaakt,  m et usual VIN als prem align ite it .  
De meerderhe id  w o rd t  veroorzaakt op een HPV onafhanke li jke manier, in een 
achtergrond van LS. dVIN w o rd t  veronders te ld  het d irec te voo rs tad ium  te zijn 
van dit  type  vu lvacarc inoom. Hoe LS zich o n tw ikke l t  to t  dVIN en verder to t  vulva 
carc inoom, is op d i t  m om e n t  nog onbekend.
Dit  p roe fsch r i f t  hee ft  als doel de vraag te bean tw oorden  w a t  de rol is van dVIN in 
de oncogenese van het vu lvacarc inoom. H iertoe hebben we verschil lende 
subvragen ge form uleerd  welke besproken worden  in d it  p roefschr i f t .
1. W at is de precieze rol van HPV in het ontstaan van de tw ee  typen  vu lva­
carcinoom? (Hoofdstuk 3)
2. W at is de inc ident ie  van sol ita ire dVIN, is deze inc ident ie  veranderd over 
de afgelopen ja ren en w a t  is de maligne po ten t ie  van dVIN? (Hoofdstuk 4)
3. Zijn er verschil len tussen LS b iopten van pat iën ten die la ter wel o f  n ie t zijn 
gediagnosticeerd m et een vu lvacarc inoom? (Hoofdstuk 5)
4. Gaat de maligne progressie van LS en dVIN to t  vu lvacarc inoom gepaard 
m et een veranderde DNA Ínhoud? (Hoofdstuk 6)
5. Kunnen we bewijs leveren dat dVIN het voorstadium is van het HPV negatieve 
vu lvacarc inoom  op basis van de ontstekingsrespons? (Hoofdstuk 7)
Hoofdstuk 2
Hoofdstuk 2 is een review over vulvaire premaligniteiten, te weten LS, dVIN en uVIN. 
Van deze laesies worden de symptomen, klinische kenmerken, maligne potentie  en 
behandelopties beschreven.
Hoofdstuk 3
In hoofds tuk  3 beschri jven we w a t  de exacte rol van HPV is bij de tw ee  typen 
vu lvacarc inoom. We hebben naast 130 vu lvacarc inomen gekeken o f  er sprake 
was van LS, dVIN o f  uVIN, de p l6  expressie, HPV DNA aanwezigheid en o f  d it  
gevonden HPV geïntegreerd in het genoom aanwezig was. M e t  deze resultaten 
w i l len we tevens kijken w a t  het p reventieve e f fec t  kan zijn van de HPV vaccinaties. 
Het bleek dat HPV aanwezigheid n iet au tomatisch betekende dat d it  een causale 
re lat ie had m et het ontstaan van de tum or.  W anneer het preventieve e f fec t  al leen 
gebaseerd w o rd t  op het aan- o f  afwezig zijn van HPV, le id t  d i t  to t  een overschatt ing.
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Ook bleek dat de overlev ing van pat iën ten m et een dVIN geassocieerd vu lva­
carc inoom slechter was in vergel i jk ing m et pa t iën ten m et een uVIN geassocieerd 
vu lvacarc inoom, te rw i j l  een vergel i jk ing gebaseerd op HPV aanwezigheid d it  
verschil  n iet toonde. De overlev ing van HPV posit ieve, dVIN geassocieerde 
tum ore n  was erg slecht in onze populatie . De conclusie van d i t  hoofds tuk  is dat 
als er HPV w o rd t  gevonden in een dVIN geassocieerd carc inoom, d i t  HPV nie t de 
oorzaak is van de tum or. Alleen uVIN geassocieerde tum ore n  kunnen voorkom en 
wo rden  door de HPV vaccinaties. Echter, de tum oren  m et de slechtste overlev ing 
blijven na HPV vaccinatie bestaan.
Hoofdstuk 4
Over dVIN w o rd t  vaak geschreven dat deze onder gediagnosticeerd w o rd t  in zijn 
sol ita ire vorm  en dat de maligne po ten t ie  ervan hoog is, maar d i t  werd noo it  
eerder aangetoond. In hoofds tuk  5 hebben we de inc ident ie  van de beide VIN 
soorten  en het vu lvacarc inoom in Nederland in de periode 1992-2005 bestudeerd. 
Van alle VIN laesies bestond het overgro te  deel u i t  uVIN, waarvan de inc ident ie 
s ignif icant is toegenom en gedurende de stud ie periode. Slechts een klein deel 
bestond uit sol i ta ire dVIN laesies, maar een toenam e in de inc ident ie  werd ook 
voo r  dVIN gezien, in het b i jzonder vanaf 2002. Ondanks deze st ijg ing van beide 
VIN laesies, is de inc ident ie  van het vu lvacarc inoom geli jk gebleven. De maligne 
po ten t ie  van uVIN was 5.7% in onze studie, w a t  aanmerkeli jk  lager is dan de 32.8% 
die we vonden voor dVIN. De t i jd sduur  van VIN laesie to t  het on tw ikke len  van het 
vu lvacarc inoom  verschilde tussen uVIN (41.4 maanden) en dVIN (22.8 maanden). 
Tevens bleek dat de maligne po ten t ie  van uVIN toenam  m et een toenem ende 
lee f t i jd  waarop uVIN werd vastgesteld, w a t  verklaard zou kunnen w o rden  door  de 
veranderde im m u n ite i t  op hogere leeft i jd ,  w aardoor  de HPV in fect ie  niet 
o n de rd ruk t  kan worden. Dit kan mogeli jk  eerder le iden to t  rec id iverende uVIN 
laesies en mogeli jk  een uVIN gere la teerd vu lvacarc inoom. Tevens had 41% van 
de pa t iën ten m et uVIN een voorafgaande, ge li jk t i jd ige, o f  toekom st ige  HPV 
geïnduceerde laesie van cervix, vagina e n /o f  anus.
Hoofdstuk 5
Slechts een kle ine m inderhe id  van alle pa t iën ten m et LS o n tw ikke l t  op latere 
le e f t i jd  een vu lvacarc inoom, maar het is nog onbekend welke pa t iën ten hierop 
een hoger risico hebben. We hebben LS b iopten vergeleken van pat iën ten die 
la ter wel en die geen vu lvacarc inoom hebben gekregen. Alle b iop ten werden 
gereviseerd doo r tw ee  pathologen m et expert ise op gynaecologische pathologie.
Histopathologische kenmerken werden bekeken en gescoord. In de b iop ten van 
pa t iën ten die la ter een vu lvacarc inoom  hebben on tw ikke ld ,  vonden we in 42% 
dVIN. Deze hebben we uit  de vergel i jk ing tussen de LS b iopten m et en zonder 
la ter vu lvacarc inoom gelaten. Deze vergel i jk ing liet zien dat LS b iop ten m et latere 
progressie vaker dys- o f  parakeratose, a typ ie  o f  hyperplasie hadden. Ook waren 
de pat iën ten die la ter een vu lvacarc inoom  hebben on tw ikke ld  ten t i jde  van het 
b iop t  ouder dan de pa t iën ten die geen vu lvacarc inoom hebben on tw ikke ld .  
De t i jd  tussen LS en vu lvacarc inoom on tw ikke l ing  was langer dan de t i jd  tussen 
dVIN en het vu lvacarc inoom. Deze stud ie laat zien dat sol ita ire dVIN nie t zo 
zeldzaam is, maar dat deze laesie vaak over hoofd werd gezien in het verleden.
Hoofdstuk 6
In hoofds tuk  6 hebben we ons ger ich t op de vraag w a t  de p53 expressie en ploid ie  
status is in LS, dVIN en het HPV negatieve vu lvacarc inoom. Het doel van deze 
stud ie was om te kijken o f  de progressie van LS naar dVIN en het vu lvacarc inoom 
gepaard gaat m et een veranderde DNA Ínhoud. Ook hebben we gekeken naar de 
p53 expressie van deze laesies om de relat ie  tussen p53 expressie en DNA Ínhoud 
te bestuderen. Bijna alle LS laesies waren dip lo id , w a t  een normale DNA Ínhoud 
imp liceert .  In laesies waar zowel dVIN als vu lvacarc inoom voorkwam en, was de 
DNA Ínhoud van dVIN noo it  méér dan in het naastgelegen vu lvacarc inoom. In de 
dVIN laesies, was de p53 expressie alleen in de basale en suprabasale lagen 
aanwezig, soms m et suprabasale extensie. Er was een posit ieve corre la t ie  tussen 
de p53 expressie en de DNA Ínhoud in alle laesies. Ook hebben we gekeken naar 
DNA op cel niveau, w a t  een verschil  in Feulgen Integrated Optical Density toonde  
tussen p53 posit ieve o f  negatieve cellen. In sol ita ire dVIN laesies bevatten de 
cellen in het onders te  1 /3  gedeelte een verhoogde DNA Ínhoud, w a t  verschilde 
van cellen in de bovenste 1 /3  laag van het ep itheel. Ook bleek dat cellen in het 
basale deel p ro l i fe ra t ieve r  waren dan in de bovenste lagen. In deze s tud ie hebben 
we laten zien dat, gebaseerd op p lo id ie gegevens en p53 expressie, dVIN een 
hogere maligne po ten t ie  hee f t  dan LS. Het oncogenetische mechanisme h ierachter 
kunnen we h iermee niet achterhalen.
Hoofdstuk 7
Progressie van een prem align ite it  naar een invasief carc inoom gaat vaak gepaard 
m et een reactie in het onder l iggende stroma. In hoofds tuk  zeven hebben we naar 
de samenstel l ing van het on tstek ings in f i l t raa t  gekeken in LS, dVIN en het 
vu lvacarc inoom. We hebben de lokalisatie  en hoeveelheid van T he lper cellen,
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cytotox ische T cel len, B cellen, macrofagen, dendr it ische cellen en mestcellen 
bestudeerd. LS laesies bevatten we in ig  cel len in het sub-ep ithe l ia le  com part im ent,  
en het aantal ontstek ingscel len was s ignif icant verhoogd in dVIN en vulva- 
carc inoom. W at erg opvie l was de aanwezigheid van mestcellen in het ep itheel 
van dVIN, welke n iet aanwezig waren in LS en slechts we in ig  in het vulvacarc inoom. 
In een vergel i jk ing m et andere in traep ithe l ia le  o f  hyperp lastische laesies bleek d it  
karakter is t iek  te zijn voo r  dVIN. In de omgeving van mestcellen vonden we een 
verhoogde pro l i fe ra t ie  van kera tinocyten, maar ook vonden we p ro l i fe ra t ie  
verder weg van mest cellen w a t  suggereert  dat mestcellen geen voo rwaarde  zijn 
voo r  cel p ro l i fe ra t ie .  De e lectronen dichthe id van in traep ithe l ia le  mestcellen was 
verlaagd ten opzichte van s trom ale mest cel len w a t  degranulat ie  suggereert. 
In deze studie hebben we laten zien dat in traep ithe l ia le  mestcellen als marker 
voo r  dVIN kunnen dienen, w a t  de herkenning hiervan makkeli jker maakt. Op basis 
van het ontstek ings in f i l t raa t  hebben we aanwijzingen dat er een graduele 
progressie is van LS via dVIN naar het vu lvacarc inoom. Ook bleek dat mescellen 
cel p ro l i fe ra t ie  kunnen bevorderen. W aarom  mestcellen in het ep itheel van dVIN 
voo rkom en en wat, naast cel p ro li fe ra t ie ,  hun func t ie  is, b l i j f t  nog onduide li jk .
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Abstract
Objective: Lichen sclerosus (LS) is a chronic skin d isorder most ly  seen on the 
female anogenita l skin. The aim o f  this s tudy was to  evaluate the  QoL and sexuality 
in fem a le  LS pa t ien ts  and to  com pare th e i r  scores w i th  hea lthy  contro ls .  
Add it ional ly ,  we wanted  to  f ind  fac tors  associated w i th  impaired sexual func t ion ing  
in LS patients.
Methods: M em bers  o f  the  Dutch LS founda tion  and suppo rt  g roup were asked to 
fi l l  in th ree  questionnaires: the  Derm ato logy Quality  o f  Life Index (DLQI), Female 
Sexual Distress Scale (FSDS) and the Female Sexual Function Index (FSFI). 215 ou t  
o f  368 pat ien ts re turned the ir  quest ionna ire  (58.4%). Their scores w ere compared 
to  a contro l group wh ich consisted o f  61 w om en o f  sim ilar age (p=0.472) w i th o u t  
a skin disorder.
Results and Conclusions: Of all domains o f  QoL, LS in te r fe red  m ost w i th  sexual 
func t ion ing .  Patients s ign if icant ly  scored lower on all subscales o f  the  FSFI (desire 
(p=0.016), arousal (p<0.001), lubrication (p<0.001), orgasm (p<0.001), satisfaction 
(p<0.001) and pain (p<0.001), indicat ing worse sexual func t ion ing .  These problems 
w i th  sexual fu n c t io n in g  b rough t  ab ou t  s ign if ican t  sexual distress (p<0.001). 
Patients w ho experienced more in fluence on the ir  QoL had more sexual d i f f icu lt ies, 
leading to  more sexual distress independent o f  the ir  age.
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Introduction
Lichen sclerosus (LS) is a chronic skin d isorder tha t  affects pat ien ts o f  all age 
groups, part icu lar ly  wom en. It is m ost com m only  seen on the female anogenital 
skin, bu t it may occur on extragen ita l areas as well .  LS is a t issue destruct ive 
disease tha t  may lead to  anatomical changes; resorpt ion o f  the  labia minora, 
hood ing and burial o f  the cli toris , labial fusion and in tro ita l stenosis may occur 
(Figure 1). The origin o f  LS is unknown and in LS pat ien ts the re  is an increased 
incidence o f  vu lvar squamous cell carcinomas w i th  a l i fe - t im e risk o f  abou t 5%, 
wh ich is a relat ive risk o f  300 compared to  w om en  in the general popu la t ion .2930 
M os t  pat ien ts compla in o f  i tching, bu t  a burn ing sensation, dyspareunia, dysuria 
and painfu l de fecat ion are also rep o r ted .258 The current  s tandard t re a tm e n t  o f  LS 
is the use o f  superpo ten t  cort icos te ro id  o in tm e n t.130 132 A lthough this  t re a tm e n t  is 
e f fec t ive  in the  m a jo r i ty  o f  LS patients, most experience exacerbations at t imes.
Figure 1 LS w ith  n a rro w in g  o f th e  in tro itu s  
by a n te r io r  lab ia l fu s io n .
Limited data tha t  focus on the  e f fec t  o f  LS on qua l i ty  o f  life (QoL) and sexual 
func t ion ing  are available. Probably many LS pat ien ts feel embarrassed and do 
have sexual prob lem s.6162 Patients may be un com for tab le  by the  dis f iguring 
changes tha t  may occur and may the re fo re  avoid sexual in timacy. In a study on 
the QoL in 43 chronic LS patients, i t  was found th a t  pat ien ts w ho are seeking care
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fo r  LS have considerable QoL im pa irm ent:  the  m a jo r i ty  o f  pat ien ts repor ted  both 
an im pact on sexual func t ion ing  and f rus t ra t io n  and a s ignif icant im pact on 
general happiness. Their self esteem and conf idence were also affected. Data in 
th a t  s tudy showed tha t  all major QoL domains were  affec ted except fo r  w o rk /  
school func t ion ing .349 Dalziel repor ted  th a t  LS had a de tr im en ta l e f fec t  on 
sexual func t ion ing ,  bu t  on ly  a small num ber o f  pat ien ts (45) were questioned. 
Furtherm ore, she did no t use a val idated quest ionna ire  and the  results were not 
compared w i th  a con tro l g roup .66
QoL and sexuality may be assessed in various ways; in our s tudy on QoL and sexual 
func t ion ing  in female LS pat ien ts we choose to  use the Derm ato logy Life Qua lity  
Index (DLQI), the  Female Sexual Distress Scale (FSDS) and the  Female Sexual 
Function Index (FSFI).
Few studies have addressed QoL and sexual ity in LS patients, and these studies 
included a l im ited num ber o f  pat ien ts and /o r  lack a con tro l group. In addition, 
they  did no t use val ida ted questionnaires. There fore, it is still largely unknown 
w h a t  the  exact e f fec t  o f  LS on the QoL and sexual ity is. The aim o f  this  study was 
to  evaluate the QoL and sexual ity w i th  val idated quest ionnaires in detail  in a large 
group o f  female LS pat ien ts and to  compare the ir  scores w i th  healthy contro ls. 
Add it ional ly ,  we wanted  to  f ind  fac tors  associated w i th  impaired sexual func t ion ing  
in LS patients.
Methods
Patients
The Dutch LS founda tion and support  group was in it ia ted in 2006. At the  beginning 
o f  our study, 430 LS pat ien ts (32 male, 398 female) w ere  m em ber o f  this 
founda tion .  Patients are on ly a l lowed to  become a m em ber o f  the  founda t ion  
a f te r  they declare th a t  they have a diagnosis o f  LS, pre ferab ly by tak ing  a biopsy. 
Since LS is a chronic skin disease, all patients are under fo l low  up by a gynaecologist, 
de rm ato log is t  or fam ily  doctor. Un fo rtuna te ly ,  we did not know w h e the r  they all 
used some fo rm  o f  t re a tm e n t  at the  t im e  o f  the  study. All female m embers were 
inv ited to  part ic ipa te  in our s tudy by an email message. T h ir ty  email messages 
could not be delivered. As a result, a to ta l num ber o f  368 female patients w i th  LS 
were  asked to  part ic ipa te  in the  study. In the  email message a link to  a website  
was included w here  the quest ionnaires could be f i l led  in e lec tron ica l ly  and
anonymously. In addit ion, pat ien ts were asked fo r  several sociodemographic 
pa t ien t characteristics (age and marita l status) and medical data (duration of LS).
Control group
W ith in  the  Radboud Univers ity  Nijmegen Medical Centre, the re  is co l labora tion 
be tween the  depa r tm en ts  o f  Obstetr ics &  Gynaecology and the de pa r tm e n t  o f  
Dermatology. These tw o  depa rtm en ts  designed a QoL study fo r  psoriasis patients 
using the same quest ionnaires as used in this  s tudy on LS patients. Both LS and 
psoriasis pat ien ts were  asked to  inv ite female fr iends o f  abou t the  same age to  fi ll  
in the  quest ionnaires to  fo rm  a con tro l group fo r  bo th studies. They could 
part ic ipa te  in the study when they did no t  have psoriasis, LS or another 
derm ato log ica l condit ion.
Questionnaires
The DLQI is the f i rs t  dermatology-specif ic  QoL ins trum ent and to  date it is the most 
com m only  used.350 351 It consists of 10 questions concerning patients' perception of 
the impact of the ir  skin disease on d i f fe ren t  aspects of the ir  QoL and has been 
validated fo r  derm ato logy patients.349 (Some examples o f  questions: "Over the last 
week, how much has your skin influenced the clothes you wear?" and "Over the last 
week, how much has your skin made it d i f f icu lt  fo r  you to do any sport?") 
The quest ionnaire  is s t ruc tu red  w i th  each quest ion having fo u r  a lte rnative 
responses: 'not at all', 'a li t t le ',  'a lot' , or 'very much', w i th  corresponding scores of 
0, 1, 2, 3 respectively. The answer 'no t  re levant '  is scored as '0'. The DLQI is 
calculated by summing the score o f  each question, result ing in a m in im u m o fO a n d  
a maximum o f 30. The higher the  score, the  greater the  im pa irm ent o f  QoL.351
The FSFI is a 19 item quest ionnaire  tha t  has been developed as a brief, m u l t id i ­
mensional se lf- repo r t  in s trum en t fo r  assessing the  key dimensions o f  sexual 
func t ion ing  in wom en . The FSFI has six subscales: desire, arousal, lubricat ion, 
orgasm, satisfaction and pain. The quest ionnaire  was designed and val idated fo r  
the  assessment o f  female sexual func t ion ing  and QoL in clinical t r ia ls and 
epidemio log ica l stud ies.352 Indiv idual domain scores are ob ta ined by adding the 
scores o f  the  indiv idual i tems tha t  comprise the  domain and subsequently 
m u lt ip ly ing  the  sum by the  domain factor. The fu l l  scale score is ob ta ined by 
adding the six domain scores.352 Higher scores indicate be t te r  sexual function ing . 
A FSFI to ta l score o f  26.55 or less is the c u t -o f f  po in t fo r  d i f fe re n t ia t ing  w om en 
w i th  and w i th o u t  sexual dys func t ion .353
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The FSDS is a 12 item self-ra t ing ins trum en t fo r  assessing sexually related personal 
distress and has been extensive ly used. The scale showed a high degree of 
d iscr im inat ive ab i l i ty  in distinguish ing be tween sexually dysfunct ional and 
sexually func t iona l w o m e n .354 355 Every item requires an answer tha t  is rated as: 
never (0 points), rare ly (1 poin t), occasionally  (2 points), f requ en t ly  (3 points), or 
always (4 points). The to ta l score, ranging f rom  0 to  48, provides a measure of 
sexual distress, in which the  higher the score, the  higher the  level o f  sexual 
distress355 A to ta l score o f  >15 on the  FSDS is the  recom m ended c u t -o f f  score to 
establish the  presence o f  sexually related personal distress.355 Both the  FSFI and 
FSDS have been val idated fo r  a Dutch popu la t ion .356
Statistics
Data were entered in a com puter ised database and analyzed using SPSS so f tw are  
(version 16.0.1 fo r  W indows, SPSS). Differences be tween pat ien ts and contro ls 
were  calculated using the  M ann-W h itney  U tes t  fo r  independent,  nonparam etr ic  
d is tr ibu te d  data. Corre la t ions w e re  calcu la ted using Pearson b ivaria te  
co rre la t ions  and a l inear regression model was used to  calcu la te w h ich  fac to r  
was associated w i th  sexual dys func t ion ing .  P values <0.05 w ere  considered 
s ta t is t ica l ly  s ign if icant.
Results
Patients o f  the  Dutch LS founda tion  and suppo rt  g roup re turned 215/368 (58.4%) 
questionnaires. The median age was 50 years (range 20-76 years). The m a jo r i ty  of 
the  pat ien ts (80%) were marr ied or liv ing together.  Only 82 pat ien ts f i l led in fo r  
how long they had suffered f rom  LS. The median dura t ion  o f  compla in ts was 5.0 
years (mean 8.0, range 1-45 years). S ixty-one healthy contro ls  f i l led  in the 
questionnaires. The median age o f  the  con tro l group was 50 years (range 24-69), 
which did not differ signif icantly w ith  the median age of the LS patients (p=0.472).
DLQI
To f ind ou t  w h e the r  LS has in fluence on the QoL in pat ien ts w i th  LS, they  were 
asked to  f i l l  in the DLQI. As this is a quest ionnaire  abou t the  in fluence o f  
de rm a to logy  disorders on QoL, only LS pat ien ts were asked to  com ple te  this 
quest ionnaire , because the  con tro l group consisted o f  pat ien ts w i th o u t  a 
dermato log ica l cond it ion . The mean to ta l score o f  LS pat ien ts was 11.92 poin ts
(SD 6.18), wh ich indicates a very large e f fec t  on the QoL.350 LS pat ien ts had the 
highest mean score on the  item regarding sexual d i f f icu lt ies . LS did not in te r fe re  
much w i th  w ork ing  or s tudying (Figure 2).
Q_
Figure 2 M ean DLQI scores.
In to ta l,  212 p a tie n ts  f i l le d  in a ll qu e s tio n s  o f th e  DLQI q u e s tio n n a ire .
FSFI
LS pat ien ts had a mean to ta l score o f  18.79 (SD 7.95), tha t  o f  the  con tro l group 
was 27.43 (SD 4.03) (p<0.001). W ith  a cut o f f  value o f  26.55,353 this  indicates 
sexual dysfunc t ion ing  in LS patients, no t  in contro ls. Patients (n=187) scored 
sign if icant ly  lower on all the  subscales fo r  the FSFI compared to  the  con tro l group 
(n = 61) (Mann W h itney  U test: p<0.001 fo r  subscales arousal, lubrica t ion , orgasm 
satisfaction and pain, p=0.016 fo r  desire). The smallest d i f fe rence was on the 
subset 'desire' (Figure 3).
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Figure 3 M ean FSFI scores.
In to ta l,  187 p a tie n ts  f i l le d  in all q u es tions  o f th e  FSFI q u e s tio n n a ire . These scores w e re  
s ig n if ic a n tly  d if fe re n t fro m  co n tro ls  on a ll dom a ins  (M a n n -W h itn e y  U te s t).
FSDS
Mean to ta l  score fo r  the  FSDS was 26.08 (SD 11.81) fo r  pat ien ts and 9.97 (SD 8.26) 
fo r  controls (p<0.001). Using a cut o f f  score o f  >15,355 this indicates sexual distress 
in LS patients, no t in contro ls. LS pat ien ts (n=206) had s ignif icantly  higher mean 
scores on all 12 items o f  the  FSDS in comparison w i th  healthy contro ls  (n=61) 
(Mann W h itney  U test p<0.001 fo r  all items) (Figure 4).
W ith  the  aim to  f ind ou t  w h a t  fac tors  are associated w i th  sexual dysfunct ion ing, 
a regression analysis was perfo rm ed . O f the  fac tors  age, marita l status, dura t ion  
o f  LS (years) and the to ta l DLQI scores, the  to ta l DLQI score predic ted sexual 
dysfunc t ion ing  sign if icant ly  (p=0.003 B=-0.363), ind ica t ing tha t  pat ien ts w ho 
exper ience th a t  th e i r  LS has a large e f fe c t  on th e i r  QoL, have m ore  sexual 
problems.
The am oun t o f  itch and /o r  pain (DLQI quest ion 1) corre la ted sign if icant ly  w i th  the 
mean scores o f  the  FSDS (r=0.442; p<0.001). Patients w ho experienced more itch 
an d /o r  pain, had m ore sexual distress. M oreover,  they  had m ore p rob lem s 
regard ing arousal (r=-239; p<0.001), lubr ica t ion (r=-0.221; p=0.002), orgasm
vt 4
huh
Figure 4 M ean FSDS scores.
In to ta l,  206 p a tie n ts  f i l le d  in a ll q u es tions  o f th e  FSDS q u e s tio n n a ire . These scores w e re  
s ig n if ic a n tly  d if fe re n t fro m  co n tro ls  on a ll dom a ins (M a n n -W h itn e y  U te s t).
(r=-0.172; p=0.001), satis faction (r=0.239; p=0.001) and pain (r=-0.151; p=0.032). 
O lder pat ien ts had lower mean scores on the  subscales desire (r=-0.151; p=0.034), 
arousal (r=-0.241; p=0.001), lubr ica t ion (r=-0.251; p<0.001), pain (r=-0.317; 
p<0.001) and to ta l score (r=-0.246; p<0.001) o f  the  FSFI quest ionnaire , indicating 
worse sexual func t ion ing .  The age o f  patients did no t corre late w i th  the  FSDS 
scores (r=-0.50; p=0.485).
There was no corre la t ion  be tween the  am oun t o f  i tch /pa in  and desire (r=-0.111; 
p=0.117). Patients tha t  repor ted  to  have sexual problems (DLQI quest ion 9), had 
more sexual distress (total score FSDS) (r=0.624; p<0.001). In pat ien ts w i th  LS, the 
marita l status was not associated w i th  sexual func t ion ing  (Chi square p=0.596).
Discussion
In th is  s tudy we show tha t  LS has a cons iderab le  in f luence on the  QoL and 
sexual func t ion ing .  This in fluence on sexual func t ion ing  causes s ignif icant sexual 
distress. Patients w ho experience a great im pact on the ir  QoL, have worse sexual 
function ing .
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Sexual d if f icu lt ies  in LS patients may be a t t r ib u te d  to  th ree  main causes for  
dyspareunia. The skin is sensit ive and delicate which easily tears and may cause 
superf ic ia l dyspareunia. The fear fo r  pain lowers arousal, decreases lubrication, 
and causes the  pelvic muscles to  contract,  wh ich indeed results in dyspareunia. 
In LS, anatomical changes may also occur, like hood ing and buria l o f  the  cli toris, 
labial fusion and in tro ita l stenosis, wh ich may make in tercourse pain fu l or give 
rise to  problems w i th  achieving orgasms.
In our study, the  mean DLQI score was 11.92. Basra et al. pe r fo rm ed  a rev iew of 
va l ida t ion data abou t the DLQI, wh ich included a myriad o f  dermato log ica l 
cond it ions .350 These data show tha t  our mean score is comparable to  the  scores 
o f  a top ic  dermatit is ,  hyperhidrosis, psoriasis and derm atom yos it is  sine myositis.
There are several limitations about our study. We had no access to socio-demographic 
in formation which may have influenced the sexual functioning of patients. It may be 
hypothesized tha t patients suffering from LS may be more anxious or depressive than 
women in the contro l group, which may have influenced the results. In addit ion, only 
a m inor ity  of patients filled in the question: fo r  how long have you had LS? This may 
be because the LS was set up gradually or tha t patients did not remember this 
anymore. Moreover, we did not have a fu l ly  matched control group. Patients of LS 
and psoriasis may be embarrassed to tell the ir  friends they suffer of LS/psoriasis or 
ask them to fill in the questionnaires about sexual dysfunctioning. However, w ith 
these 61 control patients, we found highly signif icant differences between LS patients 
and controls. Furthermore, we had a response rate of 58.4% and not all patients 
comple te ly filled in the questionnaires; 28 patients did not fill in the FSFI, which might 
be due to  the very intimate and personal questions about sexual functioning in this 
questionnaire. This may introduce a responder bias, because those most bothered by 
the ir  symptoms are more likely to respond.
This study highlights the  need fo r  a t ten t ion  fo r  sexual func t ion ing  when t reat ing  
pat ien ts w i th  LS. T reatm ent (topical cort icostero ids) may make a d i f fe rence in the 
ab i l i ty  to  have in tercourse.66 Fusion o f  the  labia may require  simple pe r ineo tom y 
under local anaesthesia. However, in the  case o f  in tro ita l  stenosis, per ineop lasty 
may be pe r fo rm ed  w i th  the  aim to  am e lio ra te  sexual in tercourse.67 No data are 
available abou t the  use o f  lubricants, the  role o f  the  sexologist or o ther  t re a tm e n t  
opt ions. Despite this  lack, we o f ten  advice our pat ien ts to  use lubricants to 
diminish f r ic t ion  w i th  in tercourse. W hen pat ien ts are m otiva ted, we also refer 
them  to  a sexologist.
In conclusion, we have shown tha t  patients w i th  LS experience an e f fec t  on the 
QoL, especially w i th  sexual function ing . In addi t ion , we have found tha t  sexual 
func t ion ing  is impaired on all the  subscales. These d i f f icu lt ies  in sexual func t ion ing  
have led to  s ignif icant sexual distress. In general,  patients w ho  experienced more 
in fluence on the ir  QoL had more sexual d i f f icu lt ies , leading to  more sexual 
distress.
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Dankwoord
Juli 2010: Het is ècht k laarll
O ngeloof l i jk  maar waar, mijn p roe fsch r i f t  is helemaal af. Ruim drie jaar geleden 
begon dit  als een avon tuu r  waarvan ik n iet w is t  waar dat zou eindigen, nu ligt 
er een boekje klaar Het is een cliché, maar prom overen doe je  niet alleen. 
Een bedankt!! ! !  is voo r  velen op zijn plaats:
Prof. Dr. L.F.A.G. Massuger, beste Leon. Daar stond ik dan m et mijn verslag van 
mijn we tenschappel i jke stage in je kamer. En nu?? was jo u w  vraag. Een gesprek 
m et Joanne en vele tw i j fe ls  la ter begon ik in januar i  2007 als een van je vele 
onderzoekers. Ondanks dat de dageli jkse begele iding door Joanne en Léon werd 
gedaan, b lee f je  alt i jd  betrokken en op de hoog te  van het onderzoek. Je krit ische 
en open houd ing gaven alt i jd  aanleid ing to t  discussie over de resultaten, w a t  vaak 
to t  betere studies hee f t  geleid. W at ik a lt i jd  heel b i jzonder heb gevonden, is dat 
je  alt i jd  precies door had w a t  er bij je  onderzoekers speelde.
Dr. J.A. de Hullu, lieve Joanne. W at is het een enorm  voo rrech t  om jou  als 
c o -p rom o to r  te hebben. Onze samenwerk ing kan ik het beste samenvatten als 
'gezellige e ff ic iënt ie '.  Je hield het proces van de p rom ot ie  in de gaten, maar ook 
alles w a t  daaromheen speelde. Ik heb het a lt i jd  zeer gewaardeerd dat er ook een 
'eerste versie' ingeleverd m ocht worden  van de art ike len, waar ik dan alt i jd  weer 
mee verder kon. Heel erg bedankt voo r  de f i jne  manier van begeleiden waarin  je 
mij steeds meer ve r t rouw en  en vr i jhe id  gaf.
Dr. L.C.L.T. van Kempen, beste Léon. Hoe f i jn  is het om iemand zoals j i j  erb ij  te 
hebben. Veel verstand van zaken en zeer toegankel i jk  voor al lerlei vragen. Ik w ee t 
n ie t hoeveel coupes we samen bekeken hebben onder de microscoop, het zijn er 
honderden in to taa l geweest denk ik, maar zelfs daar w is ten we nog iets leuks van 
te maken. Ook kon het a lt i jd  op korte  te rm ijn ,  w a t  ik ook van je vroeg, vaak nog 
dezelfde dag. Heel erg bedankt voo r  al je hulp.
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Hans Bulten, je  w erk  als 'expert  gynaecopatholog is t ',  zoals vaak vermeld in de 
art ike len, was vaak veel w e rk  w aarvoor je a lt i jd  heel even enthousiast gemaakt 
moest w orden. We hebben de VIN laesies beoordee ld naast 130 vu lvacarc inomen 
en vaak even een snel coupe onder de m icroscoop gehad te r  beoordel ing. Harte l i jk  
dank voo r  al je inspanningen.
W il lem  Melchers, na een stroeve s ta r t  werd de samenwerk ing la ter beter. 
Over hoofds tuk  3 hebben we veel discussie gehad. Nadat we je hadden overtu igd 
was het art ike l ook beter geworden. Harte l i jk  dank voor het scherpe com m entaar 
en de b i jschr i f ten  bij de manuscrip ten ('God reveals, we show en Captain Kirk 
explores, we investigate’ ).
Ruud Bekkers, aanvankeli jk was mijn onderzoek meer gericht op HPV posit ieve 
vulva- en cerv ixafw ijk ingen, waarb ij we veel hebben samengewerkt.  Het art ikel 
over het adenocarc inoom  van de cervix was een hele beproeving, maar heeft  
geresulteerd in mijn eerste Pubm ed-h it  (en er kan er maar één de eerste zijn). 
Later r ich tte  het onderzoek zich meer op de HPV negatieve vulvacarc inomen, 
w aardoor  onze samenwerk ing m inder f requ en t  werd. Bedankt v o o rd e  begeleiding, 
je  s troom  aan ideeën voo r  n ieuw onderzoek en e f f ic iën te  werkwijze.
Maaike van Ham, Petra Zusterzeel en Eva-Maria Roes, ju l l ie  m oe t ik m et name 
bedanken voor de keren dat ik op de OK w eer iets nodig had. Fijn dat ju l l ie  met 
me mee dachten en me seinden wanneer de OK klaar was.
Lenno Dukel en Carine van der V leuten, onze samenwerk ing was m et name 
klinisch van aard. Ik heb veel van ju l l ie  mogen leren over de vulvaire patho log ie 
en de behandeling daarvan, hier zal ik nog veel aan hebben in de kliniek.
De epitheel w erkgroep  op maandagochtend; Jeroen van der Laak, Irene O tte- 
Höller en prof. S lootweg. Op die dag was er a lt i jd  t i jd  om de n ieuwe bevindingen 
van ons onderzoek te bespreken w aardoor  er vaak w eer oplossingen werden 
gevonden o f  ideeën voo r  n ieuw onderzoek on ts tonden. Jeroen ook bedankt voor 
alle u it leg over de verschil lende com puterp rogram m a's  die we hebben gebru ik t.
De labbespreking, eerst op woensdagochtend, la ter op dinsdagmiddag. Jeroen 
Dijkstra, Ine M am o r Cornelissen en Goos van Mui jen  bedankt voor alle goede 
ideeën van ju l l ie  kant en interesse in mijn onderzoek.
Cathy Maas, zonder jou  was het vele werk  in het lab op de v ie rde verd iep ing een 
stuk saaier geweest en vaak m is lukt vrees ik. A lt i jd  als ik iets n iet precies wist, kon 
ik bij jou  te rech t  m et mijn vragen. Je lach w e rk te  erg aanstekeli jk!
Jan Hendriks, bedankt voo r  de hulp bij de stat is t iek.
Irene van der Avoort ,  in augustus 2006 begon ik als stagia ire bij jo u w  onderzoek, 
la ter werden we collegae. We hebben veel samengewerkt,  een heel review 
geschreven, en m eerdere art ike len samen geschreven. Maar het is n ie t alleen 
dat, alles kon ik aan je vragen toen ik hier net begon. Als ik werd  beschouwd als 
'de n ieuwe Irene' was dat eigenli jk  al leen een com p lim ent.  We hebben het ook 
gezell ig gehad, aan de (alcohol vrije) borre l in Edinburgh en aan de haggis bij het 
galadiner. A lt i jd  in teressant om er na tw ee  dagen achter te komen hoe de lampen 
in het appa rtem en t  werken...  Super bedankt voor al je  inspanningen en bedankt 
dat je mijn pa ran im f w i l t  zijn.
M ijn  m e d e k a n too r tu inb ew one rs .  Lieve Sabine, Eva, Arno, Ineke, Char lo t te  
Lenselink (bedank t voo r  s te l l ing 6!), Selma, Channa Linda, Ralph, Dennis, Anne, 
Roosmarie, Suzan, Refika, Thijs, Inge, Sanne, A nnem ijn ,  Elvira, Kim, Char lo tte  
Lyb0l, Marian, Bea, W il l ianne en Gwendolyn; doo r  alleen ju l l ie  namen te noemen 
doe ik ju l l ie  tekort .  Zonder gezellige collegae w o rd t  een proefschri ft  geen succes. 
Als er een art ike l geaccepteerd was, v ierde iedereen graag mee (als je  maar taa r t  
meenam), maar ook als iets m is lukt was, een art ike l voor de zesde keer afgewezen 
o f  m ajor revisions van v ie r kantjes waar je mee aan de slag moest, kon ik bij een 
van ju l l ie  even mijn f rus tra t ies  kw i j t .  Daarnaast na tuur l i jk  de con tacten buiten 
kan toor( tu in )uren,  de e tent jes (met t ien ingrediënten), de borrels, de weekendjes 
weg, de vele koppen thee, de gezellige lunches, en niet te vergeten de congressen.
Loes, heel veel succes m et het vervo lg op het onderzoek! Je w ee t me vast te 
v inden m et al je  vragen.
Marieke, M ichelle, Marian, M ir r in  en Joyce; even lunchen tussendoor o f  samen 
eten, erachter komen dat p rom overen bij de dermato log ie , chirurgie, in terne 
geneeskunde o f  neuro log ie n ie t eens zoveel verschil  u i tm aakt;  je loop t tegen 
dezelfde dingen aan.
Gijs, bij mijn p rom ot ie  ben je al klaar m et je op le id ing en m oe t ik nog beginnen. 
Ik w eet je verhalen u it  de hu isartsenprakt i jk  al t i jd  zeer te waarderen.
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Lieve jaa rc lubgenoot jes ,  ju l l ie  w aren zeer geïnteresseerd in mijn w e rk  en 
onderzoek. Jammer dat nu iedereen een beetje is u itgevlogen over Nederland en 
zelfs Duitsland en we elkaar m inde r zien, maar ik kijk er a lt i jd  w eer naar u it  ju l l ie  
weer te zien. Lieve Mari je , als mijn dokters  jaarc lubgenoot je  heb ik jou  gevraagd 
mijn pa ran im f te zijn vandaag, ik vind het super dat je  dadeli jk  naast me staat!
Hans en Elizabeth, bedankt voo r  de interesse en hulp bij sommige statis t ische 
vragen.
Jelske, Astr id en Huub, ook voo r  ju l l ie  b leef het alt i jd  een beetje vaag w a t  ik nu de 
hele dag op mijn w e rk  aan het doen was. Ik hoop dat het m et d i t  boekje wa t 
du ide l i jker is geworden.
Papa en mama, ondanks dat ju l l ie  geen idee hadden w a t  ik ging doen toen ik ging 
'promoveren ',  zijn ju l l ie  alt i jd  zeer geïnteresseerd geweest in mijn onderzoek. 
Van ju ll ie heb ik geleerd door te zetten en dat heeft mede geleid to t  d i t  proefschrift.
Joep, lief vriendje. Ben ik toch nog eerder klaar dan ji j!!! We hebben vele discussies 
gehad over mijn zeer dunne p roe fschr i f t  (waarschi jn li jk  net zo dik als jo u w  eerste 
hoofdstuk) en het nut van jo uw  onderzoek. We hebben erom kunnen lachen en ik 
w e e t  zeker dat je  t ro ts  bent vandaag. Ik hoop dat j i j  je p roe fsch r i f t  ook snel en 
goed kunt a fronden. Jij bent mijn beste vriend je!!
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Curriculum Vitae
Hedw ig van de N ieuw enho f w erd  geboren op 21 novem ber 1980 in Veghel waar 
zij ook opg roe ide . M e t een d u id e lijk  plan om geneeskunde te  gaan studeren  
w o rs te ld e  zij zich do o r een (3 pakket aan het Gym nasium  van he t Zwijsen college 
te  Veghel. D oor een u it lo t in g  vo lgde er ee rs t een ja a r psycho log ie  aan de 
un ive rs ite it van M aastricht, maar in 2000 kon aan de stud ie geneeskunde worden 
begonnen. Haar s tud en ten tijd  begon in een klein, koud kam ertje  in de W ate rs traa t 
w aar toch  nog 8 andere dames b ijpaste  voo r he t w e ke lijks te  ja a rc lu b  eten. 
Al snel o n tm o e tte  zij Joep van G ennip en zij g ingen snel op zoek naar een 
gesch ikte re  kam er aan de Heijendaalseweg. Voor de aanvang van de coschappen 
h e e ft zij 2 m aanden rondgere isd in Ecuador, Peru en Bolivia waarna er een IFMSA 
stage gynaecolog ie  volgde in M arilia , Brazilië. Na de regu lie r coschappen volgde 
er een keuze coschap ob s te tr ie  in het Jeroen Bosch Z iekenhuis (loka tie  G root 
Z iekengasthuis) en een a fs lu itend  coschap gynaecologische oncolog ie  in he t UMC 
St Radboud. Na een w e tenschappe lijke  stage op d ieze lfde afde ling , behaalde zij 
he t artsexam en in novem ber 2006. Enthousiast gem aakt voo r w e tenschappe lijk  
onderzoek do or die laatste  stage, s ta rtte  zij in 2007 m et een p rom otieonderzoek  
bij de p ijle r gynaecologische oncologie van het UMC St Radboud (p ro m o to r 
pro f. dr. Leon M assuger en c o p ro m o to re s  dr. Joanne de Hullu en dr. Léon van 
Kempen). Een AGIKO aanvraag w erd  gehonoreerd , en in m aart 2010, b ij 38 weken 
zwangerschap, w erd  het onderzoek afgerond. In april 2010 is Floris geboren. 
In augustus 2010 begon zij als ANIOS te  w erken  op de a fd e ling  V erloskunde en 
G ynaecolog ie  van he t Jeroen Bosch Z iekenhuis ( lo ka tie  G roo t Z iekengasthu is) 
en zal daar in ja n u a ri 2011 s ta rte n  m et de op le id in g  to t  gynaeco loog  (op le ide r 
dr. H.P. O osterbaan).

